Bronchoprovocation studies to define mechanisms in asthma and airway inflammation by Lazarinis, Nikolaos
From DEPARTMENT OF MEDICINE HUDDINGE 
Karolinska Institutet, Stockholm, Sweden 
BRONCHOPROVOCATION STUDIES TO 
DEFINE MECHANISMS IN ASTHMA AND 
AIRWAY INFLAMMATION 
Nikolaos Lazarinis 
 
Stockholm 2019 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-Print AB, 2019 
© Nikolaos Lazarinis, 2019 
ISBN 978-91-7831-292-4 
BRONCHOPROVOCATION STUDIES TO DEFINE 
MECHANISMS IN ASTHMA AND AIRWAY 
INFLAMMATION 
 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
 
Public defence occurs on Friday 22th of February 2019, at 09.00 in lecture hall C1.87, 
Karolinska University Hospital, Huddinge.  
By 
Nikolaos Lazarinis M.D. 
Principal Supervisor: 
Professor Barbro Dahlén 
Karolinska Institutet 
Department of Medicine, Huddinge 
Lung and Allergy Research 
 
Co-supervisor(s): 
Professor Sven Erik Dahlén 
Karolinska Institutet 
The National Institute of Environmental Medicine 
Unit for Experimental Asthma and Allergy 
Research 
 
Associate Professor Craig Wheelock 
Karolinska Institutet 
Department of Medical Biochemistry and 
Biophysics  
Division of Physiological Chemistry II 
Opponent: 
Professor Brian Lipworth 
University of Dundee 
Scottish Centre for Respiratory Research 
Division of Molecular and Clinical Medicine 
 
Examination Board: 
Professor Marja-Liisa Dahl 
Karolinska Institutet 
Department of Laboratory Medicine 
Division of Clinical Pharmacology 
 
Docent Marina Korotkova 
Karolinska Institutet 
Department of Medicine, Solna 
Division of Rheumatology 
 
Professor Arne Egesten 
Lund University 
Department of Respiratory Medicine and 
Allergology 
Division I-II 
 
 

  
To Evi, Christos and Stavros 
  
  
  
ABSTRACT 
Bronchial provocations with a variety of stimuli have been widely used over the past 70 years in 
both asthma research as well as in daily clinical praxis in order to aid the physician to establish the 
asthma diagnosis. In research, the bronchoprovocation model represents an excellent tool to better 
understand asthma pathophysiology, and to assess the effects of different interventions and new 
investigational therapies. Most of the currently approved asthma therapeutic options have shown 
efficacy in previous studies using the bronchoprovocation setting.  
In the current thesis, a range of bronchial provocations was performed prior to and after treatment 
with pharmacological interventions with different mode of actions. Responses were measured in 
the airways in the form of induced bronchoconstriction and airway inflammation (sputum cell 
counts), as well as in other matrices (skin, blood, urine).  
For the first time, it was shown that treatment with the combination of budesonide-formoterol 
(bud/form) in a single inhaler taken three to four times per week provided the same magnitude of 
protection against exercise-induced bronchoconstriction (EIB) as to regular treatment with a low 
dose of budesonide. Moreover, subjects who received monotherapy with the short acting β2 
agonist (SABA) terbutaline had no protection against EIB over time. These results question the 
place of SABA monotherapy in asthma treatment even for subjects with mild asthma. It is 
recommended to replace SABA monotherapy with intermittent use of bud/form, which can also 
be an alternative option to regular treatment with low dose inhaled corticosteroids (ICS). 
Furthermore, using an allergen bronchoprovocation model, it was demonstrated that treatment 
with the second-generation anti-IgE monoclonal antibody QGE031 (ligelizumab) elicited an 
inhibition of the early allergic response (EAR) that was three times greater than what was 
achieved by the currently approved anti-IgE treatment with omalizumab. In addition, the data 
showed that there were important differences in the allergen response in the airways compared to 
the skin during QGE031 therapy; the highest dose of QGE031 consistently supressed allergen 
induced skin test responses that persisted six weeks after the last dose was given, while there was 
a variable effect on the airway response that did not last six weeks after the last dose. These 
results elucidate the complexity of the IgE pathway and the different kinetics and tissue responses 
to anti-IgE therapy. 
Finally, this thesis answered some important questions about the role of cysteinyl leukotrienes 
(CysLTs) and in particular leukotriene E4 (LTE4) in asthma. The data showed that treatment with 
the potent CysLT1 receptor antagonist montelukast completely abolished the bronchoconstriction 
elicited by LTE4 inhalation in subjects with mild asthma. Urine was collected during the LTE4 
provocations for analysis of lipid mediator excretion, which led to the serendipitous discovery of 
increased urinary excretion of metabolites of prostaglandin (PG) D2, as well as other lipid 
mediators after LTE4 inhalation. These novel findings add a new dimension, namely that LTE4, in 
addition to a direct bronchoconstrictive action, can also activate both the mast cell as well as other 
cells to produce secondary responses that can amplify or modify its primary effect. 
Thus, this thesis demonstrates that carefully planned and conducted studies using bronchial 
provocations in combination with various pharmacological interventions, can elucidate important 
mechanisms in asthma pathogenesis and reveal potential new targets for treatment.  
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1 INTRODUCTION 
Asthma is a common, chronic respiratory disease, which is characterized by a history of 
symptoms of wheeze, shortness of breath, chest tightness and/or cough that vary over time 
and in intensity together with variable expiratory airflow limitation (GINA report 2018). 
These symptoms can be triggered by factors such as exercise, allergen, and change in weather 
or viral respiratory infections. Asthma is usually associated with airway hyperresponsiveness 
(AHR) to exogenous stimuli (Hargreave, Ryan et al. 1981) and with chronic inflammation. 
The disease is heterogeneous with different underlying mechanisms and continues to 
increase. It is estimated to affect more than 300 million individuals worldwide (Global 
Burden of Disease Study 2015) and about 800,000 persons in Sweden (Socialstyrelsen 2015). 
More than half of asthma patients have a mild disease where symptoms and airflow limitation 
may resolve spontaneously or in response to medication. On the other hand, some patients 
will experience episodic flare-ups (exacerbations) that may be life threatening and carry a 
significant burden for the community. Over the past 15-20 years asthma mortality has 
declined due to progress that has been made not only in asthma therapy but also in 
establishing a correct diagnosis and better assessing the disease; however, there is evidence 
that overdiagnosis of asthma occurs (Aaron, Vandemheen et al. 2008), which probably is also 
true for underdiagnosis. This problem is due to the lack of measurement and documentation 
of typical physiological asthma features such as variable airway obstruction and AHR. 
According to both international (British Thoracic and Scottish Intercollegiate Guidelines 
2014, GINA report 2018) and Swedish asthma guidelines (Socialstyrelsen 2015), although a 
diagnosis of asthma could be suspected on the basis of patient reported symptoms, it should 
be supported by objective measures of variable airway obstruction or AHR. 
Spirometry is the preferred method to measure airway obstruction and a reduced FEV1 with a 
low ratio of FEV1 to FVC indicates its presence. A positive bronchodilator reversibility test 
(BD) in adults usually defined as an increase in FEV1 of 12% or more with at least a 200 ml 
change after administration of a SABA (GINA report 2018), suggests the presence of asthma 
when other diseases have been excluded. Asthma is a variable disease and airway calibre can 
change over time, such that patients when assessed for suspected asthma might have normal 
pulmonary function or non-significant reversibility after a BD test, and thus fail to have the 
correct diagnosis. In these patients bronchoprovocation tests can be performed to confirm the 
presence of AHR. 
Almost all asthmatic patients will respond to either direct bronchoprovocation challenges, 
acting directly on airway smooth muscle, such as methacholine or indirect acting through 
activation of inflammatory cells such as exercise, eucapnic voluntary hyperpnoea (EVH), 
hypertonic saline, allergen, adenosine monophosphate (AMP) or mannitol inhalation 
(Cockcroft 2001, Cockcroft 2003). The degree of AHR may not directly correlate with 
asthma severity in all patients, though in general indirect challenges are considered good 
markers of airway inflammation, they correlate with airway eosinophilia (Polosa, Ciamarra et 
al. 2000, Van Den Berge, Meijer et al. 2001) and AHR to indirect stimuli decreases with anti-
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inflammatory therapy (van den Berge, Kerstjens et al. 2001). The latter makes them useful 
not only for establishing the diagnosis but also for treatment monitoring (Sont, Willems et al. 
1999) and AHR to inhaled mannitol is known to normalize with adequate therapy (Brannan, 
Koskela et al. 2007). In addition, mannitol AHR has been used as a method of ICS titration in 
persistent asthma (Lipworth, Short et al. 2012). Thus it is evident that bronchoprovocations 
are important tools for everyday clinical praxis, and are recommended in most asthma 
guidelines. 
Bronchoprovocations can with the same utility be used for asthma research not only to 
establish the diagnosis but also to trigger a standardized, reproducible airway reaction and 
thereby obtain integrated in vivo information on inflammatory and functional responses in 
subjects with asthma. Asthma is a complex and heterogeneous disease with a range of 
subgroups or phenotypes emerging during the last years (Wenzel 2012) with different 
underlying pathophysiological mechanisms. Most of these mechanisms can be explored using 
bronchoprovocation studies with a goal to target specific receptors or cells/signalling 
molecules and in the end define which patients will benefit most from each therapeutic 
intervention. The latter is a major focus of asthma research today. 
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2 AIMS OF THE THESIS 
The overall objective of this thesis was to use different bronchoprovocations in order to 
elucidate distinct underlying mechanisms in asthma and airway inflammation. 
Bronchoprovocations were performed prior to as well as after pharmacological interventions 
with both currently approved and new investigational drugs. In this way by blocking one or 
several steps in the response induced by the various bronchoconstrictive stimuli, we can gain 
further knowledge about certain pathophysiological mechanisms and eventually establish 
new targets for treatment of asthma. 
This project included a series of different bronchoprovocations/challenges, namely exercise, 
allergen and inhalation of LTE4 in subjects with asthma. The effect of both the challenges and 
the specific interventions were used to answer the following questions: 
1. Does on-demand treatment with the combination of budesonide-formoterol 
(bud/form) improve asthma control as assessed by exercise induced 
bronchoconstriction (EIB)? 
2. Is treatment with the new investigational anti-IgE antibody QGE031 (ligelizumab) 
superior to omalizumab in inhibiting the early asthmatic response (EAR) following an 
allergen inhalation challenge? 
3. Does treatment with the potent CysLT1 antagonist montelukast block both the 
bronchoconstriction and airway inflammation, as assessed by sputum eosinophils, 
induced by inhalation of LTE4 in asthmatic subjects? Which lipid mediators are 
released after a LTE4 challenge and how is this release affected by treatment with 
montelukast? 
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3 BACKGROUND 
3.1 BRONCHIAL PROVOCATIONS 
Airway hyperresponsiveness (AHR) is an abnormal increase in airflow limitation following 
exposure to exogenous stimuli (Lotvall, Inman et al. 1998). Bronchoprovocation challenges 
using allergen aerosols were widely used over the first half of the 20th century much more than 
non-allergic challenges, after the classic work of Blackley (CH. 1873) who in the 1870s used 
provocation tests with whole pollen to show that grass pollen was a cause of allergic rhinitis and 
asthma. Over the years with the spread of the bronchial provocations, AHR has progressed from 
a concept to a physiological measurement. Already in 1945 Tiffeneau and Beauvallet reported, 
“bronchodilation and bronchoprovocation challenges should be helpful in the assessment of 
patients with lung disease” (Tiffeneau R 1945). In the 1950s, Herxheimer performed the first 
provocation study using various stimuli (Herxheimer 1951) and was also the first to describe in 
the lab the late asthmatic reaction (LAR) following an allergen challenge (Herxheimer 1952). In 
the following years, the first bronchoprovocation studies using a pharmacological intervention 
with sodium cromoglycate in order to block the elicited response were performed (Pepys, 
Hargreave et al. 1968, Booij-Noord, Orie et al. 1970, Pelikan, Snoek et al. 1970, Booij-Noord, 
Orie et al. 1971). In fact in recent years most of the currently approved asthma therapies have 
shown efficacy in inhibiting the response elicited by either inhaled allergen or exercise; this 
includes ICS (Vathenen, Knox et al. 1991, Gauvreau, Doctor et al. 1996), combination of 
ICS/LABA (Weiler, Nathan et al. 2005, Dahlen, Lantz et al. 2009) and leukotriene antagonists 
(Dahlen, Zetterstrom et al. 1994, Leff, Busse et al. 1998, Diamant, Grootendorst et al. 1999). 
AHR to a certain stimulus during a bronchial challenge is reflected both by the magnitude and 
the ease of the induced bronchoconstriction (Woolcock, Salome et al. 1984). An increase in the 
magnitude of the reaction is defined by a progressive elevation of the plateau response in the 
dose-response curve and in the ease of bronchoconstriction by a leftward shift of the curve. The 
leftward shift can be further defined by the reduced provocation concentration or dose producing 
a 20% fall in FEV1, called the PC20 or PD20 respectively. Even if the magnitude of the 
bronchoconstriction is an important parameter, traditionally AHR is defined by the PC20/PD20. 
Bronchial provocations are usually categorized into direct and indirect depending on the agent 
that is used and the mechanism of action (Figure 1) (Pauwels, Joos et al. 1988). Direct agents act 
directly on airway smooth muscle receptors (e.g., muscarinic receptors for methacholine, H1 
receptors for histamine, CysLT1 receptors for cysteinyl leukotrienes) but also in mucous glands 
and on airway microvasculature without involving intermediate pathways. Direct challenges, for 
example methacholine, are widely used and are highly sensitive with a negative predictive value 
approaching 100% provided symptoms are clinically current (Hopp, Bewtra et al. 1984, 
Cockcroft, Murdock et al. 1992, Crapo, Casaburi et al. 2000). An exception to that are high-
intensity or elite athletes who may have EIB with a negative methacholine challenge (Holzer, 
Anderson et al. 2002). Specificity on the other hand of methacholine is low and a positive test is 
not diagnostic of asthma especially in the absence of typical symptoms, though it may indicate 
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airway dysfunction. The positive predictive value (PPV) of a histamine challenge PC20 below 
8mg/ml in a random population was less than 50% (Cockcroft, Murdock et al. 1992), which 
improved with an increased pre-test probability (increased asthma probability based on 
symptoms) and was even higher if the provocation induced symptoms which mimicked the 
symptoms that the patient reported (Crapo, Casaburi et al. 2000). When using a lower threshold 
for the test (1mg/ml), PPV increased almost to 100% with a much lower sensitivity of course. It 
must also be noted that direct AHR reflects airway smooth muscle function and airway calibre 
and is influenced by remodelling, which can explain why some COPD patients might also have 
a positive methacholine test. AHR in these patients is possibly caused by a geometric 
phenomenon related to the airway lumen obstruction (Ramsdell, Nachtwey et al. 1982, 
Ramsdale, Morris et al. 1984). Thus it is difficult to interpret a positive methacholine test for 
asthma diagnosis in patients with resting airflow obstruction. 
 
Figure 1: Categorization of bronchial provocations according to their mode of action 
In contrast to direct challenges, indirect stimuli act through different intermediate pathways 
mostly through inflammatory (predominantly mast cells) and neuronal cells, which then release 
mediators and cytokines to cause bronchoconstriction. These stimuli are osmotic (exercise, 
EVH, mannitol, hypertonic saline) or non osmotic (AMP, propranolol, allergen, aspirin) and 
because the responses to these challenges are modified or inhibited by ICS they are considered 
to reflect closer active airway inflammation and to be more clinically relevant for asthma (Joos, 
O'Connor et al. 2003). A wide spectrum of mediators such as histamine, leukotrienes, 
prostaglandins, neuropeptides are involved in the bronchoconstriction induced by indirect 
stimuli (Van Schoor, Joos et al. 2000). Data from previous studies have shown that compared to 
direct challenges (methacholine), indirect provocations can differentiate better between asthma 
and COPD (Joos, O'Connor et al. 2003, Hassan, Hargreave et al. 2010), correlate better with 
airway eosinophilia and improve more with ICS treatment (Taylor, Jensen et al. 1999, Hofstra, 
Aspirin, AMP 
Allergen, Exercise 
EVH, Mannitol 
Hypertonic saline 
Histamine 
Methacholine 
Leukotriene D4 
Direct 
Indirect 
Direct – hyperreactivity 
Indirect – inflammation (+ hyperreactivity) 
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Neijens et al. 2000). After the completion of an indirect challenge tachyphylaxis to a second 
indirect stimulus is frequently observed (cross refractoriness) (Van Schoor, Joos et al. 2000, 
Larsson, Perry et al. 2011) a phenomenon, which is not so evident after repeated challenges with 
inhaled histamine or methacholine (Laprise and Boulet 1996). Another characteristic of the 
indirect tests is that they can be inhibited by pre-treatment with single doses of cromones 
(sodium cromoglycate, nedocromil), which are known mast cell stabilizing agents and thus 
indicating that mast cells are activated during these challenges (Van Schoor, Joos et al. 2000, 
Cockcroft and Davis 2009). 
3.2 AIRWAY RESPONSE TO CHALLENGES AND HOW TO MEASURE IT 
Over the past years, spirometry with measurement of FEV1 has been the method of choice in 
order to measure bronchoconstriction following an airway challenge. Already in 1968, Pepys et 
al used repeated measurements of FEV1 in order to describe the effect of treatment with sodium 
cromoglycate on both the EAR and LAR following an allergen inhalation challenge. In the 
following years, some bronchoprovocation studies used a 35% fall in specific airway 
conductance (SGaw) as outcome for calculation of PC35 and not PC20 FEV1 (Arm, O'Hickey et 
al. 1990). A comparison of the two methods by Cockcroft and colleagues showed that the PC35 
SGaw was consistently approximately four-fold lower than the PC20 FEV1 both in mildly 
hyperreactive asthmatics as well as moderately hyperreactive asthmatics and concluded that 
FEV1 may be preferable to SGaw because of better separation of asthmatics from other groups 
(Cockcroft and Berscheid 1983). Thus, FEV1 is now considered the method of choice to detect 
changes in lung function in the bronchoprovocation setting, although it has its own pitfalls. The 
main problem is that in many subjects it is difficult to obtain good quality, highly reproducible 
flow-volume curves, which are essential when performing an airway challenge, because 
spirometry requires effort-dependent expiratory manoeuvres. This becomes more evident in 
preschool children and the elderly who might not be able to perform spirometry at all. In 
addition, it is known that FEV1 reflects mainly changes in the larger airways (Annesi, Oryszczyn 
et al. 1992), without providing any information about the smaller airways that have been a major 
focus in asthma research in recent years. 
3.2.1 Small airways impairment following a bronchial challenge 
Small airways (less than 2 mm luminal diameter) have been a major focus of respiratory 
research over the past few years. It is now evident that airway inflammation involves also the 
peripheral airways (Wenzel, Szefler et al. 1997, Gelfand and Kraft 2009, Hyde, Hamid et al. 
2009). This has resulted in the development of inhalers containing extra-fine particles of ICS 
alone or in combination with LABA, that demonstrate better deposition in the peripheral airways 
compared to conventional devices (De Backer, Devolder et al. 2010). A major step towards this 
development in order to be able to understand better the pathophysiology of the small airways 
was the introduction of impulse oscillometry (IOS) as an alternative technique to assess lung 
function. IOS is one type of forced oscillation technique (FOT), that was first developed by 
Dubois et al (Dubois, Brody et al. 1956) over 50 years ago. The method uses the 
superimposition of pressure fluctuations in the airway over the subject`s normal breathing. IOS 
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delivers a regular square wave of pressure 5 times per second with the advantage of providing 
more detailed characterization of respiratory function compared to other FOT techniques (Smith 
HJ 2005). IOS is non-invasive, requires only quiet, tidal breathing and provides information 
about both lung resistance (Rrs) as well as reactance (Xrs) in various frequencies, which together 
reflect total pulmonary impedance (Zrs). Measurements are under one minute long, thereby 
pressure and flow volume tracings are produced giving the investigator the possibility to choose 
the best tracings afterwards. IOS has been widely used to measure lung function in children 
(Marotta, Klinnert et al. 2003), as well as evaluate AHR after bronchial challenge with 
methacholine (Aronsson, Tufvesson et al. 2008), mannitol (Horsman, Duke et al. 2009) and 
exercise (Lee, Lee et al. 2010). Furthermore, it has been reported that significant increases in Rrs 
can be seen earlier than a FEV1 response during a methacholine challenge, suggesting that IOS is 
more sensitive than spirometry (Schulze, Smith et al. 2012).  
3.3 MAST CELLS AND THEIR ROLE IN BRONCHIAL CHALLENGES 
Although discovered for more than hundred years ago, the role of mast cells in human 
pathophysiology is not clearly outlined. They are usually located around blood vessels and 
mucosal surfaces that are more exposed to the external environment, such as the skin or the 
lungs. They normally contribute to tissue homeostasis and defence against bacterial infections 
(Echtenacher, Mannel et al. 1996) as well as tissue damage and revascularization (Weller, 
Foitzik et al. 2006). Mast cells are central effectors in asthma and allergies, both in acute 
reactions but also in sustaining the chronic inflammation in the airways (Bradding, Walls et al. 
2006). They can be activated through a variety of stimuli although the classical and best-studied 
mechanism which is also implicated in the EAR following an allergen challenge is through the 
high affinity IgE receptor FcεRI, causing mast cell degranulation. The mediators released upon 
activation had been stored (e.g. histamine, heparin, tryptase), de novo synthetized upon 
activation (e.g. PGD2, leukotrienes) or both (e.g.TNF-a, interleukins). In asthma compared to 
healthy airways, mast cells are not increased in number (Laitinen, Laitinen et al. 1993a), 
although they infiltrate some of the most important structures in the airways i.e. the airway 
epithelium, the mucosal glands and the airway smooth muscle (Carroll, Mutavdzic et al. 2002, 
Begueret, Berger et al. 2007, Dougherty, Sidhu et al. 2010). Mast cells play a key role for EIB 
pathogenesis as will be discussed later on as well as for both the EAR and LAR after exposure to 
allergen. Previous studies have shown a rapid increase in the concentration of the specific mast 
cell marker tryptase in bronchoalveolar lavage (BAL) fluid within minutes following a local 
bronchial allergen challenge (Wenzel, Fowler et al. 1988, Salomonsson, Gronneberg et al. 
1992). In recent years, non-invasive methods have been developed in order to confirm mast cell 
activation in asthma and in the bronchoprovocation setting, namely the measurement of mast 
cell derived lipid mediators in body fluids. 
3.3.1 Mast cell derived lipid mediators and their receptors 
Mast cell activation and degranulation leads to the release of preformed mediators, such as 
histamine and tryptase but also de novo synthesis and release of several lipid-derived molecules. 
These substances are derived from arachidonic acid (AA) that is cleaved from the cell membrane 
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by phospholipase A2 and the products are called eicosanoids because they contain 20 carbon 
atoms. These include prostaglandins (PG), leukotrienes (LT), thromboxanes (TX), lipoxins (LX) 
as well as hydroxyl and hydroperoxy fatty acids (HETE and HPETE).  
The synthesis of PGs begins with cyclooxygenase (COX) catalysed reactions. AA is first 
oxygenated to PGG2, which is a highly unstable metabolite. PGG2 is then further metabolised to 
PGH2 through a peroxidase reaction. PGH2 is then subsequently metabolised to the individual 
prostanoids depending on which specific synthase that is expressed by the individual cells. The 
PGs are divided into two classes; the stimulatory PGs namely PGD2, PGF2α and TXA2 that have 
bronchoconstrictive effects and inhibitory PGs such as PGE2 that can inhibit bronchoconstrictive 
responses and release of bronchoconstrictive mediators (Claar, Hartert et al. 2015). The PGs are 
metabolised further primarily through 15-hydroxy dehydrogenation by 15-PGDH and Δ13 
reduction by 13-15 ketoprostoglandin reductase  (13-PGR). Oxidation of TXB2 follows another 
pathway catalysed by 11-TXB2DH. The final metabolites are formed after subsequent β- and ω-
oxidation and excreted in the urine. 
All prostanoids act through distinct transmembrane, G-protein coupled receptors (GPCRs). The 
biological effects of PGD2 are mediated through DP1, DP2 that is also known as CRTH2 and TP 
receptors (Pettipher, Hansel et al. 2007). The bronchoconstrictive effects of PGD2 are mediated 
through the TP receptors (Coleman and Sheldrick 1989). PGD2 also has a chemotactic effect for 
eosinophils and TH2 lymphocytes, as well as a modulatory effect of TH2 cytokine production, 
which are mediated by PGD2 stimulation of the CRTH2 receptor (Hirai, Tanaka et al. 2001). The 
inhibitory prostanoid PGE2 acts through four GPCRs that are termed EP receptors 1 through 4. 
All four are expressed in the lungs and activation of EP2 and EP4 by PGE2 increased intracellular 
cAMP concentrations resulting in smooth muscle relaxation (Coleman, Smith et al. 1994). 
Stimulation of the EP2 receptor by PGE2 inhibits mast cell mediator release (Safholm, Manson et 
al. 2015) 
The synthesis of LTs begins when activated 5-lipoxygenase (5-LOX) translocate near the 
nuclear membrane where it interacts with 5-lipoxygenase-activating protein (FLAP). Although 
FLAP has no enzymatic activity, it enhances the ability of 5-LOX to convert AA to the unstable 
metabolite 5-hydroxyperoxyeicosatetranoic acid (5-HPETE). 5-HPETE can then be converted to 
5-HETE or to leukotriene A4 (LTA4) by 5-LOX. Depending on the type of cell, LTA4 can be 
then converted to leukotriene B4 (LTB4) (e.g. in neutrophils) or it can be conjugated with 
glutathione by leukotriene C4 (LTC4) synthase (e.g. in mast cells and eosinophils) in order to 
convert to LTC4. LTC4, which is the first of the family of the cysteinyl leukotrienes (CysLTs) is 
then exported from the cell. The released LTC4 is rapidly converted to leukotriene D4 and 
subsequently to leukotriene E4 (LTE4) by sequential amino acid hydrolysis. The largest part of 
LTE4 is eliminated through the faecal route, while about 20% is excreted into the urine within 24 
hours (Maltby, Taylor et al. 1990). 
There is well-documented pharmacological evidence confirming the existence of two receptor 
subtypes for the CysLTs, namely CysLT1 and CysLT2. The nomenclature was based on the fact 
that the CysLT1 receptor was sensitive to inhibition by classical antagonists like zafirlukast, 
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pranlukast and montelukast, whereas the effects mediated by the CysLT2 receptor were not 
inhibited by these antagonists (Back, Dahlen et al. 2011). They belong to the rhodopsin family 
of the GPCR gene and are located on the outer plasma membrane of various structural and 
inflammatory cells (e.g. mast cells, eosinophils, neutrophils, smooth muscle cells). When 
CysLTs are ligated to the receptor, there is an increase in intracellular calcium and reductions in 
intracellular cAMP that activates kinase cascades downstream. The CysLT1 receptor has an 
important role in asthma pathophysiology and upon activation mediates bronchoconstriction, 
mucous secretion and airway oedema. The CysLT2 receptor is not involved in 
bronchoconstriction but may contribute to increased inflammation, vascular permeability and 
tissue fibrosis (Back, Dahlen et al. 2011). 
 
Figure 2: Simplified overview of eicosanoid metabolism. Underlined metabolites can be measured 
in urine. Reproduced with permission from Balgoma et al 2013. 
3.3.2 Urinary excretion of lipid mediators 
Measurement of eicosanoids is a challenge due to the fact that they are very rapidly metabolised 
and removed from the circulation (Samuelsson, Granstrom et al. 1975). In addition, it has been 
shown that it is difficult to measure them in the blood because some eicosanoids like TXB2 can 
be produced ex vivo when withdrawing the blood sample (Patrono, Ciabattoni et al. 1986). 
Hence, measurement of the different eicosanoid metabolites in the urine has been used as 
alternative method. Primary PGD2 is not detectable in urine, instead a variety of metabolites 
have been discovered. The earliest metabolite was 11β-PGF2α that has some biological activity 
and is further metabolised to 2,3-dinor,11β-PGF2α. The most abundant PGD2 metabolite in the 
urine is tetranor-PGDM. For PGE2 it is demonstrated that a very small part of the primary 
mediator is measured in the urine and that the main measured metabolite is tetranor-PGEM. 
Likewise, TXB2 was measured in small amounts and 11-DH-TXB2 and 2,3-dinor-TXB2 are the 
major metabolites. The terminal product of the CysLT metabolism, namely LTE4 is also 
measured in the urine. The method of measuring lipid mediator metabolites in the urine is now 
widely accepted and has been used for many years in the bronchoprovocation setting in order to 
investigate important pathophysiological mechanisms in asthma (Kumlin, Dahlen et al. 1992, 
Dahlen and Kumlin 1998, Brannan, Gulliksson et al. 2003, Bood, Sundblad et al. 2015). In 
Craig&Wheelock&
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particular, measurement of PGD2 metabolites in the urine following an airway challenge is 
considered a sign of mast cell activation because PGD2 is released predominately by mast cells 
and to a very small proportion by macrophages.  
3.4 RATIONALE FOR THE PERFORMED STUDIES 
3.4.1 Exercise induced bronchoconstriction (EIB) 
Exercise induced bronchoconstriction (EIB) is defined as a syndrome, where airflow limitation 
lasting 30 to 90 minutes in the absence of treatment is triggered from a brief period of vigorous 
exercise. It is known that EIB is a common feature in asthma, with much higher prevalence up to 
70% among elite-athletes in some studies, depending on the implemented methods (Parsons, 
Hallstrand et al. 2013). Exercise-related symptoms have a substantial impact on daily life and 
about 45% of adults with asthma reported that they avoid physical activities due to symptoms 
(Parsons, Craig et al. 2011). 
3.4.1.1 Pathogenesis of EIB 
It is useful to think of EIB as an asthma component and not an isolated disorder; because 
exercise itself does not cause asthma, the often-used term “exercise-induced asthma” should be 
avoided. It is well established that a similar reaction in the airways can be triggered by increase 
in ventilation or by using hypertonic aerosols like mannitol, that activate the same pathways. 
The amount of ventilation, as well as the water content and temperature of the inspired air are 
critical factors for the development of EIB. At tidal breathing at rest, minimal conditioning of 
the inspired air takes place beyond the upper airways and the trachea, while during periods of 
high ventilation large amounts of incompletely conditioned air penetrate the lower airways over 
a short period, leading to water loss from the airway surface with resulting stress to the 
epithelium (Anderson and Schoeffel 1982, Zawadski, Lenner et al. 1988, Gilbert and McFadden 
1992). As water is moved from the airways, the osmotically sensitive epithelium rapidly corrects 
the osmolarity of the airway surface liquid through water movement (Tarran 2004). Though this 
hyperosmolarity through evaporative water loss is transient (Kotaru, Hejal et al. 2003), it serves 
as the initial stimulus to the epithelium for subsequent release of adenosine tripshosphate (ATP), 
which through specific GPCRs activates chloride channels and increases intracellular calcium 
(Tarran 2004). This epithelial stress/injury is demonstrated by an increased concentration of 
columnar epithelial cells in induced sputum in asthmatics with EIB compared to asthmatics 
without EIB (Hallstrand, Moody et al. 2005a). Not only epithelial cells, but also mast cells are 
activated from hyperosmolar stimuli. It is known that after an exercise challenge histamine and 
the mast cell protease tryptase are released in the airways (Hallstrand, Moody et al. 2005b). 
Release of bronchoconstrictive eicosanoids such as CysLTs and PGD2 is also increased after 
exercise challenge (O'Sullivan, Roquet et al. 1998) and pre-treatment with the mast cell 
stabilizing drug sodium cromoglycate has a protective effect against mannitol-induced 
bronchoconstriction (Anderson, Brannan et al. 2010), thus supporting the key role of mast cells 
in the pathogenesis of EIB. 
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3.4.1.2 Diagnosis and treatment of EIB 
The diagnosis of EIB should be made by changes in lung function provoked by exercise and 
should not be based only on exercise related symptoms, which are neither sensitive nor specific 
in order to identify subjects with EIB (Parsons, Hallstrand et al. 2013). It is recommended that 
an indirect challenge (e.g. exercise with dry air or a surrogate challenge) should be performed to 
establish EIB diagnosis instead of a direct challenge (e.g. methacholine), due to the higher 
sensitivity to detect EIB (Parsons, Hallstrand et al. 2013, Weiler, Brannan et al. 2016). Surrogate 
challenges include EVH, inhalation of dry powder mannitol or hyperosmolar aerosols of 4.5 % 
saline and are considered easier to perform compared to the exercise challenge. 
Inhalation of a β2 agonist, SABA or LABA, prior to exercise or after EIB has occurred is 
effective in reducing or even abolishing EIB (Jones, Wharton et al. 1963, Anderson, Caillaud et 
al. 2006). Nonetheless, it is known that with regular treatment, the bronchoprotective effect of β2 
agonists diminishes over time and does not offer the same degree of protection as after the first 
dose (Cheung, Timmers et al. 1992, O'Connor, Aikman et al. 1992). In subjects with insufficient 
control, despite using β2 agonists prior to exercise, the addition of controller medications, such as 
ICS or LTRAs is recommended (Parsons, Hallstrand et al. 2013). Although both ICS and 
LTRAs can reduce the degree and severity of EIB, they do not completely abolish it, meaning 
that subjects still need to rely on their SABA for symptom relief. If it is taken in mind that these 
subjects have predominately mild asthma with no other or minimal asthma symptoms, besides 
the ones that are triggered by exercise, this treatment option would lead inevitably to poor 
adherence to the therapy. An alternative treatment option, which is investigated in Paper I is the 
use of a fixed combination of ICS with a LABA that has a rapid onset of action, like 
budesonide/formoterol (bud/form) taken on demand i.e. before exercise and for symptom relief. 
3.4.2 Asthmatic response to allergen and anti-IgE therapy 
3.4.2.1 Early and late asthmatic response to inhaled allergen 
In the airways sensitization begins when antigen-presenting cells and dendritic cells (DCs) 
detect the inhaled allergen through their FcεRI receptors and present it to naïve T-cells that 
stimulate the development of Th2 cells. These release a variety of type-2 cytokines (IL-4, IL-5, 
IL-9 and IL-13) that promote IgE production, eosinophil production and maturation, mast cell 
development as well as goblet cell hyperplasia and increase in AHR (Gauvreau, El-Gammal et 
al. 2015). These cytokines can be also released from other cells, e.g. type II innate lymphoid 
cells (ILC2). The response to inhaled allergen is initiated when IgE that is bound to FcεRI 
receptors on the surface of mast cells and basophils cross-links to the allergen leading to mast 
cell degranulation and release of preformed mediators, such as histamine and chemotactic 
factors, as well as activation of the eicosanoid pathways and release of newly formed mediators, 
such as CysLTs and PGD2. These mediators are potent bronchoconstrictors and are responsible 
for the EAR, which is observed shortly after an allergen challenge, reaches max at 10 to 20 
minutes or slightly later and resolves spontaneously by 2 to 3 hours (O'Byrne, Dolovich et al. 
1987). EAR slightly resembles exercise in its time course although it is more prolonged. 
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Approximately 30 to 50% of subjects challenged with inhaled allergen will also develop a late 
asthmatic response (LAR). The LAR consists of an episode of airway obstruction that appears 
after the spontaneous resolution of the EAR, which is usually about four to five hours but can be 
measured up to 8 to 12 hours after an allergen challenge (Diamant, Gauvreau et al. 2013). The 
type of the allergen used for the challenge seems to have importance for the development of 
LAR, with house dust mites inducing a greater response than animal allergens and pollens 
(Boulet, Gauvreau et al. 2015). The bronchoconstriction observed during the LAR is also caused 
by release of histamine and CysLTs and treatment with a combination of antihistamine and 
antileukotriene predominately inhibited both responses to inhaled allergen (Roquet, Dahlen et al. 
1997, Davis, Illamperuma et al. 2009). Nonetheless, mast cell activation and degranulation is not 
the only important mechanism involved in the airway response to allergen; it is known that LAR 
is related to eosinophilic airway inflammation measured in BAL (Djukanovic, Feather et al. 
1996), as well as in sputum (Gauvreau, Watson et al. 1999) and release of type-2 cytokines. It 
has been shown that asthmatics that develop isolated EAR have a smaller increase in sputum 
eosinophils compared to those that develop LAR with the same degree of bronchoconstriction 
(Imaoka, Gauvreau et al. 2011) and that exercise, which also activates the mast cell does not 
cause eosinophilic inflammation (Gauvreau, Ronnen et al. 2000). Another important mechanism 
involved in the allergen-induced responses is the role of DCs, which are the most potent antigen-
presenting cells in the airways and are also involved in the regulation of the allergen response in 
the airways. In fact, it is shown that after an allergen challenge in asthmatics, there is a rapid 
reduction of circulating DCs in the blood (Upham, Denburg et al. 2002) with a subsequent 
increase in the bronchial mucosa (Moller, Overbeek et al. 1996) and in induced sputum 24 hours 
after the challenge (Dua, Watson et al. 2010). 
3.4.2.2 Treatment with anti-IgE 
Thus, it is evident that the interaction of IgE with its receptors is crucial for the development of 
both the EAR and the LAR after allergen inhalation. This has led to the approach of developing 
antibodies that are directed against the region of the IgE molecule that binds to the IgE receptors 
and hence interrupts the allergic cascade by preventing IgE binding with FcεRI receptors on 
mast cells, basophils, DCs and other inflammatory cells. Omalizumab is a humanized anti-IgE 
monoclonal antibody directed against an epitope on the constant region (Cε3) of the IgE 
molecule, which is the region that binds to the IgE receptors. Omalizumab does not interact with 
the variable allergen-specific region of IgE and that is why it inhibits the allergic response 
regardless of allergen specificity. Moreover, omalizumab does not bind to cell-bound IgE 
because in those IgE the epitope is already attached to the receptors and thus avoids FcεRI 
crosslinking that could increase the anaphylaxis risk (Holgate, Casale et al. 2005). This binding 
of IgE by omalizumab leads to a rapid decrease in serum free IgE, that in turn causes a 
downregulation of FcεRI surface expression on effector cells, such as mast cells, basophils as 
well as DCs (MacGlashan, Bochner et al. 1997, Prussin, Griffith et al. 2003, Beck, Marcotte et 
al. 2004). This reduction of FcεRI expression on mast cells contributes to further dampening of 
the effector cell response to allergen, as well as reduced facilitated allergen presentation by DCs 
(Oliver, Tarleton et al. 2010, Kuhl and Hanania 2012). 
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Omalizumab has been effective in inhibiting both the EAR and the LAR following an allergen 
inhalation challenge in previous studies (Boulet, Chapman et al. 1997, Fahy, Fleming et al. 
1997, Zielen, Lieb et al. 2013). In addition, treatment with omalizumab has shown efficacy in 
reducing the allergen-induced responses on the skin. Using an intradermal allergen challenge 
model, it was shown that omalizumab given at the approved dose suppressed both the early and 
late phase allergen induced cutaneous response (Ong, Menzies-Gow et al. 2005). In the study by 
Corren et al, treatment with high doses of omalizumab given intravenously (i.v.) suppressed the 
allergen-induced wheal and flare reactions on skin prick tests, although this effect returned to 
baseline after discontinuation of treatment (Corren, Shapiro et al. 2008). Beyond the provocation 
setting, there are several studies that have investigated the clinical efficacy of omalizumab in 
subjects with moderate-to-severe allergic asthma. A pooled analysis of data from seven clinical 
trials with omalizumab (two open label and five double-blind, placebo controlled) showed that 
omalizumab reduced the rate of asthma exacerbations by 38 % and the rate of total emergency 
visits by 47 % (Bousquet, Cabrera et al. 2005). Moreover, omalizumab treatment reduced 
asthma symptoms and was associated with improvements in asthma-related quality of life as 
measured by the asthma quality of life questionnaire (AQLQ) in subjects with severe persistent 
asthma (Humbert, Beasley et al. 2005). 
However, omalizumab therapy has its caveats and some patients will not respond to treatment. 
In a 2-year real world effectiveness study with 943 patients with uncontrolled persistent asthma 
treated with omalizumab, 30.1 % were assessed as non-responders to treatment according to 
physicians global evaluation of treatment effectiveness (GETE) (Braunstahl, Chen et al. 2013). 
It is unclear why some subjects do not respond to omalizumab treatment, as it is also difficult to 
predict responders. Interestingly, Johansson et al (Johansson, Oman et al. 2006) reported that 
specific IgE antibodies to allergens, such as cat and house dust mite, consisted a much higher 
fraction of total IgE in patients with low serum IgE levels (30-74 kU/L) compared to patients 
with higher levels. Using a mathematical model the authors concluded that despite suppression 
of serum IgE to 10 kU/L or lower, 25 % of this population would still have enough 
concentrations of specific IgE in order to elicit an allergic response. Because omalizumab dosing 
depends on bodyweight and the amount of total IgE, these results indicate that the recommended 
dose of omalizumab would be insufficient for those patients and higher doses would be 
necessary. An alternative approach in this group of patients would be to use the basophil 
allergen threshold sensitivity test (CD-sens), as a means to monitor omalizumab treatment more 
effective (Nopp, Johansson et al. 2006, Dahlen, Nopp et al. 2011). 
Nonetheless, it is evident that there is a need for better and more effective anti-IgE treatment. 
Correlations between free IgE levels and asthma symptoms indicate that more effective IgE 
suppression leads to better asthma control and more clinical benefits (Lowe, Tannenbaum et al. 
2009). QGE031 (ligelizumab) is a fully humanized monoclonal antibody that binds to the Cε3 
domain of IgE with higher affinity than omalizumab and is designed to suppress free IgE and 
IgE bound to mast cells and basophils in greater extent than omalizumab (Arm, Bottoli et al. 
2014). In Paper II the efficacy of QGE031 to suppress the EAR after an allergen inhalation 
challenge was compared to omalizumab and placebo.  
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3.4.3 What is known about the role of LTE4 in asthma 
The CysLTs are potent bronchoconstrictors of human airways (100 to 1000 times more potent 
than histamine) with equal potency of LTC4 and LTD4 (Adelroth, Morris et al. 1986). LTE4 is 
the most stable and abundant CysLT in vivo and LTE4 has been detected in BAL fluid and urine 
in patients with severe asthma, acute asthma exacerbations as well as aspirin exacerbated 
respiratory disease (AERD) (Christie, Tagari et al. 1991, Kumlin, Dahlen et al. 1992, Vachier, 
Kumlin et al. 2003, Green, Malice et al. 2004, Austen, Maekawa et al. 2009). LTE4 is also a 
potent bronchoconstrictor in human subjects (Davidson, Lee et al. 1987), although its potency as 
agonist of the two known CysLT receptors is variable (Lynch, O'Neill et al. 1999, Heise, 
O'Dowd et al. 2000). Although LTE4 is similar to LTC4 and LTD4 in its bronchoconstrictor 
activity, it has been reported to have a unique relationship with one of the cardinal features of 
asthma, namely AHR. Previous studies suggest that airway responsiveness to inhaled LTC4 and 
LTD4 is relatively greater in healthy than in asthmatic subjects (Holroyde, Altounyan et al. 1981, 
Weiss, Drazen et al. 1982, Griffin, Weiss et al. 1983), whereas subjects with asthma are 
relatively more sensitive to LTE4. Accordingly, asthmatic subjects were 26 times more sensitive 
to inhaled LTE4 than healthy subjects, whereas they were only 7 times more sensitive to 
methacholine and histamine, suggesting that asthmatic airways selectively might be 
hyperresponsive to LTE4 in contrast to other CysLTs (O'Hickey, Arm et al. 1988). This 
observation was confirmed and extended in a subsequent study by the same investigators in 
which the relative potencies of LTC4, LTD4 and LTE4 were directly compared with those of 
histamine and methacholine in the same healthy and asthmatic subjects. Compared with healthy 
subjects, the airways of the asthmatic subjects were on average only 14-fold more responsive to 
inhaled histamine, 16-fold more responsive to methacholine, 6-fold more responsive to LTC4 
and 9-fold more responsive to LTD4 but 219-fold more responsive to LTE4 supporting that the 
mechanism of the bronchoconstriction induced by LTE4 might be distinct from that produced by 
LTC4 and LTD4, and possibly reflecting functionally important CysLT receptor heterogeneity 
(Arm, O'Hickey et al. 1990).  
In addition to bronchoconstriction there seem to exist also differences in the pro-inflammatory 
effects of CysLTs; inhalation of LTE4 increased the number of eosinophils in both sputum and 
airway mucosa in patients with mild asthma (Laitinen, Laitinen et al. 1993a, Gauvreau, 
Parameswaran et al. 2001, Laitinen, Lindqvist et al. 2005), whereas LTD4 was not as effective 
(Mulder, Gauvreau et al. 1999). These observations has led to the theory that there might be a 
third separate receptor that could be controlling the pro-inflammatory effects and the 
eosinophilic response to LTE4. Experiments with CysLT1 and CysLT2 receptor double knockout 
mice have shown the existence of a pro-inflammatory pathway independent of these two 
receptors having ligand specificity for LTE4 (Maekawa, Kanaoka et al. 2008). Further 
experimental studies on mice have tried to identify such a receptor with the ADP-reactive 
platelet P2Y12 receptor being one candidate (Paruchuri, Tashimo et al. 2009). Moreover, studies 
in genetically modified mice have identified GPR99 as a predominantly epithelial receptor that 
is distinctly sensitive to LTE4; mice lacking all three receptors i.e. CysLT1, CysLT2 and GPR99 
lost all ability to respond to CysLTs, including LTE4 (Kanaoka, Maekawa et al. 2013). Similarly, 
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in experiments in mice it was shown that GPR99 was expressed in respiratory epithelial cells 
and mediated mucin release in response to LTE4 (Bankova, Lai et al. 2016). This has however 
not been confirmed in human subjects; current LTRAs such as montelukast target only the 
CysLT1 receptor and may thus not provide sufficient anti-inflammatory effect against inhaled 
LTE4. All in all, if the hypothesis of a functionally important and distinct LTE4 receptor is 
correct, there will be a scientific rationale to develop broader antagonists of CysLTs that also 
block such a receptor. In Paper III an inhalation challenge with LTE4 in subjects with mild 
asthma was performed prior to and after treatment with montelukast, in order to further elucidate 
the role of LTE4 in asthma and airway inflammation. 
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4 MATERIAL AND METHODS 
4.1 SUBJECTS AND STUDY DESIGN 
Paper I 
 
Figure 3. Study design Paper I 
The aim of Paper I was to evaluate the magnitude of the bronchoprotective effect of three 
different pharmacological treatments on EIB in adults and adolescents with mild intermittent 
asthma. Regular daily treatment with budesonide and terbutaline on demand (arm A) was 
compared with terbutaline inhaled on demand (arm B), which still is the currently recommended 
treatment, and with a fixed combination of bud/form inhaled only on demand (arm C). On 
demand means that subjects inhaled the medication before exercise and for symptom relief. The 
hypothesis was that treatment with the fixed combination on demand would be superior to 
monotherapy with terbutaline on demand and non-inferior to regular budesonide treatment with 
terbutaline on demand regarding protection against EIB. 
Sixty-six subjects with mild asthma according to the guidelines at the time of the study 
(Bateman, Hurd et al. 2008) were recruited from 10 study sites in Sweden and Norway. Subjects 
performed physical exercise three to four times per week and had a history of EIB using a 
reliever medication also for prevention up to four times per week. Adolescents were ≥ 12 years 
of age and all subjects had a FEV1 greater than 80% of the predicted normal value (Solymar, 
Aronsson et al. 1980, Quanjer, Tammeling et al. 1993). The study was registered at 
ClinicalTrials.gov (NCT00989833). 
On the first screening day spirometry, a standard skin prick test, physical examination and a 
maximal exercise test on a treadmill were performed while breathing ambient air in order to 
calculate the maximal aerobic capacity. Control of vital signs, medical history, concomitant 
 18 
medications was also conducted and all subjects filled out a shortened version of the Asthma 
Control Questionnaire ACQ5 (Juniper, Svensson et al. 2005). The ACQ5 was also filled at visits 
3, 4 and 6.  
On the second screening day, a six-minute standardized exercise test on a treadmill at 90% of 
maximal aerobic capacity was performed, while subjects were breathing dry air. FEV1 was 
measured up to 30 min after exercise cessation. If a fall of ≥10% compared to pre-exercise value 
was recorded, the subject was included. At the third visit a mannitol bronchial challenge was 
performed, and subjects were randomized to one of the three treatment arms. They also gained 
access to an electronic diary for daily recording of physical exercise, asthma symptoms, and use 
of as needed medication. They were instructed to perform physical exercise three to four times 
per week, and use the as needed medication for prevention and treatment of asthma symptoms 
during exercise. The six-minute standardized exercise test was repeated three weeks (visit 4) and 
six weeks (visit 5) after randomization to treatment. The mannitol bronchial challenge was 
repeated at visit 6.  
All subjects abstained from asthma medications 24 hours prior to all exercise tests, thus the aim 
was not to study the direct effect of treatment on EIB but the long-term bronchoprotective effect 
of the medication given.  
Paper II 
 
Figure 4. Study design Paper II 
The aim of Paper II was to compare the potency of a new anti IgE drug QGE031 (ligelizumab) 
with omalizumab and placebo in inhibiting the early asthmatic response (EAR) to inhaled 
allergen. The efficacy of three doses of QGE031 in inhibiting EAR as well as the 
pharmacokinetics, pharmacodynamic effects of QGE031 on total IgE, basophil bound IgE, 
basophil FcεRI levels and skin prick test responses to allergen were also assessed. The 
hypothesis was that treatment with the highest dose of QGE031 (240mg) would be more 
effective in inhibiting EAR compared to omalizumab at the end of the treatment period.  
Thirty-seven subjects with mild allergic asthma were recruited from 7 study sites in Canada and 
Sweden, of which thirty-five completed the study. All subjects had at the time of the 
investigation well-controlled or asymptomatic asthma with a FEV1 ≥ 70% of predicted and only 
use of rescue SABAs no more than twice a week, with the exception of in conjunction with 
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exercise. Atopy was documented by the presence of a positive skin prick test to one or more 
common airborne allergens. The study was registered at ClinicalTrials.gov (NCT01703312). 
The study consisted of a 28-day screening period, a baseline evaluation, a treatment period of 10 
weeks, a follow up period of 12 weeks and a study completion evaluation (Figure 4). At 
screening, a standard skin prick test as well as skin prick titrations and a methacholine inhalation 
challenge were performed. For inclusion in the study, the provocative concentration of inhaled 
methacholine to reduce FEV1 by 20% (methacholine PC20) should be 16mg/ml or less. At 
baseline, an allergen inhalation challenge was performed where subjects should demonstrate a 
decrease in FEV1 ≥ 15% from baseline within two hours of the challenge. The allergen PC15 was 
calculated. Eligible subjects were then randomized to receive one of three subcutaneous doses of 
QGE031 (24, 72 or 240 mg), omalizumab or matching placebo for 10 weeks. QGE031 was 
administered every two weeks (six doses) and omalizumab every two or four weeks (three or six 
doses) depending on bodyweight and screening IgE levels. An allergen inhalation challenge as 
well as skin titrations were performed 6, 12 and 18 weeks after the first dose and allergen PC15 
was calculated. Blood samples were collected throughout the study for measurements of serum 
total QGE031, total IgE, basophil bound IgE and FcεRI levels on basophils and DCs. 
Paper III 
 
Figure 5. Study design Paper III. * LTE4 challenge. 
The aim of Paper III was to investigate whether the effect of inhaled LTE4 in asthmatics is 
mediated solely via the CysLT1 receptor or if there is possibly another receptor involved as 
indicated by previous animal studies. In order to answer that question a double blind, 
randomized, placebo-controlled study with a crossover design was performed, where asthmatic 
subjects inhaled LTE4 before and after treatment with the potent CysLT1 receptor antagonist 
montelukast or matching placebo (Figure 5). The hypothesis was that if there were a functionally 
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important and distinct LTE4 receptor for chemotaxis, treatment with montelukast would block 
the bronchoconstriction but not the cellular response induced by inhaled LTE4. 
Fourteen subjects with mild intermittent asthma according to current Global Initiative for 
Asthma guidelines (GINA report 2015) and two subjects with aspirin-exacerbated respiratory 
disease (AERD) with a history of unequivocal severe bronchoconstriction after intake of aspirin-
like drugs were included. All subjects had well-controlled asthma using only rescue SABAs no 
more than twice a week with the exception of the two AERD patients who were on regular 
treatment with a fixed combination of ICS/LABA. Subjects were 18-55 years of age with FEV1 
at screening more than 70% of predicted. The study was registered at ClinicalTrials.gov 
(NCT01841164). 
Spirometry for measurement of baseline lung function as well as measurement of FENO was 
performed on all study days. On the first screening day a standard skin prick test, physical 
examination and a methacholine inhalation challenge were performed during which eligible 
subjects would display a fall in FEV1 of 20% or more from baseline after inhalation of ≤ 3621 µg 
cumulated dose of methacholine (methacholine PD20). Blood samples for routine laboratory tests 
were also collected. Subjects were then scheduled for the next screening day after at least 24 
hours, when the first inhalation challenge with LTE4 was performed. The provocation was 
terminated when FEV1 had fallen at least by 20% from baseline value or the maximum dose of 
LTE4 was reached. Blood samples were collected five minutes after inhalation of the last dose of 
LTE4 for analysis of circulating white blood cells.  
After a washout period of one to two weeks subjects continued in the crossover phase where 
they were randomized to treatment with montelukast or placebo for five to seven days. 
Inhalation challenge with LTE4 was then repeated on the last day of each treatment period. 
Impulse oscillometry (MS-IOS) was conducted prior to spirometry in order to examine the effect 
of inhaled LTE4 on small airways. 
Urine samples were collected before, during and after the end of the challenge at hourly intervals 
for up to four hours for measurement of lipid mediator excretion. Sputum induction was 
performed four hours after the end of the challenge for calculation of sputum cell counts. In 
order to validate the results regarding excretion of lipid mediators in the urine, we also analysed 
urine samples from one of our previous bronchoprovocation studies with LTD4 (Gyllfors, 
Kumlin et al. 2005), that included asthmatics with mild asthma using ICS (n=10), asthmatics 
using only rescue SABAs (n=10) as well as healthy individuals (n=10). These samples had been 
biobanked at -20 °C for 12 years. 
4.2 ETHICS 
All studies were approved from the local Ethics Committees (Dnrs 2009/920-31/2, 2012/2180-
31/2 and 2011/1016-31/1). All participants gave their written informed consent prior to 
inclusion. 
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4.3 BRONCHIAL PROVOCATIONS 
As already mentioned, airway hyperresponsiveness (AHR) is a key asthma characteristic that 
can be used in the research lab to study a controlled asthma attack with the use of different 
bronchial provocations. This temporary flare up of the disease gives us unique possibilities to 
study asthma pathophysiology, cellular interactions and mediator release. In my thesis bronchial 
provocations have been in the heart of every performed study and the methodology that was 
used is described in detail below.  
4.3.1 Exercise challenge 
The exercise challenge was performed in Paper I and was used to identify and quantify EIB. It 
is standardized according to the American Thoracic Society´s guidelines (ATS) (Crapo, 
Casaburi et al. 2000). The type, duration, intensity of exercise, as well as the temperature of the 
water content of the inhaled air, are important factors that determine the airway response, as 
established by previous studies (Bar-Or, Neuman et al. 1977, Chen and Horton 1977, Anderson, 
Daviskas et al. 1979, Anderson, Schoeffel et al. 1982). The challenge can be conducted using a 
treadmill or a cycle ergometer, although the rapid increase in ventilation during treadmill 
running makes it the preferable test. The patient should wear nose clips during the challenge 
because nasal breathing decreases water loss from the airways (Shturman-Ellstein, Zeballos et 
al. 1978, Mangla and Menon 1981). Most protocols recommend that the inspired air is dry (<10 
mg H2O/L) and less than 25oC. The system delivers dry air through a mouthpiece and a two-way 
valve from a talc-free meteorological balloon filled with medical-grade compressed air 
(Eggleston, Rosenthal et al. 1979). Treadmill speed and inclination are progressively increased 
during the first two to three minutes of exercise until target ventilation is achieved. The target 
should be at least 17.5 times FEV1 and preferably greater than 21 times FEV1 (Anderson, 
Lambert et al. 2001). This load should be maintained for four to six minutes (ERS 1997). 
Another important factor is that subjects must abstain from exercise before the challenge, 
because some become refractory to another exercise stimulus for up to 4 hours (Anderson and 
Schoeffel 1982, Haverkamp, Dempsey et al. 2005). The lowest FEV1 value within 30 minutes 
after exercise is recorded and the difference between this value and the pre-exercise FEV1 value 
is expressed as a per cent of the pre-exercise value. The cut-off for the per cent fall in FEV1 for a 
positive challenge is ≥10% in most guidelines (Sterk, Fabbri et al. 1993, Crapo, Casaburi et al. 
2000, Carlsen, Anderson et al. 2008). The ≥10% fall in FEV1 is based on the mean plus two 
standard deviations (SDs) of the per cent fall in normal healthy subjects without a family history 
of asthma, atopy or recent respiratory track infection (Custovic, Arifhodzic et al. 1994, 
Anderson, Pearlman et al. 2010). The severity of EIB can be graded as mild if the per cent FEV1 
fall is ≥10% but <25%, moderate if it is greater than 25% but <50% and severe if the fall is 
≥50% (Anderson and Brannan 2003). 
All subjects in Paper I during screening performed a maximal exercise test on a treadmill, while 
breathing ambient air according to a predefined protocol starting at 50 Watts (W), which was 
then increased by 10 or 15 W (depending on body weight) every minute. Heart rate was 
monitored by ECG and registered during the last 15 seconds of each workload level. Dyspnoea 
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and leg fatigue were registered according to the Borg CentiMax scale (CR100) at every second 
workload (Borg and Kaijser 2006). Maximal heart rate and the maximal aerobic capacity 
(workload) were registered. The workload at which subjects stopped was used to calculate the 
workload for the standardised exercise challenges. They were also performed on a treadmill 
while breathing through a tube connected to a gas cylinder containing dry air as recommended in 
the guidelines (Aiolos Astmatest, Aiolos Medical AB, Karlstad, Sweden). The workload was 
gradually increased from 60% to 90% of max during the first two minutes and then sustained at 
90% for the remaining four minutes of the test that lasted in total six minutes. The target 
ventilation was set to 26 times FEV1. During the challenge, patients used nose clips and were 
encouraged to cover the mouthpiece with their mouth and keep the balloon inflated at all times. 
FEV1 was measured before exercise and 1, 5, 10, 15 and 30 min afterwards. No asthma 
medication was allowed 24 hours prior to exercise, nor any physical exercise.  
4.3.2 Methacholine challenge 
Methacholine, which is a muscarinic agonist activating M3 receptors in the airways, is used to 
help assess the severity of AHR in subjects with symptoms consistent with asthma. It is the most 
commonly used direct bronchial challenge and it has almost replaced histamine, which is 
associated with more systemic adverse events such as headache and flushing (Scott and Braun 
1991). All challenge protocols use a progressive dosing regimen and focus mostly on 
standardized dose delivery. The American Thoracic Society (ATS) published in 2000 details on 
two frequently used methacholine challenge methods (Crapo, Casaburi et al. 2000). 
In Paper II the challenge was performed according to Clinical Investigators Collaborative (CIC) 
protocol using a Wright nebulizer (Roxon Medi-Tech, Montreal, Quebec, Canada) directly 
connected to a Hans Rudolph two-way valve in order to generate aerosols (Cockcroft 1985). The 
air source used for this purpose was wall unit hospital air supply. With this method the dose of 
aerosol deposited in the lung could be altered by the nebulizer output and the duration of 
inhalation. Each concentration of methacholine (0.031 up to 32 mg/mL) was inhaled during tidal 
breathing for two minutes. FEV1 was measured 30 and 90 seconds post inhalation and the per 
cent fall was calculated from the lowest baseline FEV1 value after diluent inhalation. The 
challenge was terminated when a FEV1 fall of at least 20% occurred or the highest concentration 
of methacholine was administered. The result was expressed as PC20 representing the 
concentration of methacholine that causes a fall in FEV1 of 20% and it was calculated from 
linear interpolation.  
In Paper III a dosimeter-controlled jet-nebulizer (Spira Elektro 2, Medela, Medical AB, Täby, 
Sweden) was used for inhalation of methacholine according to a slight modification of a 
protocol previously published (Nieminen, Lahdensuo et al. 1988). By changing the number of 
breaths and using different methacholine solutions, doubling increments of each dose were 
administered (Table 1). Methacholine was inhaled every third minute and a single FEV1 
measurement was performed at 2.5 minutes after each dose. The result was expressed as PD20 
representing the provocative dose causing a 20% fall from baseline post-diluent FEV1 and it was 
derived from linear interpolation between the two last doses. 
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Subjects abstained from using SABAs for at least six to eight hours and did not ingest any 
caffeine-containing beverages for four hours prior to the methacholine test. 
Methacholine 
concentration 
mg/mL 
No. Breaths Dose 
µg 
Log 
dose 
Cumulated dose 
1 
1 
1 
8 
8 
8 
64 
64 
64 
 2 
 4 
 8 
 2 
 4 
 8 
 2 
 4 
 8 
14.2 
28.4 
56.7 
114 
227 
454 
909 
1818 
3635 
1.15 
1.45 
1.75 
2.06 
2.36 
2.66 
2.96 
3.26 
3.98 
14.2 
42.6 
99.3 
213.3 
440.3 
894.3 
1803 
3621 
7256 
Table 1. Protocol for dosing of methacholine in Paper III (molar weight 160.24)  
4.3.3 Mannitol challenge 
Mannitol is a sugar alcohol and the inhalation of cumulative doses of mannitol has been 
developed as a standardized bronchoprovocation test (Anderson, Brannan et al. 1997), that is 
most often used as a surrogate measure of EIB (Brannan, Koskela et al. 1998, Brannan, 
Anderson et al. 2005). This is based on the osmotic theory of EIB pathogenesis i.e. that the 
hyperventilation that occurs during exercise leads to a hyperosmolarity of the airway lining fluid 
due to water evaporation, which in its turn causes bronchoconstriction due to mast cell activation 
(Anderson and Daviskas 2000, Brannan, Gulliksson et al. 2006). In Paper I the mannitol 
bronchial challenge was performed using the Aridol® provocation kit (Pharmaxis Ltd, Frenchs 
Forest, Sydney, Australia). Subjects were seated comfortably with a nose clip applied and were 
encouraged to maintain good posture in order to assist a better delivery of mannitol to the lungs. 
Mannitol was provided in capsules with different doses (0, 5, 10, 20, 40 mg) with a single 
capsule inserted in the Osmohaler™, one at a time. The higher doses of mannitol were given as 
multiples of smaller individual doses according to a protocol provided by the manufacturer. 
FEV1 was measured in duplicate to obtain reproducibility one minute after each step and the 
highest value recorded after inhalation of the first capsule (0 mg) was used as baseline FEV1. 
The challenge was considered as positive if there was a fall in FEV1 more than 15% from 
baseline and the PD15 was calculated or if a 10% fall occurred in-between consecutive doses. If 
the maximal cumulative dose of 635 mg mannitol was attained without reaching any of these 
endpoints, the challenge was considered as negative. The airway response to mannitol was 
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measured prior to (visit 3) as well as after six weeks of treatment (visit 6) and was used as an 
explorative variable in the study where the primary outcomes were published (Paper I).  
4.3.4 Allergen challenge 
Bronchoprovocation challenges using allergen aerosols have been used widely over the past 60 
years to examine both the early (EAR) as well as the late asthmatic reaction (LAR). In Paper II 
subjects inhaled doubling concentrations of aqueous allergen extracts (Aquagen SQ® ALK 
Nordic, Copenhagen, Denmark) using a Wright nebulizer according to CIC`s protocol (O'Byrne, 
Dolovich et al. 1987). Nebulizer output was the same as the one used for methacholine with 
duration of inhalation of 2 minutes under tidal breathing. The allergen chosen depended on the 
greatest reaction recorded on the skin prick test and the individual reported symptoms to 
previous exposure. Skin prick titration with two-fold increasing concentrations of the chosen 
allergen extract were performed in duplicate on the volar surface of one or both forearms in 
order to define the skin prick test endpoint (SS) i.e. the lowest titration of allergen that causes a 
skin wheal at least 2 x 2 mm in size. The predicted PC20 allergen was then calculated from the 
methacholine PC20 and the SS by simple linear regression (Cockcroft, Murdock et al. 1987, 
Cockcroft, Davis et al. 2005). The starting concentration of allergen extract for inhalation at 
baseline would be two to four doubling concentrations below the predicted PC20 allergen. 
FEV1 was measured twice (30 and 60 sec intervals) at 10 minutes after each inhalation of 
allergen. If FEV1 had fallen less than 10% from baseline, the next concentration was given. If the 
fall was between 10 and 15% a new measurement was done 10 minutes later. If it remained the 
same or if FEV1 started to rise, the next concentration of allergen was administered. The test was 
stopped when FEV1 had fallen by 15% or more and the allergen PC15 was calculated using linear 
interpolation. If FEV1 at the highest concentration of allergen had fallen by 8% to 14% then PC15 
was extrapolated using the following formula PC15=concentration x (15/% fall in FEV1). If 
FEV1 at the highest concentration of allergen had fallen by 0% to 7% the next doubling 
concentration was used.  
4.3.5 Leukotriene E4 challenge 
Challenges with CysLTs are used almost exclusively in research due to the high cost of their 
production. Early studies confirmed that CysLT1 receptor antagonists could inhibit the 
bronchoconstriction induced by inhalation of LTD4 (De Lepeleire, Reiss et al. 1997). Formal 
evaluations of the repeatability and sample size requirements for leukotriene inhalation 
challenges have not been published. There is considerable and unique experience with these 
challenges in our lab (Kumlin, Dahlen et al. 1992, Gyllfors, Kumlin et al. 2005, Gyllfors, Dahlen 
et al. 2006), to support that the leukotriene challenge is highly repeatable and considerable less 
variable than the exercise challenge. Moreover, a rising dose challenge is more repeatable than a 
fixed dose challenge (Kumlin and Dahlen 2000). 
In Paper III, GMP grade LTE4 was purchased from Cayman Chemicals Corp (USA, Ann Arbor 
Michigan) in color-coded vials with ten fold increasing concentrations from 0.042 to 4200 
µmol/L dissolved in ethanol-water (Figure 6). The leukotriene was administered for inhalation 
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after nebulization by a dosimeter-controlled jet-nebulizer (Spira Elektro 2, Respiratory Care 
Center, Hameenlina, Finland). By using five or sometimes six different solutions of LTE4 and by 
variations in the number of tidal breaths (normally 1 to 7), stepwise increments of the 
cumulative dose of LTE4 were administered (Table 2). The LTE4 solution was inhaled every 10 
minutes with approximately half-log dose increments administered at every step. FEV1 was 
obtained at 5 and 10 minutes after each dose increment. The provocation was terminated when 
FEV1 had fallen 20% from baseline or the maximum dose of LTE4 had been reached. If FEV1 
was reduced between 15 and 19%, the investigator waited 5-10 minutes and reassessed the FEV1 
before further increases in the dose of LTE4. If the drop in FEV1 remained just below 20%, the 
responsible physician would make a decision as to whether or not the next dose should be given. 
In subjects with a steep dose-response curve for LTE4 it was recommended to repeat the 
previous dose once more before giving the next dose in the protocol. After a positive reaction, 
FEV1 was followed every 15 minutes during the first hour, thereafter at hourly intervals 
according to the protocol. Dose-response relations for LTE4 were constructed and used for 
calculation of the LTE4PD20. The lowest FEV1 measurement at 5 or 10 minutes after each dose 
was plotted against the log-cumulated dose of LTE4. The PD20 value was derived from linear 
interpolation between the two last doses. 
 
Figure 6. Color-coded vials with increasing concentrations of LTE4 
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  Conc. LTE4   
 in nebuliser No. Of breaths Delivered dose          Cumulated dose  
      µM                            pmol                          pmol 
FOR EXTREMELY SENSITIVE SUBJECTS ONLY 
Yellow: 
 0.042 1 0.3 0.3 
 0.042 2 0.6 1 
 0.042 7 2.3 3 
NORMAL START LEVEL at screening 
Green:  
 0.42  1 3.4 3 
 0.42 2 6.7 10 
 0.42 7 23.5 34 
ED 0.42 14 47  
Turquoise: 
 4.2 2 67.5 100 
 4.2 7 235 336 
ED 4.2 14 473 
Blue: 
 42 2 672 1,008 
 42 7 2,350 3,360 
ED 42 14 4,700 
Lilac: 
 420 2 6,720 10,080 
 420 7 23,500 33,580 
ED 420 14 47,000 
Red solution: 
 4,200 2 67,200 107,800 
 4,200 7 235,000 335,780 
ED 4,200 14 470,000 
ED 4,200 21 705,000 
Table 2. Protocol for dosing of LTE4. ED: extra dose of LTE4 used if FEV1 decreased between 15% 
and 20% from baseline. 
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4.4 LUNG FUNCTION MEASUREMENTS 
In order to monitor how lung function was affected by the various challenges, spirometry was 
used. In particular, impulse oscillometry was included to determine the effect on small airways. 
4.4.1 Spirometry 
Spirometry was performed before, during and after each challenge, as well as on most of the 
study days according to the European Respiratory Society/American Thoracic Society 
guidelines (ATS 1995). Following a maximal inspiration subjects performed a fast and powerful 
exhalation manoeuvre whilst connected to a mouthpiece and wearing a nose clip. The forced 
expiratory volume in one second (FEV1), the forced vital capacity (FVC), the forced expiratory 
flow between 25% and 75% of FVC (FEF25-75) and the peak expiratory flow rate (PEFR) were 
recorded.  
4.4.2 Impulse oscillometry  
In Paper III, impulse oscillometry (MS-IOS, Jaeger, Friedberg, Germany) was performed 
according to current guidelines (Oostveen, MacLeod et al. 2003, Smith HJ 2005). Subjects were 
sitting upright with their hands supporting the cheeks wearing a nose clip. One-minute 
measurements were obtained during tidal breathing and airway resistance at 5 Hz (R5) and 20 Hz 
(R20), reactance at 5 Hz (X5), frequency dependence of resistance (FDR; R5-R20), area of 
reactance (Ax) and resonance frequency (Fres) were calculated. At least two technically 
acceptable recordings were performed on each subject, sequences with possible artefacts due to 
subject swallowing were excluded from analysis. 
 
Figure 7. Impulse oscillometry system used in Paper III 
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4.5 SKIN PRICK TESTING 
In all three papers skin prick testing was performed at screening to assess allergy; in Paper II a 
skin prick titration was also done over a range of dilutions just for the allergen extract that was 
chosen for the inhalation challenge. Standardized extracts of 10 common allergens (ALK Abello 
Soluprick SQ Allergen solution, Copenhagen, Denmark) were used with histamine (10mg/ml) as 
a positive, and the diluent as a negative control. Positive response was specified as a wheel 
diameter ≥ 3 mm. 
4.6  MEASUREMENT OF FENO 
Nitric oxide (NO) is produced by airway epithelial cells mostly through inducible NO synthase 
(iNOS) which is upregulated in asthmatic inflammation and suppressed by corticosteroid 
treatment (Dweik, Boggs et al. 2011). Measurement of the fraction of exhaled NO (FENO) at a 
fixed flow rate is a non-invasive test and is widely considered as a surrogate marker of 
eosinophilic inflammation (Barnes, Dweik et al. 2010, Bjermer, Alving et al. 2014). In Paper 
III FENO measurements (NIOX analyzer, Aerocrine AB, Solna, Sweden) were performed at a 
flow rate of 50 mL/s according to American Thoracic Society guidelines (Dweik, Boggs et al. 
2011) on all study days. 
4.7 SPUTUM INDUCTION AND PROCESSING 
Sputum is a safe, non-invasive and reproducible method of sampling airway secretions and 
associated cells from proximal airways (Pizzichini, Pizzichini et al. 1997, Szefler, Wenzel et al. 
2012). The processing of sputum allows for the investigation of the cellular and fluid space 
components to assess the current inflammatory state of the airways. The non-invasive nature of 
sputum induction gives the technique several advantages over other methods, such as 
bronchoalveolar lavage (BAL) and bronchial biopsy that involve bronchoscopy. It allows for 
repeated assessment of large number of subjects with varying degrees of airway obstruction. 
Sputum induction was performed in Paper III four hours after the end of the LTE4 challenge. 
Although relatively mild, sputum induction is de facto a bronchoprovocation procedure. 
Therefore subjects inhaled 0.2 mg of salbutamol prior to inhalation of an aerosol containing 
increasing concentrations of saline (3%, 4% and 5%) for 7 minutes through an ultrasonic 
nebulizer (De VilBiss Ultraneb 3000, Dolema AB, Täby, Sweden). Baseline FEV1 should be ≥ 
70% of predicted prior to the test. FEV1 was measured after each concentration and the induction 
stopped if FEV1 fell by 20%. Sputum plugs were identified and extracted and processed within 2 
hours as described previously (Pizzichini, Pizzichini et al. 1996). Tryptan blue solution (0.4%) 
was then used to assess cell viability and the cells were classified as viable, nonviable and 
squamous. Samples with high squamous cell contamination (≥ 20% of all cells) were rejected 
(Efthimiadis, Spanevello et al. 2002). Cytospins were stained with May-Grünvald-Giemsa 
solution and differential non-squamous cell counts were performed.  
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4.8 URINE SAMPLING AND ANALYSIS  
Urine was collected in Paper III in order to investigate lipid mediator release from the lungs in 
response to inhaled LTE4. The platform measured the main urinary metabolites of 
prostaglandins (PG), thromboxanes (TX), isoprostanes and the CysLTs. Urine collection was 
performed prior to, during and after bronchial challenge with LTE4; collected samples were 
distributed into smaller plastic tubes, stored at -70oC until time of analysis.  To normalize for 
changes in urine production, creatinine was measured in all samples using a colorimetric assay. 
In order to analyse several lipid mediators simultaneously in the same sample, an in-house and 
validated ultra performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) 
method was used (Balgoma, Larsson et al. 2013). Enzyme immunoassay (EIA) was also applied 
to measure the PGD2 metabolite 11β-PGF2a  (Cayman Chemicals, Ann Arbor, Mi, USA) as 
described previously (Bood, Sundblad et al. 2015). 
4.9 MEASUREMENTS IN BLOOD 
In Paper II, blood samples were collected before dosing and every other week up to 24 weeks 
after the first dose. QGE031 concentrations were measured with ELISA and total IgE was 
measured using the ImmunoCAP® total IgE assay (Phadia AB, Uppsala, Sweden). Free IgE in 
serum was calculated using a sandwich ELISA and flow cytometry was used to measure FcεRI 
on basophils and dendritic cells, CD23 on B cells and bound IgE on basophils and B cells.  
In Paper III, routine blood samples were collected during the screening visit to exclude 
comorbidities that might eventually influence the study results. Blood samples were also 
collected at study visits 4 and 6 prior to LTE4 inhalation, as well as 5 minutes after peak fall in 
FEV1 or following the last dose of LTE4 (20 ml each occasion) for analysis of circulating white 
blood cells.  
4.10 RECORDING OF ASTHMA SYMPTOMS 
In Paper I, at the third visit enrolled subjects gained access to an electronic diary in order to 
record their physical activity, asthma symptoms as well as daily use of on demand medication. 
Asthma symptoms were rated on a scale from 0 to 4, with higher scores indicating worse asthma 
control. ACQ5 was completed at visits 1, 3, 4 and 6. 
4.11 DRUGS AND INTERVENTIONS 
In all the papers included in this thesis, therapeutic interventions were performed and compared 
with either current recommended treatments and/or matching placebo. All studies were 
randomized and double blind; subjects, investigators, and study centre staff were blind to the 
identity of study treatments. Randomization data were kept strictly confidential until the time of 
unblinding and all packaging, labelling, appearance and schedule of administration of the study 
drugs were identical.  
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4.11.1 Budesonide and Formoterol  
In Paper I, a combination of budesonide an inhaled corticosteroid (ICS) and formoterol 
(formoterol fumarate dehydrate), a long acting β2 agonist (LABA) delivered via a dry-powder 
inhaler (DPI) (SYMBICORT® TURBUHALER® Astra Zeneca) inhaled on demand was tested 
as an alternative treatment of EIB. The drug is approved since 2007 as both maintenance and 
reliever therapy in persistent asthma in many countries all over the world. The device is an 
inspiratory-flow-driven, multi dose DPI that accurately dispenses very small amounts of dry 
powder when the subject inhales through the mouthpiece; thus there is no need to coordinate 
dose actuation with inhalation.  
Budesonide is an efficacious glucocorticosteroid with high affinity for the glucocorticosteroid 
receptor displaying a wide variety of anti-inflammatory effects in pharmacological studies 
(Szefler 1999). A unique property of budesonide is its reversible esterification with fatty acids 
(Tunek, Sjodin et al. 1997), which prolongs binding of the drug in the airways and possibly 
contributes to high airway activity and selectivity (Miller-Larsson, Jansson et al. 2000). The 
drug undergoes a 90% hepatic first-pass biotransformation into metabolites of low 
glucocorticosteroid potency, which results in a favourable profile regarding systemic steroid side 
effects, such as adrenal suppression, growth inhibition and catabolic changes of the skeleton and 
connective tissues (Szefler, Lyzell et al. 2004).  
Formoterol is a potent and selective β2 adrenoreceptor agonist with a rapid onset of action and a 
long duration of effect when inhaled (Lofdahl and Svedmyr 1989, Bartow and Brogden 1998, 
Lotvall 2002). The primary pharmacological effect of formoterol is smooth muscle relaxation, 
although it also inhibits the release of inflammatory mediators from mast cells, microvascular 
leakage as well as mucosal plasma exudation (Erjefalt and Persson 1991, Lindberg, Khan et al. 
1995, Barnes 2002). Systemic side effects include tachycardia, hypokalaemia, muscle tremor 
and hyperglycaemia as for all β2 adrenoreceptor agonists. 
4.11.2  QGE031 (ligelizumab) 
In Paper II, treatment with a new humanized IgG1 monoclonal antibody against IgE was 
compared to currently recommended treatment with omalizumab, and placebo. QGE031 binds 
to the Cε3 domain of IgE and efficiently blocks its interaction with both the high affinity IgE 
receptor (FcεRI) and the low affinity (FcεRII/CD23). The drug is designed to achieve higher IgE 
suppression compared to omalizumab with low equilibrium dissociation constant (Kp= 139 pM) 
that could lead to better clinical efficacy. Preclinical experiments have demonstrated that the 
antibody inhibits completely the release of histamine from mast cells and basophils induced by 
human recombinant IgE linking by preventing its binding to FcεRI. QGE031 also inhibited IgE-
dependent activation and subsequent degranulation of human cord blood derived mast cells at 
IgE concentrations up to 19 times higher than those inhibited by omalizumab. In a rhesus 
monkey local passive cutaneous anaphylaxis model, QGE031 showed an at least 25 times higher 
specific activity than omalizumab.  
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QGE031 has been administered in clinical studies both intravenously in single doses ranging 
from 0.1 to 10 mg/kg and subcutaneously in doses between 0.2 mg/kg x 2 to 4.0 mg/kg x 4 
given at two-week intervals and before this study up to 196 patients were exposed to the drug. 
QGE031 suppressed the levels of free circulating IgE below the lower limit of detection when 
administered both intravenously and subcutaneously. The extent and duration of suppression of 
free IgE, basophil FcεRI expression, basophil IgE and skin prick test response to allergen was 
greater than after administration of omalizumab. Safety assessments showed good tolerability 
with six severe adverse events reported although none of them were considered to be related to 
treatment. Urticarial events were reported after intravenous administration that appeared to be 
dose dependent, although no such events were seen in the subjects that received biweekly 
subcutaneous doses of 4.0 mg/kg QGE031. 
4.11.3  Montelukast 
In Paper III an intervention with the potent CysLT1 receptor antagonist montelukast 
(Singulair™; Merck Sharp & Dohme, Stockholm, Sweden) was performed in a cross over 
manner with a placebo comparator. Montelukast belongs to the “lukast” family of leukotriene 
antagonists and is a highly selective pharmacological antagonist of the CysLT1 receptor (Jones, 
Labelle et al. 1995). The recommended daily dose for asthma treatment in adults is 10 mg once a 
day. As it is a competitive receptor antagonist, higher doses provide greater antagonism, as 
thoroughly documented in vitro (Back, Dahlen et al. 2011). Accordingly, bronchoprovocation 
studies have documented that doses higher than 10 mg cause progressively increasing inhibition 
of the bronchoconstriction induced by inhalation of LTD4 (De Lepeleire, Reiss et al. 1997). In 
the early clinical development up to 250 mg of montelukast were given to subjects with asthma 
for several weeks without reports of significant adverse events. Taken together for this study the 
daily dose of 40 mg was selected to get significant antagonism on the CysLT1 receptor, thereby 
optimizing the testing of the overall study hypothesis that some effects of LTE4 may be resistant 
to CysLT1 antagonism.  
Montelukast was purchased from the Karolinska University Hospital Pharmacy (KUH) and the 
matching placebo from Recipharm Pharmaceutical Development AB, Stockholm, Sweden. The 
drugs were kept under appropriate storage conditions at ≤ 30°C with tightened cover in the 
Clinical Research Unit. The dispensation and coding was done by the KUH pharmacy and kept 
in sealed envelope in the Clinical Research Unit.  
4.12 PHARMACOKINETICS MODELING AND SIMULATIONS 
In Paper II, a pharmacokinetics/pharmacodynamics mathematical model descriptive of drug 
pharmacokinetics (either omalizumab or QGE031), as well as total circulating IgE, basophil 
FcεRI and surface IgE levels was implemented as previously described (Lowe 2015). 
Simulations from the applied model were performed for approximately 1000 virtual patients 
with the same demographics as the subjects studied in the actual paper.  
 32 
4.13 STATISTICAL ANALYSIS 
In Paper I, results were presented as mean ± standard deviation (SD) or 95% confidence 
intervals (CI). Analysis of covariance was performed for the analysis of the primary endpoint 
with treatment as a factor and the baseline value of the post-exercise FEV1 before treatment as a 
covariate. Most of the secondary endpoints were analysed similarly while some using 
descriptive methods. For the non-inferiority part of the study regarding comparison between the 
budesonide/formoterol group with the regular budesonide group, non-inferiority was defined as 
a difference in post exercise FEV1 fall < 7.28% and a SD of 7.13 estimated from a previous 
study (Jonasson, Carlsen et al. 2000). A sample size of 66 randomized subjects provided 80% 
power with 5% significance level was calculated to be enough for the non-inferiority analysis. 
In Paper II, the primary statistical analysis focused on the comparison of QGE031 240 mg to 
omalizumab and to obtain 95% CI of the difference. The difference to baseline log2 transformed 
allergen PC15 was assumed to be normally distributed and was analysed using a linear mixed 
effect model for repeated measurements. The model included effects for baseline (last 
measurement prior to first dose of study drug), treatment (dose of QGE031, omalizumab, 
placebo), time, and treatment by time interaction and baseline by time interaction. A covariance 
matrix was used to model the correlation of log2 PC15 measured on the same patient. Treatment 
contrasts were estimated separately for each study day, 95% CI were provided and the contrasts 
tested for statistical significance at the one-sided 2.5% alpha level. The estimated differences 
and CIs were back transformed to obtain geometric means. The sample size was selected to 
provide adequate power for the statistical tests of the primary contrasts in log2 PC15. Based on a 
previous study (Boulet, Chapman et al. 1997), the SD of log2 PC15 was assumed to be 1.5. Then 
six subjects per group provide 80% power to detect a treatment difference of 2.7 doubling 
solutions, the reported difference between placebo and omalizumab treated subjects, using a one 
sided test at 2.5% alpha level. Assuming that no more than two subjects in a treatment group 
would drop out, 40 subjects (8 each group) were planned to be randomized. Enrolment stopped 
after 37 patients because drop out rate was smaller. 
In Paper III, for the primary endpoint LTE4PD20 values were logarithmically transformed and 
results presented as geometric means and ranges; repeated measures ANOVA was performed. 
Correlations were also performed on log-transformed data. Values from IOS measurements and 
sputum cell counts were presented as median with ranges and the Wilcoxon signed rank test was 
used for analysis. Paired t tests were used to calculate differences in blood cell counts and 
changes in the levels of urinary metabolites. For a two period crossover treatment study, a 
minimum of 9 patients is required to demonstrate a 50% reduction of the airway response to 
inhaled allergen (Gauvreau, Watson et al. 1999), whereas a minimum of 16 subjects would be 
required when using an exercise challenge (Dahlen, O'Byrne et al. 2001). Formal evaluations of 
the repeatability and sample size requirements for leukotriene inhalation challenges are not 
available but there is considerable experience with these challenges in our lab (Kumlin, Dahlen 
et al. 1992, Gyllfors, Kumlin et al. 2005, Gyllfors, Dahlen et al. 2006) to support that the 
leukotriene challenge is highly repeatable and less variable than the exercise challenge. 
Moreover a rising dose challenge is more repeatable than a fixed dose challenge (Kumlin and 
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Dahlen 2000). Therefore we assumed that a sample size of 14 subjects would be sufficient to 
detect a significant shift in the dose response curve to inhaled LTE4.  
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5 RESULTS AND DISCUSSION 
5.1 DEMOGRAPHICS AND BASELINE CHARACTERISTICS 
The subjects that where recruited for all three studies had mild intermittent asthma that was 
stable at the time of the investigations. They only used rescue SABA medications with the 
exception of the two AERD subjects in Paper III who were on regular treatment with a 
combination of ICS/LABA. 
5.1.1 Paper I 
189 subjects went through screening (visits 1 and 2) of which 66 were eligible and were 
randomized to study treatment. The most common reasons for exclusion was a negative exercise 
challenge test at visit 2 (FEV1 fall < 10%), low baseline lung function (FEV1 < 80% of 
predicted), significant comorbidities, or obvious indication for regular treatment with ICS 
according to the investigator´s judgment. Subject’s baseline characteristics are shown in Table 3. 
By chance, most of the ex-smokers (had quit > 1 year prior to inclusion) were randomized to the 
budesonide/formoterol (bud/form) group, although their baseline lung function did not differ 
from never-smokers. More than half of the subjects in each group were atopic with a positive 
skin prick test to at least one aeroallergen, and all of them had normal lung function. During the 
maximal exercise test, subjects that were randomized to the terbutaline group on demand had 
slightly more symptoms and achieved lower max workload compared to the other to two groups 
although the difference was not significant. There were more women (n=16) randomized to that 
group compared to the other two. All treatments groups had a higher maximal dyspnoea Borg 
score than maximal leg fatigue score, which indicated that breathlessness and not leg fatigue was 
in most cases the main reason for ceasing the test.  
Results for the primary outcome were obtained at visit 5 in 59 of 66 subjects. For the 7 subjects 
that had missing data from visit 5, the last observation carry-forward principle was performed 
and data from visit 4 were used in the full analysis set. Four of the subjects were excluded from 
the per protocol analysis set (three in the budesonide group due to low compliance to treatment 
and one in the bud/form group due to excessive training/medication).  
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Table 3. Baseline characteristics at visit 1. Data are presented as mean ± SD. 
5.1.2 Paper II 
Thirty-seven subjects were randomized to treatment of whom thirty-five completed the study. 
One subject in the QGE031 24 mg treatment group was excluded due to difficulties to complete 
the whole study and one due to the decision of the sponsor (dosing error). The baseline 
characteristics of all subjects are shown in Table 4. All had normal lung function and there were 
no significant differences in demographics between the treatment cohorts.  
 
Characteristics*
Regular*placebo*once*daily*
+*budesonide/formoterol*
on*demand*
N=23*
Regular*placebo*once*
daily*+*terbutaline*on*
demand*
N=22*
Regular*budesonide*once*
daily*+*terbutaline*on*demand*
N=21*
Age$(years)$ 31±12$ 28±12$ 26±10$
Female/male$ 9/14$ 16/6$ 11/10$
BMI$(kg/m2)$ 25.0±4.0$ 23.4±3.6$ 24.6±3.6$
Ex@Smokers$(n)$ 8$ 1$ 1$
Smoking$cessation$(years)$ 7.1±5.6$ 3.4±0.0$ 7.2±0.0$
FEV1.$baseline$(liters)$ 3.8±0.8$ 3.4±0.6$ 3.8±0.8$
FEV1.$%$predicted$value$ 100±12$ 97±10$ 99±9$
Positive$skin$prick$test.$n$(%)$ 14$(61)$ 16$(73)$ 15$(71)$
$ $ $ $
Maximal*exercise*test* $ $ $
Max$work$load$(W)$ 251±66$ 232±57$ 255±63$
Max$dyspnea$(Borg$CR100)$ 86.5±20.6$ 95.9±21.2$ 85.3±25.5$
Max$leg$fatigue$(Borg$CR100)$ 77.0±25.0$ 87.3±23.2$ 79.1±26.5$
Max$heart$rate$(beats/min)$ 186±9$ 189±12$ 181±25$
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Table 4. Baseline characteristics at visit 1. Data are presented as mean ± SD unless specified. 
5.1.3 Paper III 
Thirty-one subjects went through the screening phase of the study of which sixteen subjects 
(fourteen subjects with mild asthma and two AERD subjects) were randomized to treatment. 
The most common reason for exclusion was a negative methacholine challenge at visit 1; four 
subjects did not display sufficient sensitivity to inhaled LTE4, and one subject withdrew consent 
due to incapacity to complete all study visits. Demographics as well as bronchial responsiveness 
to inhaled methacholine and LTE4 at screening are shown in Table 5. All subjects had normal 
lung function with a geometric mean FENO value at screening (24.2 ppb) within normal range (< 
25 ppb) including the two AERD subjects, indicating that they had a stable asthma at the time of 
the investigation. The mean ratio between PD20 methacholine and PD20 for LTE4 at screening 
was 76.9 meaning that LTE4 was about 75 times more potent on a molar basis than methacholine 
as bronchoconstrictor. Eleven subjects were sensitized to one or more aeroallergens according to 
skin prick test results at visit 1 (data not shown). 
 
Parameters  QGE031 24mg 
(N=8) 
QGE031 72mg 
(N=8) 
QGE031 240mg 
(N=8) 
Omalizumab 
 
(N=6) 
Placebo 
 
(N=7) 
Age, years 
(range) 
26.3  
(24 – 29) 
32.3  
(22 – 59) 
34.4  
(18 – 55) 
33.0  
(22 – 48) 
30.1  
(18 - 50) 
Male, n (%) 2 (25.0) 3 (37.5) 4 (50.0) 2 (33.3) 1 (14.3) 
Race, n (%)      
Caucasian 3 (37.5) 8 (100.0) 7 (87.5) 5 (83.3) 7 (100.0) 
Asian 4 (50.0) 0 0 0 0 
Other 1 (12.5) 0 1 (12.5) 1 (16.7) 0 
Weight, kg 64.0 (14.60) 67.8 (18.20) 82.6 (18.64) 77.8 (16.43) 68.4 (14.73) 
BMI, kg/m2 23.2 (4.45) 23.6 (3.91) 28.6 (6.22) 26.2 (4.17) 24.4 (3.17) 
FVC, L 3.93 (0.93) 4.28 (1.09) 4.43 (1.28) 4.50 (1.10) 4.06 (0.93) 
FEV1, L 3.06 (0.62) 2.98 (0.62) 3.33 (1.00) 3.55 (0.88) 3.18 (0.96) 
% FEV1 
predicted 87.63 (7.96) 83.31 (9.93) 90.45 (17.57) 95.17 (11.34) 87.07 (10.75) 
Screening total 
IgE (IU/mL) 
Median (range) 
163.00   
(83.7, 695.0)  
117.00   
(37.0, 336.0)  
98.90   
(77.1, 521.0)  
97.95  
 (41.6, 604.0) 
97.10  
 (67.7, 295.0)  
!1!
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Table 5. Patient characteristics and airway sensitivity to methacholine and LTE4 at screening. ¶ 
Geometric mean. 
5.2 AIRWAY RESPONSE TO CHALLENGES AND THE EFFECT OF 
INTERVENTIONS 
In all three papers, an airway challenge was performed at screening and after treatment with the 
interventional drug and/or placebo. The airway response was measured using spirometry and 
IOS (only in Paper III), and the bronchoprotective effect was compared to screening for each 
treatment arm as well as in between treatment arms. The nature of the stimulus and the challenge 
methodology defined the differences with respect to how the data was analysed and presented. 
Exercise challenge differs in as much that it uses a maximal stimulus for a short period of time, 
where spirometry can be performed continuously only after the end of the challenge and data are 
plotted against time. Unlike exercise, mannitol, allergen and inhaled LTE4 challenges are 
cumulative with a number of dose steps, where spirometry can be performed in between and the 
challenge is terminated when a predefined threshold of FEV1 fall is reached (15 or 20% from 
baseline) or the maximal dose is delivered. This allows for determination of a shift in the dose-
response curve from the screening provocation as well as assessment of group differences in 
Patient Age 
(y) 
M/F FeNO 
(ppb) 
FEV1  (L) FEV1 % 
predicted 
Mch PD20 
(nmol) 
Screening 
LTE4 PD20 
(nmol) 
Ratio  
MCh PD20 / 
LTE4 PD20 
1 45 F 8 2.1 79 4986 3.8 1326 
2 24 M 68 4.2 86 1654 54.9 30.2 
3 37 F 50 2.9 114 499 39.4 12.7 
4 28 F 13 2.8 81 2565 30.8 83.4 
5 38 M 116 4.3 106 916 70.2 13 
6 29 M 24 4.3 90 2378 19.8 120.6 
7 46 F 10 2.7 99 3532 49.4 71.5 
8 20 F 11 3.5 95 2153 31.9 67.4 
9 52 F 14 2.6 101 12188 43.2 282 
10 45 F 36 2.4 96 924 8.6 107.3 
11 25 F 30 2.9 92 899 11.3 79.5 
12 44 F 52 4.1 129 4281 22.7 188.4 
13 38 F 11 2.5 103 2197 12.6 173.8 
14 28 F 48 2.6 93 649 2.9 224 
AERD 1 48 M 14 3.8 97 17206 87.4 197 
AERD 2 35 M 21 3.8 79 2528 55.7 45.4 
Mean 36.4  24.2¶ 3.2 96.3 1815¶ 23.6¶ 76.9 
Range 20-52  8-116 2.1-4.3 79-129 499-17206 2.9-54.9 12.7-1326 
 1 
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sensitivities to the respective challenging agents between the treatments. Methacholine challenge 
was used as a screening tool without any related intervention. That is why the results from this 
challenge are not going to be presented here.  
5.2.1 Exercise challenge and EIB treatment  
The exercise challenge described above (see section 4.3.1) was performed at screening (visit 2), 
as well as after 3 weeks (visit 4) and 6 weeks (visit 5) of treatment. No asthma medication or 
physical exercise was allowed 24 hours prior to the challenges. The mean max post exercise 
FEV1 fall from pre-exercise values was less than 20% in all treatment groups at baseline i.e. 
before treatment (Table 6), which indicates that the majority of subjects had mild EIB. 
Treatment with bud/form on demand for 6 weeks resulted in a mean max post exercise FEV1 fall 
that was 5.4% smaller than the post exercise FEV1 fall recorded at baseline (95% CI: -8.9 to -
1.8). For the group receiving regular budesonide the mean max post exercise FEV1 at 6 weeks 
was 6.6% smaller than at baseline (95% CI: -10.3 to -3.0), whereas the response was 1.5% 
greater (95% CI: -2.1 to + 5.1) for the terbutaline on demand group. This translates to a 28.5% 
reduction in EIB for the bud/form on demand group compared to a 38.6% reduction for the 
group that received budesonide regularly. In contrast there was an 8.9% increase in EIB for the 
group that was treated only with terbutaline on demand, see also Table 6. When compared to the 
terbutaline treatment group both the bud/form group and the regular budesonide group were 
accordingly significantly better in inhibiting EIB after six weeks of treatment (p= 0.017 and p= 
0.0026 respectively).  
After three weeks of treatment there was a small reduction in EIB in both the bud/form (18.7%) 
and the regular budesonide group (26.4%), whereas the response in the terbutaline group 
remained almost unchanged (1.6%). The difference after three weeks of treatment in the 
protective effect against EIB between the terbutaline group and the bud/form group was 
however not significant (p=0.113), although it almost reached statistical significance for the 
regular budesonide group (p=0.051). 
Table 6. Maximal post-exercise FEV1 fall at baseline (randomization) as well as after 3 and 6 weeks 
of treatment for all groups. The relative mean change indicates the relative change in EIB 
compared after 3 and 6 weeks of treatment. Data are presented as mean ±SD. 
When comparing the bud/form with the regular budesonide group there was no significant 
difference regarding their bronchoprotective effect against EIB at three weeks (p=0.697) or at 
  Baseline 3 weeks 6 weeks 
Regular placebo and 
terbutaline on demand 
Max post-exercise FEV1-fall  
Relative mean change (%)  
17.7 ± 8.9 
- 
16.9 ± 8.5 
-1.6  
18.8 ± 10.9 
+8.9  
Regular budesonide and 
terbutaline on demand 
Max post-exercise FEV1-fall  
Relative mean change (%)  
15.3 ± 5.7 
- 
11.3 ± 7.2 
-26.4 
9.6 ± 7.0 
-38.6  
Regular placebo and 
budesonide/formoterol 
on demand 
Max post-exercise FEV1-fall  
Relative mean change (%)  
16.4 ± 7.5 
- 
12.6 ± 7.2 
-18.7  
11.1 ± 8.2 
-28.5  
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six weeks of treatment (p=0.582). The reduction of maximal post-exercise FEV1 fall after 6 
weeks of treatment was 1.2 % in favour of regular budesonide treatment compared with the 
group who received bud/form on demand. The lower limit of the 97.5% confidence interval was 
-3.47%. Thus non-inferiority for the treatment with the combination of budesonide and 
formoterol compared with regular budesonide treatment was proven for the main outcome 
variable, see Figure 8. 
Figure 8. Demonstration of non-inferiority between regular budesonide and budesonide/ 
formoterol on demand for the primary outcome. 
Lung function measurements (FEV1) were performed for up to 30 minutes after the end of the 
challenge at which point a SABA was inhaled and lung function recovered to baseline. This 
enabled us to plot the post exercise FEV1 fall against time, as done in a previous exercise 
challenge study (Fogel, Rosario et al. 2010). Figure 9 visualizes the post exercise FEV1 fall up to 
30 minutes after the end of the exercise challenge at baseline i.e. before treatment as well as after 
six weeks of treatment for all three groups. 
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Figure 9: FEV1 before and after an exercise challenge at baseline i.e. before treatment (upper 
panel) as well as after six weeks of treatment (lower panel) for all groups. 
The nadir in FEV1 for all treatment groups occurred within 15 minutes after the end of exercise 
both at baseline as well as after treatment, which happens in most cases after an exercise 
challenge (Brudno, Wagner et al. 1994). At baseline, the post exercise FEV1 fall for all groups 
reached a plateau with very limited spontaneous recovery of lung function until subjects 
received SABAs 30 minutes after the end of exercise. At the end of study (six weeks) there was 
a better spontaneous recovery of FEV1 for the regular budesonide group that almost reached -5% 
of pre-exercise value. The bud/form on demand group had a plateau shaped curve similar to the 
baseline response (Figure 9). 
During the 6-week treatment period, the daily dose of inhaled budesonide was on average 393 
µg in the group that inhaled budesonide on a regular basis and 163 µg in the group that inhaled 
the combination on demand, see Table 7. The average total need for daily extra medication was 
0.93 ± 0.54 inhalations in the terbutaline group, 0.81 ± 0.50 inhalations in the bud/form group 
and 0.77 ± 0.67 inhalations in the regular budesonide group. The inhalations taken for symptom 
relief, i.e. not prior to training sessions, did not differ between the groups and was 0.15 ± 0.24 
inhalations per day in the terbutaline group, 0.07 ± 0.09 inhalations per day in the bud/form 
group and 0.14 ± 0.55 inhalations per day in the regular budesonide group (Table 7). 
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Table 7: Intake of study drugs throughout the study. Data are presented as mean±SD. 
In summary, the EIB study (Paper I) demonstrated that a six-week treatment with inhalation of 
a combination of budesonide and formoterol, prior to training sessions and for symptom relief, 
was superior to on demand inhalation of the SABA terbutaline in reducing the airway response 
to exercise. This was assessed by an exercise test that was preceded by a 24-hour period free of 
any medication. Furthermore, it was found that the reduction in EIB after six weeks treatment 
regimen with inhalation of bud/form on demand was similar to regular, daily inhalation of 
budesonide. This finding clearly indicates that three to four weekly doses of the combination 
treatment are sufficient to reduce EIB, to a similar degree as regular treatment with low dose 
inhaled corticosteroids in these patients with rather mild asthma. It was also shown that the 
airway response to exercise after 24 hours free from all medication was unaltered, or even 
slightly increased, after six weeks in the group that was only treated with inhaled terbutaline on 
demand, which is in agreement with the results of previous studies with methacholine 
(Vathenen, Knox et al. 1988), exercise (Hancox, Subbarao et al. 2002) and repeated low dose 
allergen (Dahlen, Lantz et al. 2009) where SABAs or LABAs were used as monotherapy. 
5.2.2 Mannitol challenge  
The airway response to a bronchial challenge with mannitol was assessed at baseline (visit 3) 
prior to randomization and at the end of the treatment period (visit 6). The mannitol data were 
not included in the original paper and are thus unpublished. All subjects that performed the 
challenge had a positive exercise test at visit 2 i.e. had a confirmed EIB diagnosis. This permits a 
preliminary comparison of the sensitivity to mannitol and exercise challenge in this cohort of 
patients. Results were available from 60 out of 66 enrolled subjects and are seen in Figure 10, 
where the FEV1 fall during the challenge was plotted against the inhaled cumulative dose of 
mannitol. Thirty subjects (50%) inhaled the maximal cumulative mannitol dose of 635 mg 
without reaching the threshold of 15% fall in FEV1. The results are thus consistent with a lower 
sensitivity of the mannitol challenge in diagnosing EIB than previously published data 
 
Placebo once daily 
and budesonide + 
formoterol  on demand 
N=23 
Regular placebo once 
daily + terbutaline  on 
demand 
N=22 
Regular budesonide once 
daily + terbutaline  on 
demand 
N=21 
Budesonide, metered dose 
400 µg/inhalation (µg /day) 
0 0 393 ± 12 
Budesonide, metered dose 
200 µg/inhalation (µg /day) 
163 ± 80 0 0 
Terbutaline (µg/day) 0 372 ± 216 309 ± 266 
Formoterol (µg/day) 3.7 ± 2.3 0 0 
Maintenance, number of 
inhalations/day 
0.96 ± 0.10 0.99 ± 0.03 0.98 ± 0.03 
Medication prior to exercise, 
number of inhalations/day 
0.74 ± 0.46 0.78 ± 0.46 0.63 ± 0.19 
Medication for symptom 
relief, number of 
inhalations/day 
0.07 ± 0.09 0.15 ± 0.24 0.14 ± 0.55 
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(Anderson, Brannan et al. 1997, Brannan, Koskela et al. 1998). The original studies however 
included subjects who were in the majority atopic with a more severe EIB compared to our 
group of asthmatics (e.g. FEV1 fall 40 ± 19% SD in the study by Brannan et al). In another study 
where mannitol was compared to EVH in elite athletes (Holzer, Anderson et al. 2003), mannitol 
showed sensitivity of 83% to identify EIB but also in that group, the FEV1 fall was greater than 
in our material (25.4 ± 15% SD). In contrast, the sensitivity of mannitol to diagnose EIB was 
reduced to 59% when tested in a group of asthmatics with mild EIB that had a FEV1 fall after 
exercise of 19 ± 9.2% (SD), which is similar to our results (Anderson, Charlton et al. 2009). 
Likewise, in another Scandinavian study with mild asthmatics mannitol was positive in 12 out of 
22 subjects (55%) with a positive EVH challenge (FEV1 fall > 10%) (Aronsson, Tufvesson et al. 
2011). 
 
Figure 10: FEV1 fall versus mannitol dose at baseline (visit 3). Blue lines represent subjects that 
were randomized to receive terbutaline on demand, green lines budesonide once daily plus 
terbutaline on demand and red lines bud/form on demand. 
After 6 weeks of treatment (visit 6) the mannitol challenge was repeated and the FEV1 fall for all 
subjects during the challenge is shown in Figure 11. Thirty-nine subjects inhaled the highest 
cumulated dose of mannitol compared to thirty at baseline; there was no significant difference in 
the mannitol airway response between baseline and end of study possibly due to the fact that at 
baseline already half of the subjects had reached the maximal inhaled dose. Interestingly of the 
remaining twenty-one subjects that were still mannitol positive at the end of the study, 
preliminary analysis indicates that fifteen belonged to the two groups that received ICS. Because 
All these patients 
reached the 635 mg 
dose 
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of the low responder rate to mannitol, there was no power to perform a meaningful comparison 
of the effects of the interventions on this outcome. 
 
Figure 11: FEV1 fall versus mannitol dose at end of study (visit 6). Blue lines represent subjects that 
were randomized to receive terbutaline on demand, green lines budesonide once daily plus 
terbutaline on demand and red lines bud/form on demand. 
5.2.3 Allergen challenge and anti-IgE treatment  
An allergen challenge was performed at baseline, after six and twelve weeks (end of treatment 
period) as well as eighteen weeks after the first dose. The change in allergen PC15 was calculated 
and presented as fold change from baseline for each individual, data plotted against time are 
shown in Figure 12. 
Figure 12: Individual subject time-course data for placebo, the three doses of QGE031 and 
omalizumab. Red-coloured data are subjects with baseline IgE levels greater than 700 IU/ml. 
0                                              7.3                                           20                                         55                                           148                                           403                                         
 44 
There was a great variety in the allergen PC15 shift between subjects, especially for the subjects 
that were treated with 72 and 240 mg of QGE031, where the change from baseline ranged from 
less than 2 to more than 500-fold at week 12 (Figure 12). This change was on its way to 
returning to baseline by week 18. The mean change from baseline for log2-transformed allergen 
PC15 was 4.96 (number of doubling dilutions) at week 12 for the group that received 240 mg of 
QGE031 with a range of 0.85 to 9.2 (Table 8). 
 
Table 8: Change from baseline of log2 PC15 (number of doubling dilutions) at week 12. CV: 
Coefficient of variation; SD: Standard deviation 
The ratio of the geometric means for allergen PC15 at week 12 compared to baseline was 
calculated for each of the three dose regimens of QGE031 and was compared to omalizumab. 
Treatment with 72 and 240 mg of QGE031 produced a mean change in the inhaled allergen 
concentration (allergen PC15) that numerically was two to three-fold greater than that for 
omalizumab at week 12 but the difference was not statistically significant (p=0.14 and p=0.10 
respectively). Treatment with 24 mg QGE031 was less effective than omalizumab (Figure 13).
  
Figure 13: Statistical analyses of the geometric mean ratios of allergen PC15 for the three different 
QGE031 doses versus omalizumab at week 12. 
When compared to placebo at week 12 there was a change in allergen PC15 of sixteen-fold for 
the groups receiving 240 mg of QGE031 (p< 0.001) and 72 mg of QGE031 (p<0.001) compared 
Change from 
baseline of 
log2 PC15 at 
week 12 
QGE031 
24 mg 
 
(n=8) 
QGE031 
72 mg 
 
(n=7) 
QGE031 
240 mg 
 
(n=8) 
Omalizumab 
 
 
(n=6) 
Placebo 
 
 
(n=6) 
Mean (SD) 1.78 (1.82) 4.23 (1.92) 4.96 (3.39) 3.17 (1.56) 0.39 (0.96) 
CV% mean 102.6 45.5 68.2 49.2 245.2 
Min-Max (-1.90, 4.66) (1.84, 7.70) (0.85, 9.19) (1.05, 5.19) (-1.14, 1.47) 
!1!
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to a five-fold improvement in the group that received omalizumab (p=0.02) (Figure 14). 
Treatment with 24 mg of QGE031 was no different than placebo (p=0.40). 
 
Figure 14: Statistical analyses of the geometric mean ratios of allergen PC15 for the three different 
QGE031 doses versus placebo at week 12. 
In summary, we have shown that treatment with the highest dose of QGE031 every two weeks 
inhibited the early airway response (EAR) to a standardized allergen bronchoprovocation 
challenge causing a shift in allergen PC15 that was sixteen times greater than placebo, twelve 
weeks after the first dose. Omalizumab inhibited also the EAR with a change in allergen PC15 
that was five times greater than placebo and almost nine times compared with the baseline (3.2 
doubling dilutions) at twelve weeks. These results for omalizumab are in agreement with 
previous allergen bronchoprovocation studies where the drug has shown similar efficacy in 
inhibiting both the EAR (Boulet, Chapman et al. 1997, Zielen, Lieb et al. 2013), as well as the 
late asthmatic reaction (Fahy, Fleming et al. 1997, van Rensen, Evertse et al. 2009). When 
comparing QGE031 with omalizumab, the shift in allergen PC15 at twelve weeks was three times 
greater for 240 mg of QGE031 compared with that after omalizumab, although the difference 
was not statistically significant. The peak of the allergen PC15 change for all QGE031 treatment 
arms occurred at twelve weeks after the first dose i.e. two weeks after the last dose, returning 
towards baseline levels by week 18, which is a pattern similar to the one observed with 
omalizumab. A great variety in the allergen PC15 shift was observed in the subjects that were 
treated with QG031 indicating heterogeneity in the inhibition of the EAR. It is known that the 
airway response to inhaled allergen in asthmatics can be regulated through other pathways that 
are not FcεRI dependent (Neighbour, Boulet et al. 2014, Kaur, Gomez et al. 2015). Mast cells 
and basophils can be activated through other mediators such as the epithelial cell-derived 
cytokines thymic stromal lymphopoietin (TSLP) and interleukin-33 (IL-33) that can partly be 
involved in airway response to allergen inhalation (Salter, Oliveria et al. 2015, Saluja, Zoltowska 
et al. 2016). Thus anti-IgE treatment does not block all the mediators that are involved in the 
EAR after allergen inhalation, which might explain the great variety in the suppression of the 
response to allergen observed in the subjects treated with QGE031 in this study. 
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5.2.4 Leukotriene E4 challenge and treatment with montelukast  
A cumulative inhalation challenge with LTE4 was performed at screening (visit 2) as well as at 
the last day of each treatment period (visits 4 and 6) with either the CysLT1 receptor antagonist 
montelukast or matching placebo. At screening the mean maximal FEV1 drop after LTE4 
inhalation was 28.7% (95% CI, -25.3% to -32%) compared to 26.3% (95% CI, -23% to -29.6%) 
after treatment with placebo and 0.45% (95% CI, -3% to 2.1%) after treatment with montelukast 
(Figure 15). Thus montelukast abolished the airway response to inhaled LTE4 compared to 
placebo (p < 0.001). 
 
Figure 15: Maximal FEV1 fall  % at screening (blue plot), after treatment with placebo (red plot) 
and montelukast (green plot). Open circles represent values for AERD subjects. Horizontal bars 
indicate mean values; *p<0.001 
When treated with montelukast subjects inhaled on average a ten-fold higher cumulated dose of 
LTE4 (geometric mean 380,277 pmol) compared to after treatment with placebo (geometric 
mean, 37,006 pmol; p< 0.001) (Figure 16). The airway response to inhaled LTE4 for the two 
subjects with AERD was similar to the rest of the asthmatic subjects (open circles in Figures 15 
and 16). 
 
Figure 16: LTE4 PD20 values at screening (blue plot) and after treatment with placebo (red plot), 
total dose of inhaled LTE4 after treatment with montelukast (green plot). Open circles represent 
values for AERD subjects.  Horizontal bars indicate geometric mean values * p<0.001  
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There was no significant difference in the LTE4PD20 when comparing results at screening 
(geometric mean 23,610 pmol) and after treatment with placebo (geometric mean 20,923 pmol) 
(Figure 16). Similarly the Bland-Altman analysis demonstrated that the challenge was highly 
repeatable (Figure 17), which is in agreement with previous studies with inhalation of 
leukotriene D4 performed in our lab (Gyllfors, Kumlin et al. 2005, Gyllfors, Dahlen et al. 2006). 
 
Figure 17: Bland-Altman plot where the difference in log LTE4 PD20 between screening and after 
treatment with placebo were plotted against their mean. 
 Interestingly, there was an inverse relation between the airway response to methacholine and 
LTE4 where subjects with the highest responsiveness to methacholine had the lowest relative 
responsiveness to LTE4 (Figure 18). This finding is in agreement with the relations demonstrated 
between inhaled methacholine and leukotriene C4 and D4 respectively in previous studies 
(Adelroth, Morris et al. 1986, Gyllfors, Kumlin et al. 2005). 
 
Figure 18: Relation between airway responsiveness to methacholine (PD20) and the relative potency 
of LTE4 compared to methacholine (difference in logMchPD20 and logLTE4PD20). r = 0.57 , p = 
0.002 (Pearson) 
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In order to extend the information about the airway response to inhaled LTE4 and examine its 
influence in the small airways, IOS measurements were performed in eleven subjects including 
both AERD subjects. Measurements were performed prior to as well as at the end of each 
challenge after the last dose of LTE4 was inhaled. Values for all major IOS parameters at 
baseline as well as after inhalation of LTE4 at the end of each treatment period are presented in 
Table 9. There was a significant change in all IOS measurements after inhalation of LTE4 when 
subjects were treated with placebo. After treatment with montelukast there was a slight increase 
in R20 after inhalation of LTE4, which is a parameter that reflects resistance mainly in the central 
airways. The total airway resistance R5 increased with 58.9% (mean, 95% CI, 41.1% to 76.8%) 
from baseline after inhalation of LTE4 with placebo compared to a 7.1% increase (mean, 95% 
CI, -3.2% to 17.2%) after montelukast, with the difference being highly significant p< 0.001. 
The increase in R5 during placebo is similar to changes observed after methacholine challenge 
(Short, Anderson et al. 2015), EVH (Rundell, Evans et al. 2005, Price, Ansley et al. 2016) and 
slightly higher than the one after mannitol challenge (Horsman, Duke et al. 2009). Frequency 
dependent resistance (R5-R20), one of the most sensitive IOS markers in the bronchoprovocation 
setting (Naji, Keung et al. 2013) increased seven fold after LTE4 inhalation during placebo 
treatment (Figure 19), which is a clear sign of peripheral airway obstruction and small airways 
impairment similar to that seen in patients with severe asthma and small airways disease 
(Williamson, Clearie et al. 2011, Anderson, Zajda et al. 2012). Changes in reactance were of the 
same magnitude, the area of reactance (Ax), which is considered to be also one of the most 
sensitive IOS indexes and the one that correlates strongest to R5-R20 (Goldman, Saadeh et al. 
2005) increased ten-fold from baseline after LTE4 inhalation (Figure 20). This conspicuous 
small-airway obstruction caused by LTE4 was abolished when subjects were treated with 
montelukast (Figures 19 and 20).  
 
Table 9: All values represent median and range. R5 resistance at 5Hz, R20 resistance at 20Hz, Fres 
resonant frequency, X5 reactance at 5Hz, Ax reactance area, R5-R20 frequency dependent resistance. 
* p<0.01, ¶p=0.04. Wilcoxon signed rank test, comparison between pre and post inhalation 
challenge with LTE4. 
Placebo Montelukast 
 Pre Post Pre Post 
R5 
(kPa/L/s) 
0.37 (0.23; 0.63) 0.56 (0.43; 1.03)* 0.31 (0.16; 0.56) 0.33 (0.21; 0.65) 
R20 
(kPa/L/s) 
0.35 (0.23; 0.59) 0.44 (0.31; 0.65)* 0.31 (0.15; 0.55) 0.33 (0.22; 0.64)¶ 
 
Fres (Hz) 9.37 (7.8; 13.8) 23.7 (11.8; 29.6)* 9.26 (6.04; 12.8) 8.94 (6.87; 15.8) 
X5 
(kPa/L/s) 
-0.09 (-0.15; -0.05) -0.21 (-0.47; -0.11)* -0.07 (-0.19; 0.1) -0.09 (-0.25; -0.03) 
Ax 
(kPa/L) 
0.15 (0.09; 0.58) 1.62 (0.33; 5.22)* 0.14 (0.01; 0.48) 0.16 (0.025; 0.8) 
R5-R20 
(kPa/L/s) 
0.02 (-0.03; 0.06) 0.14 (0.04; 0.38)* 0.01 (-0.01; 0.19) 0.02 (-0.03; 0.08) 
!1!
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Figure 19: Changes in frequency-dependent resistance (R5-R20) before and five minutes after LTE4 
inhalation challenge for both treatment periods. Horizontal bars indicate median values. * P<0.01, 
Wilcoxon signed rank test.  
 
Figure 20: Changes in reactance area (Ax) before and five minutes after LTE4 inhalation challenge 
for both treatment periods. Horizontal bars indicate median values. * P<0.01, Wilcoxon signed 
rank test. 
In summary, the airway response to inhaled LTE4 was completely blocked by treatment with 
montelukast. On the average, subjects tolerated a ten-fold higher dose of LTE4 compared to 
placebo without a fall in FEV1 indicating that the LTE4 effects on smooth muscle in asthmatics 
are mediated solely through the CysLT1 receptor. In addition, IOS results indicate that LTE4 
contributed to small-airways obstruction, which also was mediated through the CysLT1 receptor. 
This small airways impairment induced by leukotrienes is probably due to both a constriction of 
the smooth muscle as well as mucosal edema because CysLTs are potent inducers of plasma 
exudation (Dahlen, Bjork et al. 1981) in the airways (Hua, Dahlen et al. 1985, Persson, Erjefalt 
et al. 1986) and provoke profound disturbances of pulmonary gas exchange in asthma 
(Echazarreta, Dahlen et al. 2001).  
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5.3 EFFECT OF INTERVENTIONS ON MARKERS OF AIRWAY INFLAMMATION 
Measurement of FENO as well as measurement of inflammatory cells in induced sputum after 
inhalation of hypertonic saline have been widely used as surrogate markers for assessment of 
airway inflammation in subjects with asthma (Pizzichini, Pizzichini et al. 1996, Gibson 1998, 
Barnes, Dweik et al. 2010, Cowan, Cowan et al. 2010). In Paper III FENO was assessed on all 
study days in order to monitor airway inflammation and measurements were performed prior to 
baseline spirometry. Induced sputum was also collected in Paper III four hours after the end of 
the LTE4 inhalation challenge performed on the last day of each treatment period with 
montelukast and placebo respectively. 
5.3.1 Effects of montelukast on baseline FENO 
There was no significant difference in FENO values measured at screening and during the two 
treatment periods, see Table 10. The variability in the data was low with most subjects 
displaying FENO values with in normal range on most study days with the exception of subject 
5, thus indicating a low grade of inflammation in the airways. Previous studies have shown that 
montelukast may decrease FENO in asthmatics. However, in those studies montelukast was 
given as add on treatment in subjects already treated with ICS that had a higher degree of airway 
inflammation compared to our group (Ghiro, Zanconato et al. 2002, Montuschi, Mondino et al. 
2007, Kononowa, Michel et al. 2013). 
 
Table 10: FENO values in ppb throughout the study. 
5.3.2 Effects of montelukast on sputum cells 
Sputum examination was performed four hours after the end of the LTE4 challenge on both 
treatment periods and data that met pre-defined quality criteria (< 20% squamous cells) were 
Subject No Baseline Placebo start Placebo end Montelukast 
start 
Montelukast 
end 
1 8 16 14 13 12 
2 68 57 66 74 55 
3 50 64 56 49 39 
4 13 10 12 22 11 
5 116 112 105 116 113 
6 24 24 22 19 18 
7 10 8 8 8 9 
8 11 9 7 11 8 
9 14 19 18 19 18 
10 36 51 48 44 46 
11 30 24 21 23 26 
12 52 57 50 56 42 
13 11 14 14 11 12 
14 48 37 43 43 57 
AERD 1 14 8 11 9 8 
AERD 2 21 13 20 20 16 
Geom. Mean 24.1 23.4 23.7 24.6 22.2 !
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obtained on both occasions in nine subjects (including one AERD subject). There was no 
significant difference in the post-challenge percentage of sputum eosinophils between placebo 
(mean 4.5%, 95 CI, 1.8% to 7.1%) and montelukast (mean 3.2%, 95 CI, 1.4% to 4.9%) p=0.11 
(Figure 21).  
 
Figure 21: Effects of montelukast on sputum eosinophil counts from 9 subjects with paired data. 
Open circle represents values in patient number 2 with AERD. Horizontal bars indicate mean 
values.  
There was no difference in the percentage of sputum neutrophils either (mean 28.8%, 95 CI, 
18.5% to 39% for placebo compared to mean 30.4%, 95 CI, 12.9% to 47.9% for montelukast), 
p=0.82. The rest of the differential cell counts were also similar between treatments (Figure 22).  
 
Figure 22: Differential cell counts from sputum induction in the presence of placebo and 
montelukast respectively. Neutrophils p=0.82, macrophages p=0.87, lymphocytes p=0.094 
There was a small increase in the total number of cells when subjects were treated with 
montelukast compared to placebo; median 4.3, interquartile range, 2.4-8.8 x 106/g sputum for 
placebo vs 5.3 median, interquartile range, 3.6-9.9 x 106/g sputum for montelukast, p=0.039 
(Figure 23). 
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Figure 23: Effects of montelukast on total sputum cell counts from 9 subjects with paired data. The 
open circle represents values in patient number two with AERD. Horizontal bars indicate median 
values. P=0.039 
In summary, it was demonstrated that despite exposure to a ten times higher dose of LTE4 during 
treatment with montelukast, the sputum eosinophil count was the same as after treatment with 
placebo. The results thus argue against an alternative receptor being involved in the pro-
inflammatory effects of LTE4 on airways. It is quite unusual in responses mediated by dual-
receptors, that blockade of one receptor, does not allow the second receptor to be unmasked and 
express its response when higher agonist doses are administered. In this case, a ten times higher 
dose of LTE4, i.e. a one-log order of magnitude in increase, did not produce more sputum 
eosinophils. If there had been an “E-type” alternative receptor driving eosinophilia, this receptor 
would have had remarkable opportunities to display functional effects once the montelukast 
treatment had abolished the CysLT1 responses. The previous studies in the mouse ear oedema 
model, where the presence of three different CysLT receptors have been established in fact 
clearly demonstrate how sequential blockade or deletion of one receptor favours functional 
emergence of responses mediated by the remaining receptors (Kanaoka, Maekawa et al. 2013). 
In addition, the study suggests that the observed difference between inhaled LTD4 and LTE4 
with respect to their ability to cause airway eosinophilia (Gauvreau, Parameswaran et al. 2001) 
is unlikely to be explained by a different receptor for LTE4.  
5.4 EFFECT OF INTERVENTIONS ON LIPID MEDIATOR RELEASE IN URINE 
Urine samples were collected in Paper III before, during and after the end of the LTE4 
challenge at hourly intervals for up to four hours for measurement of the major lipid mediator 
metabolites of CysLTs, prostaglandins, tromboxanes and isoprostanes using UPLC-MS/MS and 
EIA (only for 11β-PGF2a). The aim was to explore both the pattern of the mediator excretion 
after the LTE4 challenge, which has not been studied before as well as the effects of the 
intervention with a CysLT1 antagonist. An overview of the pattern of mediator excretion after 
inhalation of LTE4 after treatment with placebo and montelukast is presented in Figure 24. All 
data are presented as nanograms per nanomole of creatinine. The peak values varied in between 
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subjects and between different mediators, although in the majority of cases the peak values were 
measured at the first hour interval or directly at the end of the LTE4 challenge.  
 
Figure 24: Schematic overview of the lipid mediator excretion measured with UPLC-MS/MS after 
inhalation of LTE4 at the end of each treatment period.  
5.4.1 LTE4  
As expected, the urinary excretion of LTE4 increased significantly after inhalation of LTE4 
compared to baseline on both treatment periods (placebo: 15 ± 10 baseline vs 981 ± 240 after 
LTE4 inhalation, p=0.0015; montelukast: 11 ± 5 baseline vs 3201 ± 645 after LTE4 inhalation, 
p=0.0002). The peak excretion in between treatments was significantly higher for montelukast, 
p=0.0004 (Figure 25).  
 
Figure 25: Urinary excretion of LTE4 before and after challenge with inhaled LTE4 during the two 
treatment periods. Horizontal bars indicate mean values. * P< 0.01 ** P< 0.001 
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Comparing the released amount in urine during and following the challenge with the inhaled 
LTE4 we found that there was a consistent 2% recovery of inhaled LTE4 (2.3% for placebo and 
1.9% for montelukast) across the range of inhaled concentrations (Figure 26). 
 
Figure 26: Ratio of LTE4 excreted in the urine to inhaled LTE4 (%) for the two treatment periods.  
We found a significant correlation between the inhaled dose and the amount of LTE4 excreted 
into the urine (Figure 27).  
 
Figure 27: Relation between inhaled and excreted LTE4 in the urine for both treatment periods 
r=0.68, P<0.0001 (Pearson) 
5.4.2 Prostaglandin D2  
Excretion of the most abundant metabolite, tetranor-PGDM, increased significantly from 
baseline after inhalation of LTE4 during treatment with placebo (baseline 272 ± 77 vs 3743 ± 
1335 peak, p=0.0189). This increase was abolished after treatment with montelukast (baseline 
418 ± 135 vs 509 ± 101 peak, not significant) (Figure 28).  
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Figure 28: Urinary excretion of the most abundant PGD2 metabolite as measured with UPLC-
MS/MS * P<0.05. Horizontal bars indicate mean values.  
Excretion of the early PGD2 metabolite, 2,3-dinor-11β-PGF2α demonstrated a similar pattern 
although the numeric increase during placebo did not reach statistical significance, p=0.072. 
This increase was again blocked completely by montelukast, (Figure 29). 
 
Figure 29: Urinary excretion of the early PGD2 metabolite as measured with UPLC-MS/MS. 
Horizontal bars indicates mean values. 
Next results for the urinary excretion of PGD2 metabolites measured with UPLC-MS/MS were 
replicated by using a commercially available EIA kit for the very early PGD2 metabolite 11β-
PGF2α (Figure 30). The excretion of 11β-PGF2α increased significantly after inhalation of LTE4 
from baseline on placebo (baseline 58 ± 6 vs 383 ± 120 peak, p=0.0163) and this increase was 
again blocked by montelukast (baseline 69 ± 12 vs 80 ± 10 peak, not significant). Using UPLC-
MS/MS we did not find detectable amounts of 11β-PGF2α,which is in concordance with 
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previous findings indicating that the 10% cross reactivity of the antibody against 11β-PGF2α with 
2,3-dinor-11β-PGF2α explains the use of that particular EIA on urine (O'Sullivan, Mueller et al. 
1999, Bood, Sundblad et al. 2015). 
 
Figure 30: Urinary excretion of the very early PGD2 metabolite as measured using an EIA. 
Horizontal bars indicate mean values * P<0.05. 
There was a good agreement between the two measurements by using Bland-Altman analysis 
(Figure 31). 
 
Figure 31: Bland-Altman plot to compare measurements for the early PGD2 metabolite 11β-PGF2α 
between EIA and UPLC-MS/MS 
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5.4.3 Thromboxane B2 and its metabolites 
The most abundant metabolite 2,3DN-TXB2 increased significantly from baseline after 
inhalation of LTE4 on both treatment periods (placebo; 201 ± 74 baseline vs 1853 ± 460 peak, 
p=0.0019. montelukast; 159 ± 41 baseline vs 561 ± 116 peak, p=0.0021). The peak excretion 
was however much greater with placebo compared to montelukast, p=0.0092 (Figure 32). 
 
Figure 32: Urinary excretion of the most abundant thromboxane B2 metabolite measured with 
UPLC-MS/MS during the two treatments. Horizontal bars indicate mean values. **P<0.01 
Results for the primary TXB2 showed a similar excretion pattern as levels increased following 
inhalation of LTE4 on both treatments (placebo; 20 ± 6 baseline vs 136 ± 35 peak, p=0.0038, 
montelukast; 31 ± 13 vs 95 ± 32, p=0.0486 (Figure 33A). Excretion of the metabolite 11DH-
TXB2 increased after LTE4 inhalation only during treatment with placebo 81 ± 22 baseline vs 
220 ± 54 peak, p=0024 (Figure 33B). 
 
Figure 33: Urinary excretion of (A) TXB2 and (B) 11DH-TXB2 for each treatment period. 
Horizontal bars indicate mean values. ** P<0.01 *P<0.05 
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5.4.4 PGF2α  
There was a significant increase in PGF2α after inhalation of LTE4 during placebo treatment 209 
± 74 baseline vs 711 ± 158 peak, p=0.029. During montelukast treatment there was a numerical 
increase that did not reach statistical significance 251 ± 74 baseline vs 411 ± 67 peak, p=0.06. 
Peak excretion was significantly higher with placebo compared to montelukast p=0.035, (Figure 
34).  
 
Figure 34: Urinary excretion of PGF2α during the two treatment periods. Horizontal bars indicate 
mean values. ** P<0.01 *P<0.05. 
5.4.5 Prostacyclin metabolite 2,3-dinor-6-keto-PGF1α 
This metabolite did not increase significantly following LTE4 on either treatment period, there 
was however a trend towards an increase after placebo treatment, p=0.055 (Figure 35). 
 
Figure 35: Urinary excretion of 2,3-dinor-6-keto-PGF1α during the two treatment periods. 
Horizontal bars indicate mean values. 
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5.4.6 PGE2 and its metabolites 
Primary PGE2 increased to the same extent following inhalation of LTE4 on both treatment 
periods (placebo; 57 ± 21 baseline vs 143 ± 31 peak, p=0.0219 montelukast; 69 ± 39 baseline vs 
147 ± 34 peak, p=0.0188) (Figure 36). 
 
Figure 36: Urinary excretion of PGE2 during the two treatment periods. Horizontal bars indicate 
mean values. *P<0.05. 
A similar excretion pattern was observed for the later and more abundant major metabolite of 
PGE2, tetranor-PGEM (placebo; 363 ± 111 baseline vs 1555 ± 365 peak, p=0.0056 montelukast; 
388 ± 90 baseline vs 1823 ± 407 peak, p=0.0037) (Figure 37). 
 
Figure 37: Urinary excretion of the later PGE2 metabolite during the two treatment periods. 
Horizontal bars indicate mean values. ** P<0.01. 
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5.4.7 Isoprostanes 
The most abundant metabolite, 8,12-iPF2α-VI increased following inhalation of LTE4 on both 
treatment periods (placebo; 858 ± 166 baseline vs 2139 ± 347, p=0.0035 montelukast; 1081 ± 
220 baseline vs 1756 ± 273, p=0.0274) (Figure 38).  
 
Figure 38: Urinary excretion of the most abundant isoprostane metabolite during the two 
treatment periods. Horizontal bars indicate mean values. ** P<0.01 *P<0.05. 
8-iso-PGF2α increased after LTE4 challenge only during montelukast treatment 66 ± 20 baseline 
vs 143 ± 33, p=0.0339 (Figure 39A). Excretion of 2,3-dinor-8-iso-PGF2α did not increase 
significantly after LTE4 inhalation on either treatment periods (Figure 39B). 
 
Figure 39: Urinary excretion of two major isoprostane metabolites during the two treatment 
periods. Horizontal bars indicate mean values. *P<0.05. 
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5.4.8 Validation of lipid mediator excretion in biobanked samples from 
previous study with inhalation of LTD4 
In order to validate the results, we went on and performed analysis of urine collected from a 
previous LTD4 bronchoprovocation study performed in our lab (Gyllfors, Kumlin et al. 2005) 
using the same UPLC-MS/MS platform. We found significant increases in the following 
metabolites after LTD4 inhalation: the PGD2 metabolite 2,3-DN-11β-PGF2α; the TXB2 metabolite 
2,3-DN-TXB2; the isoprostanes 8iso-PGF2α, 2,3-DN-8iso-PGF2α and 8,12-iPF2α; and LTE4. The 
results for 2,3-DN-11β-PGF2α and LTE4 are presented in Figure 40, while data for the rest are 
seen in Figure 41.  
 
Figure 40: Urinary excretion of the PGD2 metabolite 2,3-DN-PGF2α and LTE4 after inhalation of 
LTD4. *P<0.05, **P<0.01 and ***P<0.001. ICS: inhaled corticosteroids. 
 
Figure 41: Urinary excretion of 2,3-DN-TXB2 (A) as well as isoprostanes (B)(C)(D) after inhalation 
of LTD4. *P<0.05. ICS: inhaled corticosteroids. 
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No significant increases after LTD4 were observed for the following detected mediators: primary 
TXB2, 11DH-TXB2, PGF2α and the prostacyclin 2,3-DN-6K-PGF1α (Figure 42). Primary PGE2, 
tetranor-PGEM and tetranor-PGDM could not be detected, presumably due to degradation 
during storage, which is in line with previous studies (Idborg, Pawelzik et al. 2014). 
 
Figure 42: Urinary excretion of primary TXB2 (A), 11DH-TXB2 (B), PGF2α (C) and prostacyclin (D) 
after inhalation of LTD4. ICS: inhaled corticosteroids. 
5.4.9 Summary of lipid mediator urinary excretion results 
The study for the first time in human subjects in vivo demonstrated that inhalation of LTE4 
caused an increase in the urinary excretion of metabolites that are indicative of the release of 
PGD2, PGF2α, PGE2 as well as several isoprostanes, which are known markers of oxidative stress 
(Lawson, Rokach et al. 1999). The release of PGD2 is considered to be a sign of mast cell 
activation because the mast cell is known to be the major source of PGD2 in human subjects 
(Lewis, Soter et al. 1982, O'Sullivan, Dahlen et al. 1996, Bood, Sundblad et al. 2015). The 
increased excretion of PGD2 was blocked by montelukast, thus confirming that the mast cell 
activation is CysLT1 dependent. Studies in experimental models have shown that CysLTs can 
activate mast cells and cause secondary prostanoid release (Paruchuri, Tashimo et al. 2009, Liu, 
Garofalo et al. 2015). Next the effect of LTE4 on PGD2 release was replicated by measurements 
using the same UPLC-MS/MS platform on samples that had been biobanked from a previous 
LTD4 bronchoprovocation study (Gyllfors, Kumlin et al. 2005). That study in addition to 
asthmatics, included healthy subjects. They tolerated a higher dose of LTD4 and showed a more 
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pronounced PGD2 mediator excretion in urine, indicating dose-dependent mast cell activation. 
The release of TXA2 and to some extent PGF2α showed a similar pattern to PGD2 and was 
inhibited by montelukast. The mast cell could be the major source for these mediators too, 
although CysLT1 mediated release from other sources is also possible. It still remains poorly 
characterized which lipid mediators are formed in human mast cells in vivo. In contrast, the 
release of PGE2 and its major metabolite, tetranor-PGEM showed a different pattern from PGD2, 
where the increased urinary excretion following LTE4 inhalation was not abolished by 
montelukast. It could be that another receptor is involved in the PGE2 release, possibly from the 
airway epithelium, which is known to be the major source of PGE2 (Churchill, Chilton et al. 
1989, Harrington, Lucas et al. 2008). However, because the peak of urinary excretion of PGE2 
was similar between the two treatment periods despite the fact that subjects inhaled a 10-fold 
greater dose of LTE4 in the presence of montelukast, it is likely that the effect of LTE4 on PGE2 
release at least partly is mediated through the CysLT1 receptor. 
5.5 EFFECT OF INTERVENTIONS ON SKIN PRICK TEST REACTIVITY 
In Paper II a skin prick test titration over a range of dilutions was performed with the allergen 
selected for inhalation prior to the inhalation challenge. This was done in order to evaluate the 
allergen-induced skin test response and how it was affected by the interventions. The area under 
the curve (AUC) in the allergen dilution-response curves for skin wheal diameters was 
calculated by using the linear trapezoidal rule. QGE031 caused a dose- and time-dependent 
inhibition of the allergen-induced skin test response (Figure 43). The effect was greatest for the 
group that received the highest dose of QGE031 (240 mg). In contrast to the airway response to 
allergen, the suppression of the skin response in the 240 mg group was maximal at week 18 i.e. 
eight weeks after the last dose of QGE031 and was observed in all subjects (Figure 43).  
 
Figure 43: Effect of the intervention on the AUC of the wheal response to allergen skin prick 
titration. Graphs represent individual subject time-course data from each treatment group. Data 
are represented as the percentage change in AUC from baseline. Red-coloured data represent 
subjects with IgE levels greater than 700 IU/ml.  
At week 12, there was a significant difference in the allergen-skin prick test response between 
all three QGE031 treatment groups and placebo (all p<0.01), whereas there was no significant 
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inhibition in the group that received omalizumab, p=0.47 (Figure 44B). All three doses of 
QGE031 demonstrated a greater inhibition of the skin prick test response compared to 
omalizumab, which was more pronounced for the group that was treated with 72 and 240 mg of 
QGE031 (p=0.002 and p<0.0001 respectively) (Figure 44A). Omalizumab elicited 22% 
suppression of the allergen-skin prick test response compared to 74% and 85% for the 72- and 
240 mg QGE031 groups respectively at week 12.  
 
Figure 44: Statistical analyses of the geometric mean ratios of AUC of wheal size across all 
dilutions at week 12 for the three QGE031 doses versus omalizumab (A) and placebo (B). Error 
bars represent 95% CIs. Lower ratios indicate lower sensitivity to allergen and therefore better 
suppression by the drug.  
In summary, it was demonstrated that QGE031 inhibited the allergen induced skin prick test 
responses. Similar to the airway response the inhibition was more pronounced in the two groups 
that received the two higher doses of QGE031 compared to the group that was treated with 
omalizumab. It is known that the allergen induced skin wheal reaction can be blocked by 
antihistamines (Gronneberg and Dahlen 1990), which indicates that QGE031 can effectively 
prevent release of histamine in the skin. For the 24- and 72-mg QGE031 groups the mean peak 
efficacy in the skin response was observed at 12 weeks; at 18 weeks it had returned to baseline 
for the 24 mg group while in the 72 mg group some subjects had no worsening or continued to 
improve with the exception of the two subjects with the highest IgE levels, see Figure 43. For 
the 240-mg QGE031 group maximal inhibition was observed at 18 weeks for all subjects unlike 
inhibition of the airway response, which was maximal at 12 weeks in this group. Thus our 
findings highlight the fundamental differences in the allergen response of airway mucosal 
surfaces compared to the skin.  
5.6 EFFECT OF INTERVENTIONS ON MARKERS MEASURED IN BLOOD 
In Paper II blood samples were collected during the study for measurements of serum total 
QGE031, serum total and free IgE, FcεRI on basophils and dendritic cells, CD23 on B cells and 
bound IgE on basophils. In Paper III blood samples were collected before challenge with LTE4 
and five minutes after the last dose was administered for measurement of circulating white blood 
cell counts. 
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5.6.1 Pharmacokinetics of QGE031 
The average steady-state serum concentrations at week ten, before the last dose of QGE031 were 
1.8 µg/ml (coefficient of variation CV 34%) for the 24-mg-QGE031 group, 5.6 µg/ml (CV, 
33%) for the 72-mg-QGE031 group and 13.2 µg/ml (CV, 25%) for the 240-mg-QGE031 group. 
The results were similar at week twelve i.e. one dosing interval after the last dose: 2.3 µg/ml 
(CV, 38%), 6.7 µg/ml (CV, 36%) and 15.5 µg/ml (CV, 28%) respectively. Exposure increased 
with dose, with steady state accomplished at the end of the dosing period. 
5.6.2 Total serum IgE levels 
There was an increase in total IgE levels (sum of free and drug captured IgE levels) from 
baseline across all treatment groups except for placebo. The extent and duration of IgE binding 
was dependent on QGE031 dose (Figure 45A), which was also seen for omalizumab. There are 
several factors that influence levels of total circulating IgE such as cellular synthesis, binding 
affinity to FcεRI, occupancy of IgE receptors and elimination of free IgE and drug-IgE 
complexes. Measurements of free IgE were also performed although all QGE031 doses 
suppressed IgE levels to below the assay lower limit of quantification in most subjects. Because 
the results from the measurements of the downstream biomarkers basophil surface IgE and 
FcεRI showed a clear response, no further analysis of free IgE was performed.  
5.6.3 Surface IgE and FcεRI expression 
There were observed numeric dose-dependent reductions in basophil surface IgE levels in all 
treatment groups except for placebo. The responses were more pronounced in the groups 
receiving the two higher doses of QGE031 and less pronounced in the omalizumab and the 24 
mg QGE031 group (Figure 45B). At week 12 the suppression of surface IgE from baseline 
reached 66%, 99%, 99% and 95% for 24, 72, 240 mg of QGE031 and omalizumab respectively. 
When compared to placebo surface IgE levels were reduced by 71%, 99%, 99% and 95% for 24, 
72, 240 mg of QGE031 and omalizumab respectively and by 86% and 87% with 72 and 240 mg 
of QGE031 when compared to omalizumab. 
At week 12 the reduction of basophil expression of FcεRI from baseline reached 27%, 82%, 
85% and 77% for 24, 72, 240 mg of QGE031 and omalizumab respectively. When compared to 
placebo the reduction was 22%, 81%, 84% and 75% with 24, 72, 240 mg of QGE031 and 
omalizumab respectively and by 21% and 34% with 72 and 240 mg of QGE031 when compared 
to omalizumab. There was no reduction achieved for the two subjects with the highest levels of 
IgE in the group of 24 mg QGE031. Suppression of FcεRI after stopping treatment was longest 
in the group receiving the highest dose of QGE031 240 mg (Figure 45C). 
In total there was a clear reduction in the basophil FcεRI and surface IgE levels after treatment 
with QGE031, which has also been demonstrated in previous phase 1 studies (Arm, Bottoli et al. 
2014). This effect of QGE031 on expression of basophil FcεRI, surface IgE and even total IgE 
levels was rapid and in some cases a maximal change was observed in the first blood sample 
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taken two weeks after treatment start. This was different from the response both in the airways 
and the skin that lagged behind. 
 
Figure 45: Effect of QGE031 and omalizumab in IgE and IgE receptor expression. Individual 
subject time course of circulating total IgE (A), basophil surface IgE levels (B) and basophil 
expression of FcεRI (C) for placebo, the three dose levels of QGE031 and omalizumab. Red-
coloured data represent subjects with baseline IgE levels of greater than 700 IU/mL. Units for the 
basophil FACS assay were molecules of equivalent soluble fluorophore (MESF) divided by 1000. 
5.6.4 White blood cell counts  
Inhalation of LTE4 elicited a significant increase in the white blood cell count during placebo 
treatment (baseline 6.4 ± 1.5 x 10(9)/L vs. 7.01 ± 2.06 x 10(9)/L after, p=0.0257), which was not 
significant after treatment with montelukast (baseline 6.7 ± 1.6 vs. 7.2 ± 1.9 after, p=0.13) 
(Figure 46A). Neutrophils increased slightly after the challenge on both treatment periods 
although this increase was not significant (placebo; baseline 3.5 ± 1.2 vs. 3.6 ± 1.6 after, p=0.52 
and montelukast; baseline 3.6 ± 1.2 vs. 3.8 ± 1.3 after, p=0.49), (Figure 46B). There was 
predominant increase in lymphocytes after inhalation of LTE4 on both periods (placebo; baseline 
2.0 ± 0.5 vs. 2.5 ± 0.5 after, p<0.001 and montelukast; baseline 2.1 ± 0.6 vs. 2.5 ± 0.6 after, 
p=0.0235) (Figure 46D), while eosinophils slightly decreased (placebo; baseline 0.27 ± 0.15 vs. 
0.22 ± 0.14 after, p=0.0013 and montelukast; baseline 0.23 ± 0.17 vs. 0.19 ± 0.17 after, 
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p=0.0552) (Figure 46C). There was also a non-significant decrease in monocytes after LTE4 
challenge (placebo; baseline 0.55 ± 0.16 vs. 0.54 ± 0.2 after, p=0.9 and montelukast; baseline 
0.58 ± 0.15 vs. 0.54 ± 0.12, p=0.11) (Figure 46E), while basophils were undetectable on both 
treatment periods.  
 
Figure 46: Effect of inhaled LTE4 on circulating total white blood cells, neutrophils, eosinophils, 
lymphocytes and monocytes during the two treatment periods. Horizontal bars indicate mean 
values. 
In summary, we have shown for the first time that LTE4 inhalation caused a rapid increase in 
numbers of circulating white blood cells in human subjects. This was predominantly due to an 
increase in the numbers of circulating lymphocytes and a decrease in eosinophil counts; both of 
these effects were unaffected by montelukast, which might suggest involvement of other 
receptors. Future studies are needed in order to characterize this new finding in greater detail.  
5.7 EFFECT OF INTERVENTIONS ON MEASURES OF ASTHMA CONTROL 
In Paper I, participants recorded asthma symptoms as well as their physical activity in an 
electronic diary on a daily basis, and completed the ACQ5 questionnaire on study days. Results 
from ACQ5 and reported asthma symptoms are presented in Table 11. Already at baseline i.e. 
prior to treatment, all subjects had a relatively low ACQ5 score supporting that they, as 
intended, had mild asthma. After 6 weeks of treatment ACQ5 scores decreased to less than 1.0 
in all groups, which indicates that their asthma was under control. Subjects recorded symptoms 
on approximately half of the days exercise was performed with low symptom scores in all three 
groups, while there were almost no symptoms on exercise free days (Table 11). Neither 
symptom nor ACQ5 scores differed between the three treatment groups at any visit.  
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Table 11: ACQ5 and symptom scores at baseline and after six weeks of treatment during days with 
and without exercise. *Asthma symptoms associated with exercise are calculated on days when 
exercise was performed. *Asthma symptoms not associated with exercise indicate days with any 
symptom not related to exercise during the whole study. Symptoms are measured on a scale from 0 
to 4, where 0 indicates no symptoms and 4 maximal symptoms. Data are presented as mean ± SD. 
In summary, results from subject-reported measures indicate that all subjects including the ones 
receiving only terbutaline on demand perceived that they had a good asthma control and an 
effective treatment of EIB with low symptom scores on exercise days similar to the two other 
groups that were treated with ICS.  
5.8 PHARMACOKINETICS MODEL AND SIMULATION 
A mathematical pharmacokinetics/pharmacodynamics model descriptive of drug 
pharmacokinetics for QGE031 and omalizumab was built based on the data from the current 
study; model curves fitted the observed subject data well (Figure S1 in the supplementary 
material to Paper II). The model included both biomarker and clinical responses, with 
agreement between simulated and observed data, normal distributions of random variation 
between subjects and accurate predictions in quantile-quantile plots, see figure S2 in the papers 
supplementary material. Together with the precise pharmacokinetics, biomarker and allergen 
challenge pharmacodynamic parameter estimates (Tables E3 and E4 in the supplementary 
material of Paper II), were such that the model was considered valid for providing predictions 
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through simulation. Simulations were therefore performed for approximately 1000 virtual 
subjects and predicted the biomarker and allergen test response time courses from pre-treatment 
to six months for doses from zero to 600 mg of QGE031 administered every four weeks and 
omalizumab dosed as per the US dosing table (Xolair 2010). Simulation results showed that 
maximal suppression of the skin allergic response would occur after 12 weeks of treatment, 
while the airway response to allergen was predicted a bit earlier, after about 8 weeks of 
treatment (Figure S3 in the supplementary material of Paper II). The biomarker and allergen 
responses from the 168th day were taken to plot QGE031 dose responses. These indicated that 
for subjects with baseline IgE levels of less than the median value of 250 IU/mL, 36 mg of 
QGE031 every four weeks should provide equivalent inhibition of allergen-induced skin and 
airway response to omalizumab (Figure 47). Maximal QGE031- induced responses that 
exceeded those of omalizumab would occur with higher doses; subjects with lower baseline IgE 
values would reach maximal effects with 120 mg of QGE031 every four weeks, while those 
with higher values would require higher doses, such as 240 mg every four weeks.  
 
Figure 47: Simulation of steady state (week 24) dose responses to QGE031 for a population split by 
the median baseline IgE level. Simulated doses on the x-axis are those for QGE031 administered 
every 4 weeks. Omalizumab error bars refer to simulated measurements administered according to 
the US dosing table.  
5.9 SAFETY 
All interventions were well tolerated and there were no severe adverse events or withdrawals 
due to adverse events in the active treatment groups/periods. For subjects receiving QGE031 
nasopharyngitis and asthma worsening were the most common reported adverse events, which 
were not dose dependent. Most suspected drug-related adverse events were related to injection-
site reactions that were of mild nature. No cases of urticarial or anaphylaxis were reported.  
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6 CONCLUSIONS 
The main conclusions of this thesis are: 
• Treatment with a combination of bud/form on-demand was non inferior to regular 
treatment with budesonide in subjects with mild asthma and EIB. 
• Treatment with three to four doses per week with bud/form combination on-demand was 
sufficient to provide good asthma control, indicating that this could be an alternative to 
regular budesonide treatment in mild asthmatics.  
• Both treatment with a combination of bud/form on-demand and regular budesonide were 
superior to terbutaline monotherapy on-demand on inhibiting EIB.  
• Monotherapy with terbutaline slightly increased the bronchial response to exercise 
propably due to tachyphylaxis regarding the β2 protective effect, indicating that 
terbutaline monotherapy should be avoided in subjects with mild asthma. 
• The mannitol bronchial challenge was not as sensitive as the exercice challenge in 
diagnosing EIB in subjects with mild asthma.  
• Treatment with QGE031 caused a shift in the allergen PC15 that was three times greater 
for the highest dose of QGE031 (240 mg) compared to omalizumab and sixteen times 
greater compared to placebo.  
• There was a remarkable variability on the shift of allergen PC15 among subjects treated 
with QGE031 (2-fold to 500-fold change). 
• The maximal response regarding allergen PC15 was seen at 12 weeks (2 weeks after the 
last dose) in subjects treated with QGE031, with effects declining by week 18.  
• Allergen skin prick test responses were inhibited by treatment with QGE031 with greater 
inhibition for the highest dose, whereas omalizumab made no difference from treatment 
with placebo.  
• There was no variability regarding the skin response among subjects treated with 
QGE031, and those receiving the highest dose (240 mg) continued to improve at week 
18, six weeks after the last dose. 
• The effects of QGE031 on total serum IgE levels, surface IgE and expression of FcεRI 
were dose dependent with greater effects for subjects receiving the two higher doses.  
• Subjects with high baseline IgE levels had poor responses to lower doses of QGE031 
whereas dependancy on baseline IgE was not seen for those treated with the highest dose 
of 240 mg. 
• QGE031 was well tolerated in all treatment groups. 
• Montelukast completely inhibited the bronchoconstriction induced by inhaled LTE4 
indicating that the effect of LTE4 on smooth muscle in asthmatics is mediated solely 
through the CysLT1 receptor. 
• Inhalation of LTE4 elicitated significant small airway obstruction that was also inhibited 
by montelukast. 
• Sputum eosinophils post LTE4 inhalation remained the same when subjects were treated 
with montelukast compared to placebo, despite inhaling a ten-fold higher cumulative 
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dose of LTE4. This argues against the presence of another receptor for the 
proinflammatory effects of LTE4 on airway cells.  
• Inhalation of LTE4 led to increased urinary excretion of PGD2 metabolites, which is a 
sign of mast cell activation; this activation was also mediated through CysLT1. 
• The findings indicate that CysLTs may need to be reclassified as dual 
bronchonconstrictors, with direct effects on smooth muscle and indirect effects by mast 
cell activation and release of PGD2 which is a known bronchoconstrictor. 
• TXA2 and PGF2α release was aslo increased after LTE4 inhalation and was likewise 
sensitive to inhibition by montelukast. 
• PGE2 release was however not blocked by montelukast, possibly implying the presence 
of another receptor probably on the airway epithelium. 
• PGE2 release was however not increased during treatment with montelukast despite 
subjects inhaling a much higher dose of LTE4 during this period, which suggests that the 
CysLT1 nonetheless is partially involved.  
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7 GENERAL DISCUSSION  
7.1 HOW SHOULD WE TREAT MILD INTERMITTENT ASTHMA AND EIB 
Mild asthma is estimated to affect about 50% to 75% of all asthmatic subjects and can lead to 
severe exacerbations that represent approximately 30% to 40% of asthma exacerbations that 
require emergency consultation (Dusser, Montani et al. 2007). One component of mild 
intermittent asthma is EIB. Subjects may have symptoms that are related to exercise despite 
otherwise well controlled asthma or exercise is the only asthma trigger.  
7.1.1 Monotherapy with β2 agonists on demand 
According to guidelines (Bateman, Hurd et al. 2008, Parsons, Hallstrand et al. 2013, British 
Thoracic and Scottish Intercollegiate Guidelines 2014), the first treatment of choice to alleviate 
EIB is administration of a SABA 5 to 20 minutes before exercise, which is effective for 2-4 
hours (Tan and Spector 2002, Carlsen, Anderson et al. 2008). This is somewhat controversial 
because it is known that airway inflammation is present already at this stage of the disease 
(Vignola, Chanez et al. 1998, Hallstrand, Moody et al. 2005a, Hallstrand, Moody et al. 2005b). 
The initial recommended treatment is therefore focusing on symptom relief rather than the 
underlying mechanism. The results of my exercise bronchoprovocation study in Paper I clearly 
demonstrate that after six weeks of intermittent treatment with terbutaline there was no long-
term bronchoprotective effect against exercise, in fact EIB slightly worsened compared to 
baseline. The focus of my study was the effect of treatment on the bronchoprotective effect 
against EIB and not the direct bronchodilator effect. The latter was maintained as indicated by 
the rapid recovery of FEV1 back to baseline after terbutaline inhalation (30 minutes after the end 
of the challenge) in all treatment groups. This included the group receiving terbutaline 
monotherapy (Figure 9 in section 5.2.1). The low symptom scores on exercise days and the 
decrease in ACQ5 value after six weeks of treatment compared to baseline for all groups 
including the terbutaline group also indirectly indicate this. 
The loss of bronchoprotection (tachyphylaxis) against exercise observed in this study has also 
been reported previously after regular use of both SABAs and LABAs with cross-tolerance to 
other β2 agonists. The degree of tachyphylaxis appears to be slightly greater regarding protection 
against indirect stimuli, such as exercise and allergen challenge compared to stimuli that act 
directly on the smooth muscles, such as methacholine challenge (Lipworth 1997). In previous 
bronchoprovocation studies using methacholine, regular treatment with salmeterol has led to 
tachyphylaxis within the first hours after treatment start in both steroid naïve subjects (Cheung, 
Timmers et al. 1992, Bhagat, Kalra et al. 1995, Drotar, Davis et al. 1998) as well as in subjects 
using ICS (Booth, Bish et al. 1996, Kalra, Swystun et al. 1996, Lipworth and Aziz 1999). 
Interestingly, it has been also reported that regular use of β2 agonists may lead to loss of the 
bronchodilator effect of rescue SABA used after bronchoconstriction with either methacholine 
(Hancox, Aldridge et al. 1999, Wraight, Hancox et al. 2003, Haney and Hancox 2005, Haney 
and Hancox 2007) or exercise (Hancox, Subbarao et al. 2002, Storms, Chervinsky et al. 2004). 
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This increases the risk that asthma patients with an on-going worsening have less bronchodilator 
responsiveness when they need it the most.  
Similar to methacholine, tachyphylaxis with regard to the protective effect of β2 agonists has 
been reported following indirect challenges with allergen (Cockcroft, McParland et al. 1993, 
Giannini, Carletti et al. 1996, Dahlen, Lantz et al. 2009), AMP (O'Connor, Aikman et al. 1992, 
Aziz, Tan et al. 1998) and of course exercise (Ramage, Lipworth et al. 1994, Inman and O'Byrne 
1996, Simons, Gerstner et al. 1997, Nelson, Strauss et al. 1998, Villaran, O'Neill et al. 1999, 
Edelman, Turpin et al. 2000). 
Taken together, it has been shown that the onset of tachyphylaxis is rapid, can occur within 
twelve hours after the first dose, can increase with continuous β2 agonist use before reaching a 
plateau with recovery within 72 hours after the last dose, and can affect also subjects receiving 
ICS (Weiler, Brannan et al. 2016). Moreover, some of these studies have reported that daily use 
of β2 agonists can actually increase both EIB (Inman and O'Byrne 1996, Hancox, Subbarao et al. 
2002) and the bronchial responsiveness to methacholine (Vathenen, Knox et al. 1988) and cause 
partial bronchodilator subsensitivity (Newnham, Dhillon et al. 1993, Grove and Lipworth 1995, 
Newnham, Grove et al. 1995, Hancox, Cowan et al. 2000). 
The underlying mechanism or mechanisms of tachyphylaxis are still not clear but the most 
possible explanation is that chronic exposure of the β2 receptors to β2 agonists can cause 
uncoupling and internalization of the receptors in the cells where they are degraded (Johnson 
2006). This β2 receptor loss elicits a downregulation of the receptors and the responsiveness to β2 
agonists, which can be reversed by resynthesis of the receptors that has been shown to occur 
clinically within 72 hours after the last β2 agonist dose (Haney and Hancox 2005, Haney and 
Hancox 2006). However, this downregulation of the β2 receptors causes only a partial reduction 
in the bronchodilator response to β2 agonists due to the large reserve of these receptors in the 
airway smooth muscle cells. This is not the case for other inflammatory cells such as mast cells 
and lymphocytes, where β2 agonists can cause a rapid downregulation in vitro, which reflects the 
low density of β2 receptors in these cells (Chong, Morice et al. 1995, McGraw and Liggett 1997, 
Barnes 1999, Scola, Chong et al. 2004). If it is taken into consideration that β2 agonists also may 
block the release of bronchoconstrictive mediators from mast cells such as CysLTs and 
histamine (Chong and Peachell 1999), it appears consistent that β2 receptor downregulation leads 
to loss of the bronchoprotective effect of β2 agonists against EIB, where mast cells have a key 
role. Moreover, downregulation of the β2 receptor may result in augmentation of pathways 
mediated through the CysLTs, histamine and thromboxane receptors that can potentially 
enhance EIB (Anderson 2006, McGraw, Elwing et al. 2007). It is evident that monotherapy with 
β2 agonists leads to tachyphylaxis and loss of the drugs bronchoprotective effect and thus 
eventually a greater risk for asthma related complications, which is why it is avoided in more 
severe asthma (Spitzer, Suissa et al. 1992, Nelson, Weiss et al. 2006, Salpeter, Buckley et al. 
2006). The results of my bronchoprovocation study clearly demonstrate that β2 agonist 
monotherapy should be avoided also in subjects with mild asthma and EIB, and alternative 
treatment given.  
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7.1.2 Regular treatment with ICS 
According to previous versions of the GINA guidelines published at the time our study was 
conceived, subjects with EIB should inhale a SABA prior to exercise (step 1) and if reliever 
medication was needed more than two times a week, regular treatment with ICS should be 
considered (step 2). One of the main issues is that these subjects often inhale a SABA before 
exercise as a routine, meaning that the exact need for treatment is not known. The guidelines 
have however, been updated through the years. In the latest versions of the GINA guidelines, 
due to the emerging evidence regarding the insufficient safety of SABA monotherapy and risk 
of exacerbations already in this stage of mild asthma, low dose ICS is in fact already considered 
an alternative at step 1 (GINA report 2018). Continuous treatment with ICS is considered the 
best controller option for EIB due to its direct anti-inflammatory effect and can reduce both the 
frequency and severity of EIB but not necessarily completely abolish it (Koh, Tee et al. 2007, 
Weiler, Brannan et al. 2016). 
This change of view is very much in agreement with the results in Paper I where regular 
treatment with low dose ICS for six weeks was the best treatment option for EIB but did not 
completely eliminate it. After three weeks of treatment there was a small, although not 
significant reduction in EIB. This finding also confirms previous studies showing that regular 
ICS treatment can provide some bronchoprotection against EIB after one week, although a 
greater protection is observed after three to four weeks of treatment depending upon the dosage 
(Hofstra, Neijens et al. 2000, Petersen, Agertoft et al. 2004, Subbarao, Duong et al. 2006, 
Stelmach, Grzelewski et al. 2008). It seems that the protective effect begins to plateau after one 
week (Duong, Subbarao et al. 2008) with further improvement upon the next weeks with 
continuous treatment until the final plateau is reached, which may relate to the degree of 
underlying inflammation (Koh, Tee et al. 2007). In fact, there is substantial evidence indicating 
that even a single high dose of ICS can have some bronchoprotective effect against EIB as early 
as four hours after the dose in children (Thio, Slingerland et al. 2001, Driessen, Nieland et al. 
2011) and against EVH induced bronchoconstriction in adults (Kippelen, Larsson et al. 2010). In 
the latter study, it was also demonstrated that ICS treatment reduced the urinary excretion of 
bronchoconstrictive eicosanoid mast cell mediators, indicating that this effect is due to mast cell 
inhibition in the airways. Similarly, a single dose of ICS significantly inhibited the 
bronchoconstrictive effect of inhaled AMP, which is also mediated through mast cell 
degranulation, as early as two hours after the first dose (Ketchell, Jensen et al. 2002). A 
significant reduction in sputum eosinophils and protection against hypertonic saline induced 
bronchoconstriction has also been reported as early as six hours after the dose (Gibson, Saltos et 
al. 2001). In line with previous data, the chosen interval of six weeks of treatment in Paper I 
was sufficient to demonstrate efficacy against EIB. 
The effects of regular ICS treatment on EIB are dose dependent. Because the study in Paper I 
included a mixed group of children over 12 years of age and adults, a low daily dose of 
budesonide 400 µg was chosen. Low doses of ICS provide significant protection against EIB in 
children (Freezer, Croasdell et al. 1995, Pedersen and Hansen 1995, Jonasson, Carlsen et al. 
2000, Visser, Wind et al. 2015) and a high dose of budesonide (1600 µg daily) protected against 
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EIB in adults with more severe asthma and with a greater pretreatment FEV1 fall post exercise 
compared to our group of mild asthmatics (Vathenen, Knox et al. 1991). In the study by 
Subbarao et al, treatment with low dose of ciclesonide protected against EIB in adults, although 
a greater protection was observed with higher doses (Subbarao, Duong et al. 2006). Thus, it is 
possible that a higher dose of budesonide in the group that received regular treatment in Paper I 
would have had even greater protection against EIB. 
However, even if regular treatment with ICS has great efficacy in protecting against EIB, this 
option has its own pitfalls. The main one is that regular ICS treatment will not completely 
abolish EIB, meaning that the need for the use of a reliever medication such as a SABA before 
exercise remains. Considering that these subjects have otherwise well controlled asthma as 
indicated by the low ACQ5 values in Paper I, there is a risk of poor adherence to treatment. 
Studies in this segment of patients show that they take less than 50% and usually about 30% of 
the prescribed ICS, and that most therefore nevertheless rely on as needed SABA (Jonasson, 
Carlsen et al. 2000, Williams, Pladevall et al. 2004). In addition, with this approach, while 
initially with the use of SABA as needed patients learned to have autonomy and their own 
perception of medication need and disease control, this now has to be unlearned with the regular 
use of ICS irrespectively of symptoms. This can be confusing for many asthmatics and lead to 
the paradox that in case of asthma worsening, most of them tend to rely on their reliever 
medication instead of using their ICS inhaler (O'Byrne, Jenkins et al. 2017). It is known that 
early intervention with ICS in mild asthma can prevent more severe exacerbations (Pauwels, 
Pedersen et al. 2003). In order to cope with these issues an alternative treatment option with a 
combination of bud/form was tested in Paper I and the results are going to be further discussed 
in the next section. 
7.1.3 Treatment with a combination of ICS/formoterol on demand 
In Paper I it was demonstrated for the first time that treatment with a combination of bud/form 
three to four times per week provided the same magnitude of bronchoprotection against exercise 
compared to regular treatment with low dose budesonide, implying that this could be an 
alternative treatment in patients with mild asthma; in addition combination treatment was clearly 
superior to monotherapy with terbutaline taken on demand. These results have implications for 
asthma guidelines. In the GINA 2018 report, combination treatment is recommended in step 3, 
while low dose ICS can be considered as an alternative option already at step 1 (GINA report 
2018). However, the results of the study in Paper I argues that the combination of bud/form 
might be preferred to SABA monotherapy in step 1, and also should be considered as an 
alternative to regular ICS treatment at step 2. 
The scientific rationale for using a combination therapy with ICS/LABA in asthma (and its 
benefits) has been promoted for several years (Barnes 2002). Formoterol should be the LABA of 
choice in an as-needed treatment option due to its rapid onset of action, which makes it an 
effective reliever medication in asthma, as well as its long bronchodilator effect with systemic 
side effects similar to a SABA (Tattersfield, Lofdahl et al. 2001, Pauwels, Sears et al. 2003, 
Kaae, Agertoft et al. 2004, Cheung, van Klink et al. 2006). In one study when used three times 
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per week, little or no tolerance developed (Davis, Reid et al. 2003). Formoterol has also an 
inhibitory effect on plasma leakage in the airways, which should not be considered negligible 
(Erjefalt and Persson 1991, Tokuyama, Lotvall et al. 1991, Baluk and McDonald 1994), as well 
as a mast cell stabilising effect, which is an important mechanism in reducing EIB (Ketchell, 
Jensen et al. 2002). There is also data suggesting synergetic effects of ICS and LABA when 
taken together; corticosteroids can increase β2 receptor expression and reverse the β2 receptor 
uncoupling in experimental animal models and LABAs can enhance the translocation of the 
glucocorticoid receptors (GR) with also an increase in glucocorticoid receptor element (GRE) 
binding of the GR (Barnes 2007).  
The interactions between ICS and LABA as well as the favourable profile of formoterol for as-
needed use have contributed to the development of the combination of bud/form in a single 
inhaler for both maintenance and reliever treatment in asthma i.e. SMART treatment regimen 
(Kew, Karner et al. 2013). SMART has shown better efficacy in preventing exacerbations and 
treating asthma symptoms compared to a higher dose of budesonide with SABA for relief 
(Scicchitano, Aalbers et al. 2004, Rabe, Pizzichini et al. 2006, Jenkins, Eriksson et al. 2017), as 
well as compared to a fixed combination of salmeterol/fluticasone with SABA for relief 
(Vogelmeier, D'Urzo et al. 2005, Bousquet, Boulet et al. 2007, Kuna, Peters et al. 2007). 
SMART is also more effective in reducing exacerbations compared to the same fixed 
combination of budesonide/formoterol with SABA or LABA for relief (O'Byrne, Bisgaard et al. 
2005, Bisgaard, Le Roux et al. 2006, Rabe, Atienza et al. 2006, Edwards, von Maltzahn et al. 
2010). In addition, SMART appears to be more cost-effective than treatment with a higher 
maintenance dose of ICS/LABA with a rapid-acting β2 agonist for relief (Lundborg, Wille et al. 
2006, Price, Wiren et al. 2007). 
The efficacy of treatment with ICS on symptom-driven as needed basis alone, or when 
combined with β2 agonists versus traditional regular ICS treatment, has been debated over the 
years. It has been proposed that SABA monotherapy should be replaced with a combination 
treatment taken on demand and that more clinical trials are needed to test this approach (Papi, 
Caramori et al. 2009). This is one of the main reasons the study presented in Paper I of this 
thesis was developed. The protocol including exercise challenges was chosen because it is also 
known that the severity of EIB is considered a reflection of asthma control, or lack of control. 
Persistent EIB despite treatment often indicates a need for reassessment of therapy (Hofstra, 
Neijens et al. 2000). One previous study using beclomethasone combined with SABA in a single 
inhaler taken on an as needed basis showed similar efficacy with regular beclomethasone 
treatment (Papi, Canonica et al. 2007), whereas in another study from the same group, the 
combination of bud/form taken as-needed was inferior to regular treatment with the same 
combination (Papi, Marku et al. 2015). Because the main question remained unanswered, two 
large phase 3 clinical trials of the efficacy and safety of bud/form as needed were studied in 
slightly less than 8000 subjects with mild asthma (SYGMA programme) (O'Byrne, FitzGerald et 
al. 2017). Both trials were double blind including adults and adolescents 12 years of age or older 
with mild asthma that were followed for one year.  
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In the SYGMA 1 trial (O'Byrne, FitzGerald et al. 2018) a total of 3849 patients were randomised 
to three treatment groups: terbutaline as needed, budesonide 400 µg daily plus terbutaline as 
needed, or a combination of bud/form as needed. The interventions studied in the SYGMA 1 
trial were the same as used in Paper I. The primary endpoint in this trial was to compare the 
efficacy of as-needed bud/form to as-needed terbutaline with regard to electronically recorded 
weeks with well-controlled asthma. Treatment with bud/form as needed was superior to SABA 
monotherapy with terbutaline regarding the primary endpoint (mean percentage of weeks per 
patient 34.4% bud/formo vs 31.1% terbutaline, p=0.046). Bud/form as needed also resulted in a 
64% lower rate of severe and 60% lower rate of moderate-to-severe exacerbations compared to 
terbutaline used as needed, whereas there was no difference compared to the regular budesonide 
group regarding exacerbations. It should be mentioned that 19.7% of the subjects that underwent 
randomisation in this trial had reported a serious exacerbation the previous year. Regarding the 
mean percentage of weeks with well-controlled asthma per patient bud/form as needed was 
inferior to regular treatment with budesonide (34.4% bud/form vs 44.4% regular budesonide). 
However, the median daily dose of inhaled budesonide in the bud/form as-needed group was 
17% of the dose in the regular budesonide group.  
In the SYGMA 2 trial (Bateman, Reddel et al. 2018), 4215 patients with mild asthma that were 
eligible for regular ICS treatment (step 2 according to GINA guidelines) were randomised to 
either bud/form as-needed or regular treatment with budesonide 400 µg daily plus terbutaline. 
This was a non-inferiority study with the primary endpoint comparing the two treatment 
regimens regarding the annualized rate of severe exacerbations. The as-needed treatment with 
bud/form was non-inferior to regular treatment with budesonide (0.11 bud/form vs. 0.12 regular 
budesonide). The time to the first exacerbation was also similar between the two treatments, 
while there was a slightly greater improvement in ACQ5 in the regular budesonide group, which 
nonetheless was not considered clinically significant.  
Thus the results of both these two large studies in patients with mild asthma have confirmed the 
results from Paper I presented in this thesis i.e. that bud/form taken as-needed is superior to 
SABA monotherapy also taken as needed and non-inferior to treatment with low dose ICS. It 
seems now that there is enough evidence for a revision of the current asthma guidelines and a 
first simplified proposal of the new guidelines is presented in this thesis (Figure 48). 
 
Figure 48: Recommended revision of the GINA guidelines stepwise approach for treating asthma. 
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According to the proposed revision of the guidelines in step 1, treatment with SABA 
monotherapy for symptom relief is replaced by the combination treatment of bud/form taken 
also for symptom relief, while at step 2 intermittent use of bud/form is considered an alternative 
controller medication to regular treatment with low dose ICS.  
7.2 ANTI IGE THERAPY IN THE ALLERGEN PROVOCATION SETTING 
Anti IgE therapy with omalizumab, the only approved humanized anti-IgE monoclonal antibody 
(mAb), has been used for more than 15 years for treatment of allergic asthma with efficacy 
shown in several randomised control trials (RCTs). A recent Cochrane review including 25 
RCTs in subjects with moderate-to-severe allergic asthma concluded that omalizumab reduced 
asthma exacerbations by 25%, reduced hospitalizations due to asthma, and allowed tapering of 
the daily used ICS dose compared to placebo (Normansell, Walker et al. 2014). Omalizumab has 
shown similar efficacy in reducing asthma exacerbations also in real-life studies (Niven, 
Saralaya et al. 2016, Casale, Luskin et al. 2019), while in one study there was also a small 
improvement in lung function (Humbert, Beasley et al. 2005). Omalizumab dosing and 
administration frequency (every two or four weeks) depends on body weight and pre-treatment 
serum total IgE levels (approved range for adults 30 to 700 IU/mL in the United States and 30 to 
1500 IU/ml in the European Union). There are nonetheless reports from previous studies 
supporting the benefit of omalizumab treatment even for subjects outside the recommended 
range of bodyweight/total IgE (Kwong and Jones 2006, Zielen, Lieb et al. 2013, Kornmann, 
Watz et al. 2014, Hew, Gillman et al. 2016). 
In Paper II, treatment with different doses of a second generation of anti-IgE antibody 
(QGE031/ligelizumab) was compared to omalizumab regarding the inhibition of EAR after 
allergen challenge. The results showed that the highest dose of QGE031 caused a shift in the 
allergen PC15 that was numerically three times greater than omalizumab, although this difference 
did not reach statistical significance. There was variability in the degree of inhibition of the EAR 
among subjects treated with QGE031, which was not observed in the skin prick test responses. 
All doses of QGE031 caused a significantly greater inhibition of the skin prick test responses to 
allergen compared to omalizumab, which was dose dependent with best efficacy for the highest 
dose. As expected, serum total IgE levels increased in all groups, including omalizumab. There 
was a reduction in basophil surface IgE levels in all subjects treated with the two highest doses 
of QGE031, whereas this reduction was less pronounced for the lowest QGE031 dose and for 
omalizumab. Basophil expression of FcεRI was also reduced in all groups, including 
omalizumab, although no suppression was observed for the two subjects that had the highest IgE 
levels and were treated with the lowest dose of QGE031. In general, it was observed that 
subjects with high IgE levels (> 700 IU/mL) had poorer responses to the two lower doses of 
QGE031, especially regarding responses from the skin, as well as effects on basophil IgE and 
FcεRI. This difference was abolished in the group that received the highest dose of QGE031 
with respect to all the efficacy measurements. In addition, the response duration for all outcomes 
was longest for subjects receiving the highest dose of QGE031, and was longer than for 
omalizumab. However, there was a variation of the time the maximal response to QGE031 was 
  79 
achieved in the different compartments; the effect on total IgE, surface IgE and FcεRI 
expression was achieved after two weeks, while the airway response was maximal at 12 weeks, 
two weeks after the last dose and returned to baseline at week 18, which was also seen for 
omalizumab. Moreover, the skin response peaked also at 12 weeks for the two lowest doses of 
QGE031, whereas the group that received the highest dose continued to improve at week 18, i.e. 
six weeks after the last dose. No cases of anaphylaxis were reported with QGE031 treatment 
possibly due to the fact that similar to omalizumab it does not bind to cell-bound IgE, which 
results in avoidance of FcεRI cross-linking that would potentially increase the anaphylaxis risk.  
The results of this allergen bronchoprovocation study demonstrate the complexity of allergen-
induced responses with differences regarding the various tissues and the efficacy of anti-IgE 
therapy. Anti-IgE therapy with omalizumab has been shown to inhibit the EAR and LAR after 
allergen inhalation (Boulet, Chapman et al. 1997, Fahy, Fleming et al. 1997) as well as allergen 
induced eosinophilic inflammation in the airways (van Rensen, Evertse et al. 2009). Similarly, 
outside the bronchoprovocation setting, anti-IgE therapy significantly reduced the eosinophil 
count in both the bronchial mucosa as well as in induced sputum compared to placebo in 
subjects with mild to moderate persistent asthma (Djukanovic, Wilson et al. 2004). The 
mechanism of action of anti-IgE therapy is that the drug binds to free IgE thus forming IgE/drug 
complexes that reduce free IgE levels and prevent interaction of IgE to FcεRI receptors and low-
affinity IgE receptors on the surface of mast cells and basophils (Casale, Bernstein et al. 1997, 
Busse, Corren et al. 2001, Kuhl and Hanania 2012). This prevents mast cell degranulation and 
the release of bronchoconstrictive and pro-inflammatory mediators in the airways. Moreover, 
IgE regulates its own receptor, thus the reduction in serum free IgE causes downregulation of 
FcεRI expression on mast cells, basophils and DCs (MacGlashan, Bochner et al. 1997, Beck, 
Marcotte et al. 2004, Lin, Boesel et al. 2004, Pelaia, Gallelli et al. 2011). After three months of 
anti-IgE therapy the density of FcεRI receptors were reduced from 220,000 to 83,000 per 
basophil (MacGlashan, Bochner et al. 1997). Interestingly, this effect was also observed in non-
atopic asthma (Garcia, Magnan et al. 2013). This reduction in FcεRI expression can contribute to 
a further dampening of the effector cell response to allergen (Oliver, Tarleton et al. 2010). 
Irrespectively of the mode of action it is shown at the population level, that the reduction in free 
IgE correlates with a reduction in asthma symptoms suggesting that greater IgE suppression 
leads to better clinical benefits (Lowe, Tannenbaum et al. 2009, Slavin, Ferioli et al. 2009, Zhu, 
Zheng et al. 2013). After initiation of anti-IgE therapy total IgE increases due to measurement of 
both free IgE and drug/IgE complexes, hence measurement of total IgE cannot be used for the 
assessment of the response to therapy. After the initial increase, total IgE levels will be reduced 
in parallel to the reduction in IgE production suggesting the regulation of IgE production 
through a feedback loop determined by the free IgE levels; a pharmacokinetic-
pharmacodynamics model showed that treated subjects would be expected to reach a new 
equilibrium after approximately five years of anti-IgE therapy (Lowe and Renard 2011). The 
same model predicted that when anti-IgE therapy is withdrawn, IgE production slowly returns to 
baseline levels. This is also supported by the results of the XPORT trial where both free IgE 
levels and FcεRI expression on basophils increased after discontinuation of anti-IgE therapy 
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(Ledford, Busse et al. 2017), which was also associated with more exacerbations and worse 
asthma control compared to the group that continued on anti-IgE therapy.  
Paper II shows that the allergen bronchoprovocation model can be used as a research tool to 
better understand the complexity of the airway response to allergen as well as to investigate the 
blocking effects of new interventions, such as QGE031 treatment. The excellent repeatability 
and reproducibility of the allergen bronchoprovocation model has been validated in previous 
studies, applying incremental allergen doses (Inman, Watson et al. 1995, Gauvreau, Watson et 
al. 1999, Gauvreau, Watson et al. 1999). These studies have shown high within-subject 
repeatability of both the EAR and LAR, irrespectively the way data was analysed (maximal % 
decrease in FEV1 from baseline or area under the time-response curve) as well as high 
repeatability when other outcome measure were explored such as the degree of sputum 
eosinophilia. They have also shown excellent reproducibility with sample sizes of less than 10 
subjects providing sufficient power to detect a 50 % inhibition using a crossover design. When 
using parallel-group studies it has been shown that 15 subjects per treatment group can also 
detect a 50 % inhibition of LAR (Gauvreau, Boulet et al. 2011). A recovery period of at least 
two weeks in-between challenges is recommended for both cross-over studies as well as 
parallel-group studies with multiple challenges (Diamant, Gauvreau et al. 2013). In Paper II the 
use of biologics as interventions that are known to have a long half-life, made the parallel-group 
design the only practical option. The primary endpoint in this study was the change in the EAR 
and no measurements of other markers of airways inflammation such as FENO or sputum 
eosinophils were performed. 
The findings in Paper II elucidate some fundamental differences in the allergen responses on 
the airways compared to the skin. Skin prick test responses were measured ten minutes after 
exposure to allergen and were caused by histamine release and were effectively suppressed in all 
subjects treated with the highest dose of QGE031. On the other hand on the airways the maximal 
decrease in FEV1 is detected between 10 and 30 minutes after inhalation and is due to release of 
histamine, CysLTs and PGD2; there was variability in the airway response to QGE031 that was 
not observed in the skin response. It is known that although cross-linking of IgE on mast cells 
and basophils is the initial “trigger” for the airway response to allergen, activation of other cells 
that express FcεRI such as DCs and B cells, can enhance and prime type 2 inflammation in the 
airway microenvironment (Holgate, Smith et al. 2009, Massanari, Holgate et al. 2010). Alternate 
pathways, such as activation through protease-activated receptor 2 can cause IgE-independent 
mast cell activation by alarmins such as TSLP and IL-33 (Boitano, Flynn et al. 2011). Hence, 
anti-IgE therapy does not target all the pathways involved to the development of the allergen 
response in the airways, which might explain the heterogeneity in the suppression of the EAR by 
QGE031. In addition, it was shown that subjects with higher IgE levels might require higher 
doses of QGE031. Although previous studies have shown some correlations between levels of 
free IgE and clinical benefits of anti-IgE therapy, they were based on statistical correlations 
across large populations of patients, thus for the individual subject, it is unlikely that suppression 
of free IgE or FcεRI expression alone will be able to predict responses to treatment (Chanez, 
Contin-Bordes et al. 2010). Moreover, there are also other factors that are involved that are of 
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importance regarding the response to anti-IgE treatment, including cellular IgE receptor 
expression (FcεRI and FcεRII/CD23), specific/total IgE ratios and cellular sensitivity 
(MacGlashan 2009), before even considering local tissue IgE concentrations and permeation of 
the drug to the tissue site. Previous retrospective analyses have suggested that asthmatic subjects 
with high blood eosinophil counts, high levels of FENO and serum periostin would benefit most 
of anti-IgE therapy (Hanania, Wenzel et al. 2013); nonetheless this could be due to a higher rate 
of exacerbations in subjects with high type 2 biomarker, thus allowing more space for 
improvement with anti-IgE therapy. A recent prospective real-world study demonstrated that 
both type-2 high inflammatory profile (blood eosinophil count ≥ 300 cells/µL and FeNO ≥ 25 
ppb) and type-2 low had a similar benefit of anti-IgE therapy (Casale, Luskin et al. 2019). 
In addition, anti-IgE therapy has been investigated in other conditions than allergic asthma. A 
proof-of-concept study in subjects with severe non-atopic asthma demonstrated that anti-IgE 
therapy significantly reduced FcεRI expression on basophils and DCs compared to placebo and 
was associated with an increase of lung function compared with baseline (Garcia, Magnan et al. 
2013). There was no significant reduction in the asthma exacerbation rate, although it should be 
noted that the study was only 16 weeks long. These findings indicate that anti-IgE therapy might 
be effective in the treatment of non-allergic asthma. Moreover, anti-IgE therapy has been 
investigated in aspirin-exacerbated respiratory disease (AERD) in an open label study in 21 
adults with AERD that were also sensitised to one or more common environmental allergens. 
Anti-IgE therapy significantly improved asthma exacerbations and asthma related symptom 
scores, although it must be noted that there was no placebo comparator arm. The most important 
finding was that anti-IgE therapy induced a rapid reduction in urinary excretion of LTE4 and the 
PGD2 metabolite 9α,11β-prostaglandin F2 compared to the period prior to treatment, thus 
indicating inhibition of mast cell activation (Hayashi, Mitsui et al. 2016). If one takes into 
consideration the results from Paper III regarding the excretion of a variety of eicosanoid lipid 
mediators in the urine, it would be of great interest in future studies regarding the efficacy of 
anti-IgE therapy to include as a primary or secondary endpoint the ability of the interventional 
drug to suppress these responses. It would be extremely useful to be able to predict the 
responders to anti-IgE therapy by a simple urine test. Lastly, anti-IgE therapy has shown 
efficacy in the treatment of chronic spontaneous urticaria (CSU) (Kaplan, Ledford et al. 2013, 
Maurer, Rosen et al. 2013). After the results regarding the effects of QGE031 in suppressing 
allergen-induced skin prick responses in Paper II, the drug is now tested for treatment of CSU. 
One study regarding the dose of QGE031 in CSU has been completed (NCT02477332) and a 
continuation study regarding the long-term safety of 240 mg QGE031 (the highest dose used in 
Paper II) given every four weeks for 52 weeks is estimated to be completed in June 2019 
(NCT02649218).  
7.3 NEW INSIGHTS INTO THE ROLE OF LTE4 IN ASTHMA 
The study presented in Paper III shows how a bronchoprovocation study with drug 
interventions and measurement of molecular markers can elucidate important pathophysiological 
and pharmacological mechanisms in asthma. The results of this study have several 
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pathobiological implications. This the first study where the most widely clinically used CysLT1 
antagonist, montelukast, was used to assess efficacy against bronchoconstriction induced by 
LTE4. While previous studies have investigated thoroughly the bronchoconstrictive effect of 
LTD4, there have been only a handful of studies that have looked how the terminal CysLT LTE4 
affects human airways in vivo. Treatment with montelukast completely abolished the LTE4 
induced bronchoconstriction in all subjects while on average subjects inhaled a 10-fold higher 
dose of LTE4 without any fall in lung function. Hence, the results support that the in vivo effect 
of LTE4 on airway smooth muscle in human subjects is mediated solely by the CysLT1 receptor. 
These findings are in agreement with those of previous studies using other leukotriene receptor 
antagonists against inhaled LTE4 (Christie, Spur et al. 1991, Laitinen, Lindqvist et al. 2005). 
This is also in agreement with in vitro results from experiments performed in isolated human 
bronchi and other models where also LTE4 has a mode of action solely through the CysLT1 
receptor (Buckner, Krell et al. 1986, Mechiche, Naline et al. 2003, Back, Dahlen et al. 2011, 
Foster, Fuerst et al. 2016). As it was expected, the study confirmed that LTE4 is a more potent 
bronchoconstrictor than methacholine demonstrating 75 times greater potency on a molar basis. 
Using an identical bronchoprovocation protocol it was found that inhaled LTD4 is approximately 
1000 times more potent than methacholine (Gyllfors, Kumlin et al. 2005). These results 
confirms the potency differences observed in previous studies where inhaled LTE4 was 
compared with methacholine or histamine on the one hand, and LTC4 or LTD4 on the other hand 
(Arm, O'Hickey et al. 1990). Another finding of the study was that subjects with the highest 
hyperresponsiveness for methacholine had the lowest relative airway responsiveness to LTE4, 
which has also been found for relations between methacholine and inhaled LTC4 or LTD4 in 
previous studies (Adelroth, Morris et al. 1986, Gyllfors, Kumlin et al. 2005). 
Because FEV1 reflects mainly changes to the larger airways, IOS measurements were applied in 
Paper III in order to examine the effect of LTE4 in the small airways and how that is modified 
by montelukast. The small airways are usually defined as having a luminal diameter less than 2 
mm and are a major site of airway inflammation and obstruction in asthma (Kraft, Djukanovic et 
al. 1996, Hamid, Song et al. 1997, Verbanck, Schuermans et al. 2010). Small airways disease 
has gained recognition due to the rapid evolvement of the methods to measure it during the past 
few years. There are reports showing that it is present at about 50-60 % of all subjects with 
asthma (Usmani, Singh et al. 2016). IOS was used in Paper III for the first time in the 
bronchoprovocation setting with LTE4. At baseline prior to challenge with LTE4 during both 
treatment periods, R5-R20 was found to be within the upper limit of normal (ULN), which was 
considered at 0.030 kPa/L/s as previously reported (Williamson, Clearie et al. 2011, Alfieri, 
Aiello et al. 2014). Inhalation of LTE4 after placebo treatment led to a seven-fold increase of R5-
R20 from baseline, and a mean 59 % increase in R5, which evidences small airways impairment. 
IOS has recently more widely been used in the bronchial challenge setting, especially in studies 
with children where it has been demonstrated that the methacholine dose that provokes a 45% 
increase in R5 (PD45 R5) had the optimal correlation with PD20FEV1 (Schulze, Smith et al. 2012). 
In adults, it is recommended that PC40 R5 can be used to approximately extrapolate to PC20 FEV1 
after methacholine challenge (Galant, Komarow et al. 2017). The mean fall in FEV1 after 
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inhalation of LTE4 and after treatment with placebo was 26.3% and it was calculated that a 20 % 
decrease in FEV1 translated to a 44.8 % increase in R5, which is in agreement with previous 
findings. These results are similar to the findings of a previous study using IOS after inhalation 
of LTD4 in asthmatic subjects (Guan, Zheng et al. 2013). Moreover, treatment with montelukast 
completely abolished this small airways impairment, with essentially no significant changes in 
IOS parameters after LTE4 inhalation. There are previous studies that have tested IOS as a 
marker of therapeutic response to inhaled therapies (ICS/LABA) in adults with asthma (Galant, 
Komarow et al. 2017). In one open label study in the pediatric setting, treatment with 10 mg of 
montelukast for four weeks showed modest improvement in most IOS parameters (Nieto, 
Pamies et al. 2006). In addition, montelukast has been shown to improve regional air trapping on 
CT-scan due to small airways obstruction in adults with asthma (Zeidler, Kleerup et al. 2006).  
In Paper III a higher dose of montelukast (40 mg) than the ordinary daily clinical dose for 
adults of 10 mg, was chosen deliberately. In absolute terms, 40 mg is not a very high dose, but a 
medium range dose given the knowledge about the pharmacology of montelukast. Montelukast 
is a very selective pharmacologic antagonist of the CysLT1 receptor (Jones, Labelle et al. 1995). 
In the dose ranges achieved by oral administration of montelukast up to 250 mg, a range of other 
known G-protein coupled receptors have been found to be un-affected by the drug. This has 
been substantiated in a number of pharmacologic assays over the years (Back, Dahlen et al. 
2011). Of central importance to the hypothesis tested in our study, montelukast has no 
antagonistic effect whatsoever on CysLT2 receptors or CysLT3/GPR99 receptors in vitro 
(Kanaoka, Maekawa et al. 2013). Moreover, the early clinical development of montelukast 
included 50, 100 and 250 mg dosing in adults. In bronchoprovocation studies against LTD4 or in 
clinical treatment, there were dose-dependent progressively increasing effects from 2 up to 250 
mg. For example, the median fold shift in LTD4 responsiveness in the study of De Lepeleire et al 
at the time-points corresponding to peak plasma concentration (around 4 hours) was 85, 113, 
161 and 181 fold for 5, 20, 100 and 250 mg, respectively (De Lepeleire, Reiss et al. 1997). 
Furthermore, in the first published clinical treatment trials (Reiss, Altman et al. 1996, Altman, 
Munk et al. 1998) data were reported for groups treated with several different doses from 10 mg 
up to 200 mg taken once up to three times daily. Interestingly, the FEV1 improvements in those 
early trials were ranging between 10-to17 % for the 100 and 200 mg doses, whereas the results 
reported for the 10 mg once daily dose in later trials have been lower, for example 7.4% in the 
study by Malmström et al (Malmstrom, Rodriguez-Gomez et al. 1999). The study populations 
were similar with baseline FEV1 predicted around 65% and a mix of steroid-treated and steroid-
naïve subjects. The clinical dose-selection was however much guided by the findings in an 
exercise-provocation dose-ranging study (Bronsky, Kemp et al. 1997). ). It did not find striking 
statistical significance between 10 mg and higher doses, although the numerical values for some 
outcomes suggested better protection by 50 or 100 mg. The final clinical dose selection was also 
based on commercial factors. The main goal of this study was to understand if there was a 
significant component of the bronchoconstriction induced by inhalation of LTE4, which was 
resistant to blockade by the prototype CysLT1 receptor antagonist montelukast. Given the clear 
published data from the study with short-term administration of montelukast in the LTD4 
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bronchoprovocation setting (De Lepeleire, Reiss et al. 1997) it was not wished to test the 
hypothesis of the distinct LTE4 receptor using a too low dose of montelukast. Partial inhibition 
of LTE4 might then lead to the inconclusive result that either there is another receptor or that the 
receptor antagonism was not sufficient. Again, given the previous data and the remaining very 
selective effect of much higher doses of montelukast, the 40 mg dose was chosen to optimise 
pharmacologic antagonism without moving up into the real high dose interval. In De Lepeleire 
et al this dose at trough gave more than a 56-fold shift in the responsiveness to LTD4. As a 
corollary of the findings, perhaps it is time to revisit the dosing of montelukast? 
The results furthermore showed that despite exposure to one order of magnitude higher dose of 
LTE4 after treatment with montelukast, the sputum eosinophil count was the same as during the 
placebo period. The first thing that needs to be discussed is if the window of four hours post 
LTE4 inhalation was enough in order to assess the components of this response. There seems to 
be some uncertainty about the kinetics of the influence of the primary challenge with LTE4 and 
secondary factors released from mast cells on the cellular responses. There were unfortunately 
only a few previous studies to use as guide on the design of this particular part of the study 
protocol when the investigation was planned. In the original report of LTE4-induced airway 
eosinophilia by Laitinen et al (Laitinen, Laitinen et al. 1993b), the finding was documented at 4 
hours after inhalation of LTE4. Deykin and colleagues (Deykin, Belostotsky et al. 2000) reported 
an increase in sputum eosinophils at 4 hours following LTE4 inhalation in subjects with mild 
intermittent asthma, thus being a similar study population as in our investigation. Furthermore, 
Laitinen et al replicated their finding of increased bronchial tissue eosinophils at 4 hours post 
LTE4 challenge (Laitinen, Lindqvist et al. 2005). It appears therefore that eosinophil 
accumulation may be detected in human airways at four hours post challenge with LTE4 
irrespective of where assessed, indicating that the interval chosen in Paper III was sufficient. 
Hence, the absence of an increase in sputum eosinophils when subjects were exposed to one-log 
order of magnitude greater amounts of LTE4 in the presence of montelukast argues against the 
presence of another CysLT receptor promoting eosinophil accumulation in the sputum. If a dual 
receptor scenario had been present, blockade of CysLT1 with montelukast would have 
uncovered effects at another active receptor. Of course, it might be speculated that a putative 
second receptor is inhibitory. There is however, no experimental data supporting negative effects 
of LTE4 or other CysLTs on human eosinophil migration, therefore such a theoretical 
interpretation appears unlikely. 
One of the discoveries of the study in Paper III is that inhaled LTE4 induced increased urinary 
excretion of metabolites indicative of pulmonary release of several COX products as well as 
several isoprostanes. It is the first time this is demonstrated in human subjects in vivo and 
confirms previous results from original work on CysLTs mechanisms in animal airways 
showing also that CysLTs can cause profound release of COX products that contribute to the 
overall biological responses (Piper and Samhoun 1982, Dahlen, Hedqvist et al. 1983). In 
addition, these results may provide one potential mechanistic explanation for the previous 
finding that in asthmatic subjects prior inhalation of LTE4 enhanced histamine-induced 
bronchoconstriction that was inhibited by indomethacin, indicating that a cyclooxygenase 
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product mediated this particular hyperresponsiveness (Christie, Hawksworth et al. 1992). 
However, it was not discussed which prostanoid that might have been involved and there were 
no data on prostanoid release in that study. It must be also noted that the cyclooxygenase 
inhibition with indomethacin causes a global inhibition of the release of all PGs, including PGE2, 
which is bronchoprotective by inhibition of mast cell mediator release (Safholm, Manson et al. 
2015).  
It was accordingly shown in Paper III that LTE4 induced bronchoconstriction was associated 
with sharp increases in urinary excretion of metabolites of the mast cell derived mediator PGD2, 
as well as TXA2 and other COX pathway mediators such as PGF2a and PGE2. Moreover, this 
increased excretion was abolished by montelukast, with noteworthy exception of PGE2, thus 
confirming most of the secondary lipid mediator release to be CysLT1 dependent. This is the first 
study that directly demonstrates that LTE4 causes CysLT1 dependent activation of mast cells and 
confirms that LTE4 is able to elicit formation of several COX products, of which many are likely 
derived from mast cells (Figure 49). Increased excretion of PGD2 is considered a sign of mast 
cell activation because this cell is the major source of PGD2 in human subjects (Lewis, Soter et 
al. 1982, Bood, Sundblad et al. 2015). PGD2 is known to be a potent bronchoconstrictor and can 
contract human airways through a mechanism that is blocked by thromboxane prostanoid (TP) 
receptor antagonism (Safholm, Manson et al. 2015). The results suggest that some of the 
bronchoconstrictive effects of LTE4 are secondary to prostanoid release from mast cells, thus 
CysLTs may need to be reclassified as dual bronchoconstrictors (Figure 49). Another 
implication of this finding is that because mast cells can also produce CysLTs, this CysLT1 
dependent mast cell activation might represent a positive feedback loop sustaining the response 
to the initial stimulus. In addition, eosinophils, which are proficient producers of CysLTs, could 
prime mast cells by this particular mechanism. Moreover, PGD2 acting through the 
chemoattractant receptor-homologous receptor (CRTH2) can induce chemotaxis for Th2 
lymphocytes and eosinophils as well as activate ILC2 cells that also have a key role in asthmatic 
inflammation (Salimi, Stoger et al. 2017). In fact results from a recent in vitro study showed that 
cytokine-induced endogenous production of PGD2 is essential for human ILC2 cell activation 
(Maric, Ravindran et al. 2018). These PGD2 driven pro-inflammatory effects can be 
counteracted at least partially by PGE2, which was also increased in the urine after LTE4 
inhalation, although its excretion was not blocked by montelukast. This indicated that the release 
of PGE2 is not CysLT1 dependent, although CysLT1 could nonetheless be involved partially 
because a ten-fold greater dose of LTE4 in the presence of montelukast did not further increase 
urinary excretion of PGE2 compared to placebo. Thus, it is possible that another receptor 
(CysLTx) might be involved in PGE2 release, most likely in the airway epithelium, which is a 
major source of PGE2 (Churchill, Chilton et al. 1989, Harrington, Lucas et al. 2008). 
Irrespectively of the involved receptor, it was shown that inhalation of LTE4 triggered secondary 
release of PGE2, which has anti-inflammatory effects on both mast cells (Raud, Dahlen et al. 
1988, Safholm, Manson et al. 2015) as well as ILC2 cells (Zaslona, Okunishi et al. 2014, Maric, 
Ravindran et al. 2018). This finding of increased PGE2 excretion might be a protective negative 
feedback response intended to aid resolution (Figure 49). These results suggest that a potential 
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imbalance in the production of endogenous prostanoids may have an important role in asthma 
pathogenesesis.  
 
Figure 49: Summary of the effects of LTE4 in asthma according to findings in Paper III. 
7.4 SUMMARY 
The aim of this thesis was to use bronchial provocations and interventions in order to investigate 
mechanisms in asthma and airway inflammation. Looking back at the results of the three 
different projects one could say that major discoveries have been made. The results of the first 
study have subsequently been confirmed in two large cohort studies. Together this will probably 
change current recommendations for treatment of mild asthma. The results of the second study 
elucidated the complexity of the IgE pathway, differences between skin and airways, and new 
unmet needs regarding effective anti-IgE therapy. The third study gave clear-cut answers 
regarding the role of the receptors for CysLTs that had not been answered in years and opened 
new doors for future research in the field. Of course all the questions are not answered yet, there 
is still much to do. Bronchoprovocation studies still after more than 70 years of use remain an 
effective research model in asthma that can ultimately integrate our understanding of the 
different pathophysiological mechanisms in asthma.  
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Astma är en folksjukdom som drabbar cirka 10-12% av den svenska befolkningen, Den orsakas 
av kronisk inflammation i luftrören som är överretbara och symptomen kännetecknas av 
varierande grad av andnöd och pipande andning. När astman utlöses drar musklerna i luftrören 
ihop sig och det blir trängre för luften att komma ner i lungorna. Dessutom det blir en svullnad i 
slemhinnorna som orsakar ökad slembildning och hosta. Ett astmaanfall kan utlösas av olika 
faktorer, såsom ansträngning, exponering för allergener, virusinfektioner eller intag av 
acetylsalicylsyra (ASA) och inflammationsdämpande läkemedel (NSAID). Astma är en variabel 
sjukdom som innebär att patienter med framförallt lindrig astma ofta mår bra i sin astma när dem 
inte exponeras för trigger faktorer. Astma är också en heterogen sjukdom där det ingår olika 
subgrupper som kallas för fenotyper som skiljer sig avsevärt både avseende dem underliggande 
mekanismer samtidigt till en viss del vad det gäller behandlingen. 
Dessa karakteristika dvs. sjukdomens variabilitet och att exponering för visa stimuli kan 
framkalla ett anfall, kan vi använda vid astmaforskning genom att utföra en s.k. 
provokationsstudie. Vid en sådan studie provoceras dvs. exponeras, försökspersoner med oftast 
stabil, lindrig för olika ämnen som kan framkalla ett standardiserat och kontrollerat astmaanfall 
på forksningsenheten. Lungfunktionen mäts både innan, under och efter provokationen och man 
samlar prover från utandad luft, blod och urin för att mäta vilka molekyler som frisätts efter att 
luftvägarna har exponerats för ämnet. Provokationen upprepas efter en behandlingsperiod med 
en aktiv medicin som dämpar astmaanfallet och skyddar luftvägarna och efter behandling med 
placebo eller ett annat aktivt behandlingsalternativ. På det sättet kan man studera både 
underliggande mekanismer vid astma och samtidigt testa om en ny medicin är effektiv som 
astmabehandling. Nästan alla mediciner som är godkända idag för astmabehandling har 
studerats med provokationsstudier. I den här avhandlingen ingår 3 provokationsstudier där jag 
har studerat olika astmamekanismer och även testat nya behandlingsalternativ. 
Första delarbetet var en provokationsstudie med fysisk ansträngning hos försökspersoner med 
lindrig astma, där syftet var att jämföra den skyddande effekten av att bara använda en 
kombination av inandat kortison och luftrörsvidgande medicin (budesonide/formoterol) vid 
behov med en kortverkande luftrörsvidgande (terbutalin) vid behov eller kontinuerlig behandling 
med inandat kortison (budesonid) och terbutalin vid behov. Den primära effektvariabeln var 
sänkning av lungfunktionen efter ett 6 minuters standariserat ansträngningsprovokation på 
rullande matta som utfördes fore samt efter 3 och 6 veckors behandling. Vi fann att 
kombinationsbehandling med budesonid-formoterol som profylaktisk behandling innan 
ansträngning, var mer effektivt än standardbehandling terbutalin. Terbutalin hade ingen 
skyddande effekt mot ansträngningsutllöst luftvägsobstruktion sannolikt pga toleransutveckling 
efter användningen. Vi fann också att behandling med budesonid-formoterol som profylaktisk 
behandling innan ansträngning, var lika effektiv som kontinuerlig behandling med budesonid 
och terbutalin vid behov. Resultaten kan ha implikationer vid framtida riktlinjer för 
astmabehandling. 
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Andra delarbetet var en allergenprovokationsstudie hos försökspersoner med lindrig astma. 
Syftet var att studera effekten av olika doser av ett nytt läkemedel (QGE031-ligelizumab) mot 
IgE, dvs den typ av immunoglobulin som spelar roll vid allergi, för att se om detta läkemedel 
kunde skydda mot inandat allergen och hämma den astmatiska reaktionen. I studien jämfördes 
QGE031 med omalizumab, som är hittils det enda registrerade läkemedlet mot IgE och med 
placebo. Den primära effektvariabeln var ändringen i allergen koncentrationen som gav en 15-
procentig minskning av lungfunktionen (allergenPC15) efter högsta dosen av QGE031 och i 
jämförelse med omalizumab. Sekundära variabler var effekten av de två mindre doserna av 
QGE031 jämfört med omalizumab och placebo på luftvägssvaret samt effekten av QGE031 vad 
gäller att hämma hud prick test reaktivitet på allergen jämfört med omalizumab och placebo. Vi 
fann att högsta dosen av QGE031 ändrade allergenPC15 tre gånger mer än omalizumab och 16 
gånger mer än placebo, dock skillnaden med omalizumab blev inte signifikant. Däremot 
QGE031 var mer effektivt än omalizumab att hämma den allergen inducerat prick test reaktivitet 
på hud i alla doser. QGE031 tolererades bra av alla försökspersoner.  
Tredje delarbetet var en provokationsstudie med inandat leukotrien E4 (LTE4) hos 
försökspersoner med lindrig astma; studien var en rent experimentell undersokning av hur den 
kroppsegna mediatorn LTE4 framkallar obstruktion av luftrören hos patienter med astma. Det 
finns sedan länge ett godkänt astmaläkemedel mot leukotriener, montelukast, som blockerar en 
receptor, nämligen CysLTR1 som är viktigt för leukotrienernas verkan i luftägarna. Det finns nu 
experimentella data som tyder att LTE4 kan utöva sin effekt via andra receptorer än CysLT1. Det 
innebär då att montelukast endast delvis skyddar mot LTE4´s effekt på luftvägarna. Den primära 
effektvariabeln var ändringen i den dos av LTE4 som ger en 20-procentig sänkning i FEV1 efter 
en standardiserat inhalations ptovokation med LTE4 efter behandling med montelukast och 
placebo. Sekundära variabler var skillnaden i graden av inflammationen i upphostningsprov mätt 
som antal eosinofila celler i inducerat sputum vilket samlades 4 timmar efter provokationen och 
mätning av utsöndringen i urinen av kroppsegna lipidmediatorer med hjälp av mass 
spektrometri. Studien hade crossover design. Vi fann att montelukast skyddade mot LTE4 
inducerad luftvägsobstruktion och att försökspersonerna tolererade 10 gånger högre dos av LTE4 
när de fick montelukast jämfört med placebo. Det var ingen skillnad i sputum eosinofili mellan 
montelukast och placebo. LTE4 inhalation ledde till utsöndring i urinen av prostaglandin D2 
metaboliter som blockerades av montelukast behandling. Prostaglanding D2 frisätts huvusakligen 
från mastceller efter deras aktivering. Prostglandin D2 framkallar också luftvägsobstruktion 
Detta är således den första studie som visar att leukotriener kan aktivera mast celler in vivo vilka 
i sin tur frisätter prostaglandiner som kan bidra till luftvägsreaktivitet.  
Sammanfattnings visar avhandlingens resultat att provokationsstudier kan framgångsrikt 
användas för att studera viktiga mekanismer vid astma och luftvägsinflammation, samt för att 
testa effekten av nya behandlingsalternativ. 
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